Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project.

(“**ISIDORe**”)

Grant Agreement No.: 101046133

(Based on DESCA – Model Consortium Agreement for Horizon Europe, version 1, December 2021)

## Table of Contents

1. [Definitions 13](#_bookmark0)
2. [Purpose 15](#_bookmark1)
3. [Entry into force, duration and termination 15](#_bookmark2)
4. [Responsibilities of Parties 16](#_bookmark4)
5. [Liability towards each other 17](#_bookmark6)
6. [Governance structure 19](#_bookmark8)
7. [Mandate 30](#_bookmark23)
8. [Financial provisions 32](#_bookmark24)
9. [Results 39](#_bookmark30)
10. [Access Rights 41](#_bookmark34)
11. [Non-disclosure of information 44](#_bookmark38)
12. [Miscellaneous 46](#_bookmark39)
13. [Signatures 49](#_bookmark41)

[Attachment 1: Background included 203](#_TOC_250008)

[Attachment 2: Accession document 218](#_TOC_250007)

[Attachment 3: List of Third Parties for simplified transfer according to Section 9.3.2 219](#_TOC_250006)

[Attachment 4: Contract under mandate: One-Sided CDA 220](#_TOC_250005)

[Attachment 5: Contract under Mandate: two-sided CDA 227](#_TOC_250004)

[Attachment 6: Contract under Mandate: Advisory Agreement 236](#_TOC_250003)

[Attachment 7 : JRA project template agreement 245](#_TOC_250002)

[Attachment 8: List of RIs that hold funding for the APs who will contribute to their respective TNA Work Packages for the provision of the services as identified in Table 3.1k of Annex 1 to the Grant Agreement 246](#_TOC_250001)

[Attachment 9 List of Parties and their AP’s under the RI’s that represent them in the Governing Board 249](#_TOC_250000)

**CONSORTIUM AGREEMENT**

THIS CONSORTIUM AGREEMENT (the “**Consortium Agreement”**) is based upon Regulation (EU) No 2021/695 of the European Parliament and of the Council of 28 April 2021 establishing Horizon Europe – the Framework Programme for Research and Innovation (2021-2027), laying down its rules for participation and dissemination (hereinafter referred to as “Horizon Europe Regulation”), and on the European Commission’s General Model Grant Agreement and its Annexes, and is made effective on 1 February 2022, hereinafter referred to as the Effective Date

**BETWEEN:**

1. **EUROPEAN RESEARCH INFRASTRUCTURE ON HIGHLY PATHOGENIC AGENTS**, with legal address at Rue Du Trône 98/B4, Brussels 1050, Belgium. (“**ERINHA**” or the “**Coordinator**”);
2. **UNIVERSITE D'AIX MARSEILLE**, with legal address at 58 Boulevard Charles Livon, Marseille 13284, France (“**AMU**”);
3. **INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT**, with legal address at 147 Rue De L'université, Paris Cedex 07 75007, France “**INRAE**”);
4. **INSTITUT PASTEUR**, a French non-profit foundation with charitable status pursuant to a decree dated of June 4th, 1887, located at 25-28 rue du Docteur Roux, 75724 Paris Cedex 15, France, VAT FR 65 775 684 897, represented by xxx, Vice-President Senior Executive, duly authorized (“**IP**”) acting in its own name and on behalf of the Centre National pour la Recherche Scientifique (CNRS), a public scientific and technical research establishment, with headquarters at 3 rue Michel-Ange, 75794 Paris Cedex 16, with regards to the Laboratory "Génétique Moléculaire des Virus à ARN", headed by xxx, which is part of the mixed research unit UMR3569 – Université Paris Cité and the laboratory "Genetics and Genomics of Insect Vectors" which is part of the mixed research unitUMR2000 – Paris 6 , in accordance with the mandate resulting from the framework agreement currently in force;
5. **EUROPEAN VACCINE INITIATIVE EWIV**, with legal address at Vossstrasse 2 Geb 4040, Heidelberg 69115, Germany (“**EVI**”);
6. **INSTRUCT-ERIC**, with legal address at Oxford House, Parkway Court, John Smith Drive, Oxford OX4 2JY, United Kingdom (“**INSTRUCT**”**)**;
7. **EURO-BIOIMAGING ERIC**, with legal address at Pl 123, Turku 20521, Finland (“**EURO- BIOIMAGING**”);
8. **EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM**, established in Robert- Rossle-Str. 10, Berlin 13125, Germany (“**EU-OS**” or “**EU-OPENSCREEN ERIC**”);
9. **ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK**, with legal address at 5 Rue Watt, Paris 75013, France (“**ECRIN**”);
10. **EATRIS ERIC**, with legal address at De Boelelaan 1118, Amsterdam 1081 HZ, Netherlands(**EATRIS**”);
11. **BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM**, with legal address at Neue Stiftingtalstrasse 2/B/6, Graz 8010, Austria (““**BBMRI**”);
12. **INFRAFRONTIER GMBH**, with legal address at Ingolstadter Landstrasse 1, Neuherberg 85764, Germany (“**INFRAFRONTIER**”);
13. **EUROPEAN MARINE BIOLOGICAL RESOURCE CENTRE EUROPEAN RESEARCH INFRASTRUCTURE CONSORTIUM**, with legal address at 4 Place Jussieu, Paris 75005, France (“**EMBRC**”);
14. **EUROPEAN MOLECULAR BIOLOGY LABORATORY**, an International Organization with legal address at Meyerhofstrasse 1, Heidelberg 69117, Germany, for EMBL and for the ELIXIR Hub (EMBL as part of - and mandated by the ELIXIR Consortium) with legal address at Wellcome Genome Campus Hinxton, Cambridgeshire, CB10 1SD, United Kingdom and as a host of the Euro- BioImaging Bio-Hub (“**EMBL”** or **“IEIO”**)
15. **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE**, with legal address at Rue De Tolbiac 101, Paris 75654, France **(**“**INSERM**”);
16. **UNIVERSIDADE DO MINHO**, with legal address at Largo Do Paco, Braga 4704 553, Portugal (“**UMINHO**”);
17. **INSERM TRANSFERT SA**, with legal address at Rue Watt 7, Paris 75013, France (“**IT**”);
18. **FOLKHALSOMYNDIGHETEN**, with legal address at Nobels Vag 18, Solna 171 82, Sweden (**FOHM**”);
19. **INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE**, with legal address at Avenida Padre Cruz, Lisboa 1649-016, Portugal (“**INSA**”);
20. **NEMZETI NEPEGESZSEGUGYI KOZPONT**, established in ALBERT FLORIAN UT 2-6, BUDAPEST 1097, Hungary (“**NNK**”);
21. **ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM** (**ERASMUS MC**), an institution organized in accordance with public law of the Netherlands (article 1.13,2 WHW), with principal place of business at Dr. Molewaterplein 40, 3015GD Rotterdam, The Netherlands, and registered with the national Chamber of Commerce with number 24485070, legally represented by xxx in his capacity of Dean and Member of the Board of Directors of "Erasmus University Medical Center Rotterdam(“**EMC**”);
22. **KATHOLIEKE UNIVERSITEIT LEUVEN**, for the purposes of this Agreement represented by KU Leuven Research & Development, with legal address at Oude Markt 13, Leuven 3000, Belgium (“**KUL**”);
23. **MEDIZINISCHE UNIVERSITAT GRAZ**, with legal address at Neue Stiftingtalstraße 6, 8010 Graz, Austria (“**MUG**”);
24. **BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN**, with legal address at Bernhard Nocht Strasse 74, Hamburg 20359, Germany (“**BNI**”);
25. **CHARITE - UNIVERSITAETSMEDIZIN BERLIN**, with legal address at Chariteplatz 1, Berlin 10117, Germany (“**CUB**”);
26. **DEPARTMENT OF HEALTH**, with legal address at Quarry House, Quarry Hill, Leeds LS2 7UE, United Kingdom (“**DH**”);
27. **UNIVERZA V LJUBLJANI**, with legal address at Kongresni Trg 12, Ljubljana 1000, Slovenia (“**UL**);
28. **BIOMEDICINSKE CENTRUM SLOVENSKEJ AKADEMIE VIED**, VEREJNA VYSKUMNA INSTITUCIA, with legal address at Dubravska Cesta 9, Bratislava 845 05, Slovakia (“**BMC SAV**”);
29. **UNIVERSITAT BASEL**, with legal address at Petersplatz 1, Basel 4051, Switzerland (“**UNIBAS**”);
30. **ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO**, with legal address at Via Portuense, 292, ROMA 00149, Italy (“**INMI**”);
31. **The State of the Netherlands, represented by it’s Minister of Health, Welfare and Sport, on behalf of the Minister represented by Professor Johannes Brug, Director-General of the National Institute for Public Health and the Environment (RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU)**, with legal address at Antonie Van Leeuwenhoeklaan 9, Bilthoven 3721 MA, Netherlands (“**RIVM**”);
32. **PHILIPPS UNIVERSITAET MARBURG**, with legal address at Biegenstrasse 10, Marburg 35032, Germany (“**UMR**”);
33. **THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS**, with legal address at Area 1A, Nobel House, Smith Square 17, LONDON SW1P 3JR, United Kingdom, acting through the Animal and Plant Health Agency (APHA), Addlestone, Surrey, United Kingdom, (“**DEFRA**”);
34. **FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT**, with legal address at Sudufer 10, Greifswald-Insel Riems 17493, Germany (“**FLI**”);
35. **THE PIRBRIGHT INSTITUTE LBG**, with legal address at Ash Road, Pirbright, Woking GU24 0NF, United Kingdom (“**TPI**”);
36. **COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION**, with legal address at Clunies Ross Street, Csiro Black Mountain Science and Innovation Park, Action ACT 2601, Australia (“**CSIRO**”);
37. **ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE**, with legal address at Viale Dell Universita 10, Legnaro 35020, Italy (“**IZSVE**”);
38. **LEIBNIZ-INSTITUT DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GMBH**, with legal address at Inhoffenstrasse 7b, Braunschweig 38124, Germany (“**DSMZ**”);
39. **JULIUS-KUHN-INSTITUT BUNDESFORSCHUNGSINSTITUT FUR KULTURPFLANZEN**, with legal address at ERWIN-BAUR-STRASSE 27, QUEDLINBURG 06484, Germany (“**JKI**”);
40. **AGRICULTURAL RESEARCH COUNCIL INSTITUTE FOR SOIL CLIMATE AND WATER**, with legal address at Belvedere Street 600, Pretoria 0001, South Africa (“**ARC**”);
41. **STICHTING WAGENINGEN RESEARCH**, more specifically its institute Wageningen Bioveterinary Research with legal address at Houtribweg 39, LELYSTAD 8221 RA,, Netherlands (“**WR**”);
42. **MOREDUN RESEARCH INSTITUTE**, with legal address at Pentlands Science Park, Bush Loan, PENICUIK EH26 0PZ, United Kingdom (“**MRI**”);
43. **AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS M.P.**, with legal address at Calle Serrano 117, Madrid 28006, Spain (“**CSIC**”);
44. **INSTITUT DE RECERCA I TECNOLOGIA AGROALIMENTARIES**, with legal address at CTRA C- 59 K 12 Torre Marimon, Caldes De Montbui, Barcelona 08140, Spain (“**IRTA**”);
45. **EIDGENOESSISCHES DEPARTEMENT DES INNERN**, with legal address at Inselgasse 1, BERN 3003, Switzerland **(**“**EDI-IVI**”);
46. **PANSTWOWY INSTYTUT WETERYNARYJNY - PANSTWOWY INSTYTUT BADAWCZY**, with legal address at Partyzantow 57, PULAWY 24100, Poland (“**PIWET**”);
47. **AARHUS UNIVERSITET,** with legal address at NORDRE RINGGADE 1, AARHUS C 8000, Denmark (“**AU**”);
48. **AGENCE NATIONALE DE SECURITE SANITAIRE DE L’ALIMENTATION DE L’ENVIRONNEMENT ET DU TRAVAIL**, with legal address at 14 Rue Pierre et Marie Curie, Maisons Alfort 94700, France (“**ANSES**”);
49. **THE UNIVERSITY COURT OF EDINBURGH**, with legal address at Old College, South Bridge, Edinburgh EH8 9YL, United Kingdom (“**UEDIN**”);
50. **InSCREENeX GmbH**, with legal address at Inhoffenstrasse 7, Braunschweig 38124, Germany (“**InSCREENeX**”);
51. **NOLDUS INFORMATION TECHNOLOGY BV**, with legal address at NIEUWE KANAAL 5, WAGENINGEN 6709 PA, Netherlands (“**NOLDUS**”);
52. **STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER**, with legal address at Lange Kleiweg 161, Rijswijk Zh 2288 GJ, Netherlands (“**BPRC**”);
53. **HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH**, with legal address at Inhoffenstrasse 7, Braunschweig 38124, Germany (“**HZI**”);
54. **INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA**, with legal address at Avenida Da Republica Quinta Do Marques, Oeiras 2781-901, Portugal (“**IBET**”);
55. **STATENS SERUM INSTITUT**, with legal address at Artillerivej 5, 2300 Copenhagen S., Denmark (“**SSI**”);
56. **UNIVERSITA DEGLI STUDI DI SIENA**, with legal address at Via Banchi Di Sotto 55, Siena 53100, Italy (“**UNISI**”);
57. **VACCINE FORMULATION INSTITUTE(CH)LTD**, with legal address at Rue du Champ-Blanchod 4, Plan Les Ouates 1228, Switzerland (“**VFI**”);
58. **COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES**, with legal address at Rue Leblanc 25, Paris 15 75015, France (“**CEA**”);
59. **ACADEMISCH ZIEKENHUIS LEIDEN**, with legal address at ALBINUSDREEF 2, LEIDEN 2333 ZA, Netherlands (“**LUMC**”);
60. **STICHTING AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT**, with legal address at Paasheuvelweg 25 Tower C4, Amsterdam 1105 BP, Netherlands (“**AIGHD**”);
61. **STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG**, with legal address at OTTERSTRAAT 118-124, UTRECHT 3500 BN, Netherlands (“**NIVEL**”);
62. **MEDIZINISCHE UNIVERSITAET WIEN**, with legal address at SPITALGASSE 23, WIEN 1090, Austria (“**MUW**”);
63. **THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD**, with legal address at Wellington Square, University Offices, Oxford OX1 2JD, United Kingdom (“**UOXF**”);
64. **BRAC JANES P GRANT SCHOOL OF PUBLIC HEALTH, BRAC UNIVERSITY**, with legal address at 6th floor Medona tower, 28 Mohakhali Commercial Area, Bir Uttom A K Khandakar Road, Dhaka- 1213, Bangladesh (“**BRAC**”);
65. **UNIVERSITY COLLEGE LONDON**, with legal address at Gower Street, London WC1E 6BT, United Kingdom (“**UCL**”);
66. **CENTRE REGIONAL DE RECHERCHE ET DE FORMATION A LA PRISE EN CHARGE CLINIQUE DU VIH SIDA ET MALADIES ASSOCIEES DE DAKAR CRCF**, with legal address at Chnu De Fann, Avenue Cheikh Anta Diop, Dakar 18524, Senegal (“**CRCF**”) ;
67. **VIB VZW**, with legal address at Rijvisschestraat 120, Zwijnaarde - Gent 9052, Belgium (“**VIB VZW**”);
68. **UNIVERSITE DE LIEGE**, with legal address at PLACE DU 20 AOUT 7, LIEGE 4000, Belgium (“**ULIEGE**”);
69. **MASARYKOVA UNIVERZITA**, with legal address at Zerotinovo namesti 9, BRNO 601 77, Czechia (“**MU**”);
70. **BIOTECHNOLOGICKY USTAV AV CR VVI**, with legal address at Prumyslova 595, Vestec 252 50, Czechia (“**IBT**”);
71. **JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN**, established in Theodor W Adorno Platz 1, Frankfurt Am Main 60629, Germany (“**GUF**”);
72. **OULUN YLIOPISTO**, with legal address at Pentti Kaiteran Katu 1, Oulu 90014, Finland (“**UOULU**”);
73. **ITA-SUOMEN YLIOPISTO**, with legal address at Yliopistonranta 1e, Kuopio 70211, Finland (“**UEF**”);
74. **HELSINGIN YLIOPISTO**, with legal address at Yliopistonkatu 3, Helsingin Yliopisto 00014, Finland (“**UH**”);
75. **CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE**, a French Economic Interest Group (Groupement d’Intérêt Economique), organized under the laws of France, registred under the n° SIRET 38111246500020, with legal address at Rue Laurent Fries 1, BP 10142, Illkirch 67404, cedex, France (“**CERBM**”)
76. **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS**, with legal address at Rue Michel Ange 3, Paris 75794, France (“**CNRS**”);
77. **WEIZMANN INSTITUTE OF SCIENCE**, with legal address at Herzl Street 234, Rehovot 7610001, Israel (“**WEIZMANN**”);
78. **CONSORZIO INTERUNIVERSITARIO RISONANZE MAGNETICHE DI METALLO PROTEINE**, with legal address at Piazza San Marco 4, Firenze 50121, Italy (“**CIRMMP**”);
79. **STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS**, with legal address at Plesmanlaan 121, Amsterdam 1066 CX, Netherlands (“**NKI**”);
80. **UNIVERSITEIT LEIDEN**, with legal address at Rapenburg 70, Leiden 2311 Ez, Netherlands (“**ULEI**”);
81. **UNIVERSITEIT UTRECHT**, with legal address at Heidelberglaan 8, Utrecht 3584 CS, Netherlands (“**UU**”);
82. **CHEMICKY USTAV SLOVENSKEJ AKADEMIE VIED**, with legal address at DUBRAVSKA CESTA 9, BRATISLAVA 845, Slovakia (“**IC SAS**”);
83. **UNIVERSITY OF LEEDS**, with legal address at Woodhouse Lane, Leeds LS2 9JT, United Kingdom (“**UNIVLEEDS**”);
84. **DIAMOND LIGHT SOURCE LIMITED**, incorporated and registered in England and Wales with company number 04375679 , with legal address at Diamond House, Harwell Science & Innovation Campus Chilton, Didcot, Oxfordshire, 0X11 0DE, United Kingdom (“**Diamond**”);
85. **THE ROSALIND FRANKLIN INSTITUTE**, with legal address at Building R113, Rutherford Appleton Laboratory, Harwell, Didcot OX11 0FA, United Kingdom **(**“**RFI**”);
86. **ROUMEN TSANEV INSTITUTE OF MOLECULAR BIOLOGY BULGARIAN ACADEMY OF SCIENCES**, with legal address at Acad G. Bonchev 21, SOFIA 1113, Bulgaria (“**IMB BAS**”);
87. **USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE**, with legal address at VIDENSKA 1083, PRAHA 4 142 20, Czechia **(**“**IMG CAS**”);
88. **ABO AKADEMI**, with legal address at Domkyrkotorget 3, ABO 20500, Finland (“**ABO**”);
89. **DEBRECENI EGYETEM**, with legal address at Egyetem Ter 1, Debrecen 4032, Hungary (“**UD**”);
90. **CONSIGLIO NAZIONALE DELLE RICERCHE**, with legal address at PIAZZALE ALDO MORO 7, ROMA 00185, Italy (“**CNR**”);
91. **UNIVERSITA DEGLI STUDI DI TORINO**, with legal address at Via Giuseppe Verdi 8, Torino 10124, Italy (“**UNITO**”);
92. **ELETTRA - SINCROTRONE TRIESTE SCPA**, with legal address at Ss 14 Km 163.5 Area Science Park, Basovizza Trieste 34149, Italy (“**ELETTRA**”);
93. **STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM**, with legal address at GEERT Grooteplein 10 Zuid, Nijmegen 6525 GA, Netherlands (“**RADBOUDUMC**”);
94. **UNIVERSITAIR MEDISCH CENTRUM UTRECHT**, with legal address at Heidelberglaan 100, Utrecht 3584 CX, Netherlands (“**UMCU**”);
95. **UNIVERSITETET I OSLO**, with legal address at Problemveien 5-7, Oslo 0316, Norway (“**UiO**”);
96. **TURUN YLIOPISTO**, with legal address at YliopistonmakI, Turku 20014, Finland (“**UTU**”);
97. **VIENNA BIOCENTER CORE FACILITES GMBH**, with legal address at Dr Bohr Gasse 3, Wien 1030, Austria (“**VBCF**”);
98. **INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC**, with legal address at Rua Alfredo Allen 208, Porto 4200 135, Portugal (“**IBMC**”);
99. **FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA**, with legal address at Avda Del Conocimiento 3, Armilla Granada 18100, Spain (“**MEDI**”);
100. **INSTYTUT CHEMII BIOORGANICZNEJ POLSKIEJ AKADEMII NAUK**, with legal address at Noskowskiego 12-14, Poznan 61 704, Poland, represented by the Director of the Institute Prof. Dr. Marek Figlerowicz; (“**IBCH**”);
101. **DANMARKS TEKNISKE UNIVERSITET**, with legal address at Anker Engelundsvej 1 Bygning 101 A, Kgs Lyngby 2800, Denmark (“**DTU**”);
102. **LATVIJAS ORGANISKAS SINTEZES INSTITUTS**, with legal address at Aizkraukles 21, Riga Lv- 1006, Latvia (“**LIOS**”);
103. **FORSCHUNGSVERBUND BERLIN EV**, Leibniz-Forschungsinstitut fuer Molekulare Pharmakologie, with legal address at Rudower Chaussee 17, Berlin 12489, Germany, jointly represented by the Director of the Institute xxx (“**FMP**”);
104. **FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.**, with legal address at Hansastrasse 27c, München 80686, Germany acting as legal entity for and on behalf of its Fraunhofer institute ITMP (“**Fraunhofer**”);
105. **UNIVERZITA PALACKEHO V OLOMOUCI,** with legal address at Krizkovskeho 8, Olomouc 771 47, Czechia (“**UP**”**)**;
106. **UNIVERSITETET I BERGEN**, with legal address at Museplassen 1, Bergen 5020, Norway (“**UiB**”);
107. **SINTEF AS**, with legal address at Strindvegen 4, Trondheim 7034, Norway (“**SINTEF**”);
108. **INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK**, with legal address at Pawinskiego 5a, Warszawa 02 106, Poland (“**IBB PAN**”);
109. **NARODOWY INSTYTUT ONKOLOGII IM. MARII SKLODOWSKIEJ-CURIE - PANSTWOWY INSTYTUT BADAWCZY**, with legal address at Ul. W K Roentgena 5, Warszawa 02781, Poland (“**MSCNRIO**”);
110. **WARSZAWSKI UNIWERSYTET MEDYCZNY**, Department of Plant Sciences with legal address at Ul. Zwirki I Wigury 61, Warszawa 02 091, Poland (“**MUWa**”);
111. **FONDAZIONE PER L'ISTITUTO DI RICERCA IN BIOMEDICINA**, with legal address at VIA Francesco Chiesa 5, Bellinzona 6500, Switzerland (“**IRB**”);
112. **JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH**, with legal address at Leonhardstrasse 59, Graz 8010, Austria (“**JR**”);
113. **IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON**, with legal address at Soranou Efesiou 4, AthinA 115 27, Greece (“**BRFAA**”);
114. **SWISS CLINICAL TRIAL ORGANISATION**, with legal address at Effingerstrasse 35, Bern 3008, Switzerland (“**SCTO**”);
115. **[PLACEHOLDER]**
116. **UNIVERZITA PAVLA JOZEFA SAFARIKA V KOSICIACH**, with legal address at Srobarova 2, Kosice 04180, Slovakia (“**UPJS**”);
117. **UNIVERSIDADE NOVA DE LISBOA**, with legal address at Campus De Campolide, Lisboa 1099 085, Portugal (“**UNL**”);
118. **ST OLAVS HOSPITAL HF**, with legal address at OLAV KYRRES GATE 17, TRONDHEIM 7006, Norway (“**STOH**”);
119. **ISTITUTO SUPERIORE DI SANITA’**, with legal address at Viale Regina Elena 299, ROMA 00161, Italy (“**ISS**”);
120. **UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK**, a body incorporated under Charter with its place of address at at Western Road, Cork, Ireland (“**UCC**”);
121. **KKS-NETZWERK EV -NETZWERK DER KOORDINIERUNGSZENTREN FUR KLINISCHE STUDIEN**, with legal address at Alt-Moabit 96 A, Berlin 10559, Germany (“**KKSN**”);
122. **PECSI TUDOMANYEGYETEM - UNIVERSITY OF PECS**, with legal address at Vasvari Pal Utca 4, Pecs 7622, Hungary (“**UPecs**”);
123. **NARODOWY INSTYTUT KARDIOLOGII STEFANA KARDYNALA WYSZYNSKIEGO - PANSTWOWY INSTYTUT BADAWCZY**, with legal address at Ul. Alpejska 42, Warszawa 04 628, Poland (“**NIKARD**”);
124. **AIBILI ASSOCIACAO PARA INVESTIGACAO BIOMEDICA E INNOVACAO EM LUZ E IMAGEM**, established in Azinhaga de Santa Comba, Celas, COIMBRA 3000 548, Portugal (“**AIBILI**”);
125. **FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PAZ**, with legal address at PASEO DE LA CASTELLANA 261, MADRID 28046, Spain (“**FIBHULP**”);
126. **INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL**, with legal address at Ctra De Canyet S/N, Badalona Barcelona 08916, Spain (“**IGTP**”) ;
127. **INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES**, with legal address at Avenida Prof Egas Moniz, Lisboa 1649 028, Portugal (“**iMM**”);
128. **OSLO UNIVERSITETSSYKEHUS HF**, with legal address at KIRKEVEIEN 166 TARNBYGGET, OSLO 0450, Norway (**OUH**”);
129. **FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA**, with legal address at Passeig Vall D Hebron 119-129 Edificio De Recerca, Barcelona 08035, Spain (**VHIR**”);
130. **CENTRO DE CIENCIAS DO MAR DO ALGARVE**, with legal address at Universidade Do Algarve, Faro 8005 139, Portugal (“**CCMAR**”);
131. **STAZIONE ZOOLOGICA ANTON DOHRN**, with legal address at Villa Comunale, NAPOLI 80121, Italy (“**SZN**”);
132. **ASSISTANCE PUBLIQUE HOPITAUX DE PARIS**, with legal address at 3 AVENUE VICTORIA, PARIS 75000, France (“**APHP**”);
133. **HOSPICES CIVILS DE LYON,** with legal address at QUAI DES CELESTINS 3, LYON 69002, France (“**HCL**”);
134. **MEDITERRANEE INFECTION**, with legal address at 80 rue Brochier , Marseille 13005, France (“**IHU**”);
135. **UNIVERSITY OF GLASGOW**, with legal address at University Avenue, Glasgow G12 8qq, United Kingdom (“**UG**”);
136. **INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT**, with legal address at in Boulevard De Dunkerque 44 Cs 90009, Marseille 13572, France (“**IRD**);
137. **INSTITUT PASTEUR DE NOUVELLE-CALEDONIE**, secondary establishment of Institut Pasteur, with legal address at AVENUE PAUL DOUMER 11 CENTRE VILLE, NOUMEA 98845, New Caledonia, represented by its director duly autorised by delegation of the General Director of Institut Pasteur (“**IPNC**”);
138. **UNIVERZITA KARLOVA**, with legal address at OVOCNY TRH 560/5, PRAHA 1, 11636, Czechia (“**CU**”);
139. **CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR LEDEVELOPPEMENT - C.I.R.A.D. EPIC**, with legal address at Rue Scheffer 42, Paris 75016, France (“**CIRAD**”);
140. **IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE**, with legal address at South Kensington Campus Exhibition Road, London SW7 2AZ, United Kingdom (“**Imperial**”);
141. **MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV**, with legal address at in Hofgartenstrasse 8, Munchen 80539, Germany (“**MPG**”);
142. **IDRYMA TECHNOLOGIAS KAI EREVNAS**, with legal address at N Plastira Str 100, Irakleio 70013, Greece (“**FORTH**”);
143. **UNIVERZITET U NOVOM SADU, POLJOPRIVREDNI FAKULTET NOVI SAD**, with legal address at Trg Dositeja Obradovica 8, Novi Sad 21000, Serbia (“**FANS**”);
144. **[PLACEHOLDER]**
145. **INSTITUT PASTEUR DE DAKAR**, with legal address at Avenue Pasteur 36, Dakar, Senegal (“**IP Dakar**”);
146. **UNIVERSITE DES SCIENCES DES TECHNIQUES ET DES TECHNOLOGIES DE BAMAKO**, with legal address at in Quartier ACI 2000 Rue 405 Porte 359, Bamako Bp1805, Mali (**USTTB**”);
147. **WAGENINGEN UNIVERSITY**, Department of Plant Sciences, with legal address at Droevendaalsesteeg 4, Wageningen 6708 PB, Netherlands (“**WU**”);
148. **MINISTERE DE LA SANTE ET DE L'HYGIENE PUBLIQUE**, with legal address at, 10278

Ouagadougou, Burkina Faso ("**CNFRP**”);

1. **POLO D'INNOVAZIONE DI GENOMICA, GENETICA E BIOLOGIA SRL**, with legal address at VIA Fiorentina 1 c/o TLS.Ed.36, Siena 53100, Italy (“**POLOGGB**”);
2. **CENTRO AGRICOLTURA E AMBIENTE GIORGIO NICOLI SRL**, with legal address at Via Sant’ Agata 835 , Crevalcore 40014, Italy (“**CAA**”);
3. **TROPIQ HEALTH SCIENCES**, with legal address at Transistorweg 5 2e Verdiepin, Nijmegen 6534 at, Netherlands (“**TROPIQ**”);
4. **AVIA-GIS NV**, with legal address at Risschotlei 33, Zoersel 2980, Belgium (“**Avia**”);
5. **HITS GGMBH**, with legal address at Schloss Wolfsbrunnenweg 35, Heidelberg 69118, Germany (“**HITS**”);
6. **JRC - JOINT RESEARCH CENTRE- EUROPEAN COMMISSION**, with legal address at Rue de la Loi 200, Brussels 1049, Belgium (“**JRC**”).
7. **SCUOLA UNIVERSITARIA PROFESSIONALE DELLA SVIZZERA ITALIANA** with legal address at Stabile Le Gerre, Via Pobiette 11, 6928 Manno, Switzerland, (“**SUPSI**”)

hereinafter, jointly or individually, referred to as ”**Parties**” or ”**Party**”

relating to the Project entitled “*Integrated Services for Infectious Diseases Outbreak Research Project*” in short “**ISIDORe**”

hereinafter referred to as “**Project**”

**WHEREAS:**

The Parties, having considerable experience in the field concerned, have submitted a proposal for the Project to the Granting Authority as part of Horizon Europe – the Framework Programme for Research and Innovation (2021-2027).

The Parties wish to specify or supplement binding commitments among themselves in addition to and in accordance with the provisions of the specific Grant Agreement with Grant number 101046133, to be signed by the Parties and the Granting Authority (hereinafter “**Grant Agreement**”).

The Parties are aware that this Consortium Agreement is based upon the [DESCA model consortium](http://www.desca-agreement.eu/)  [agreement.](http://www.desca-agreement.eu/)

NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

# Definitions

 **Definitions**

Words beginning with a capital letter shall have the meaning defined either herein or in the Horizon Europe Regulation or in the Grant Agreement including its Annexes.

 **Additional Definitions**

**“Access Provider” or “AP”** means a facility or department of a Party granting TNA access to Parties or Third Parties (the case being) as users to its services, or conducting JRA within the framework of the Project.

**“Consortium Body”** means any management body described in Section [6](#_bookmark8) (Governance Structure) of this Consortium Agreement.

“**Consortium Budget**” means the agreed budget defined in the Grant Agreement including any updates to this budget agreed to by the Governing Board.

**“Consortium Plan”** means the description of the Action and the related Consortium Budget as first defined in the Grant Agreement and which may be updated by the Governing Board.

“**Executive Committee**” shall have the meaning as set out in Section [6.4](#_bookmark15) of this Consortium Agreement. “**Days**” shall mean calendar days.

**“Defaulting Party”** means a Party which the Governing Board has identified to be in breach of this Consortium Agreement and/or the Grant Agreement as specified in Section [4.2](#_bookmark5) of this Consortium Agreement.

“**Entities under the same Control**” shall mean any legal entity that is under the direct or indirect control of a Party, or under the same direct or indirect control as a Party, or that is directly or indirectly controlling a Party. Control may, in particular, take either of the following forms:

1. the direct or indirect holding of more than 50 % of the nominal value of the issued share capital in the legal entity concerned, or of a majority of the voting rights of the shareholders or associates of that entity;
2. the direct or indirect holding, in fact or in law, of decision-making powers in the legal entity concerned.

The following relationships between legal entities shall not in themselves be deemed to constitute controlling relationships:

* 1. the same public investment corporation, institutional investor or venture-capital company has a direct or indirect holding of more than 50 % of the nominal value of the issued share capital or a majority of voting rights of the shareholders or associates;
  2. the legal entities concerned are owned or supervised by the same public body

“**Fair and Reasonable conditions**”: means appropriate conditions, including possible financial terms or royalty-free conditions, taking into account the specific circumstances of the request for access, for example the actual or potential value of the results or background to which access is requested and/or the scope, duration or other characteristics of the exploitation envisaged.

“**Governing Board**” shall have the meaning as set out in Section [6.2](#_bookmark9) of this Consortium Agreement.

**“Granting Authority”** means the body awarding the grant for the Project.

“**Independent Advisory Boards**” shall have the meaning as set out in Section [6.5](#_bookmark18) of the Consortium Agreement.

“**International Organisation**” means an organisation and its subordinate bodies governed by public international law, or any other body which is set up by, or on the basis of, an agreement between two or more countries.

“**Joint Research Activities**” or “**JRA**” means those research activities meant to improve and/or expand the catalogue of services and which are conducted by certain Parties following an internal call for proposals as launched by WP2 (after the call topics were proposed by the Scientific Advisory Board and reviewed by the Executive Committee) and as governed by a separate JRA agreement according to a template that shall be approved by the Governing Board and shall automatically be part of the Consortium Agreement as Attachment 7 without a formal consortium agreement amendment. For the avoidance of doubt, the use of this template is optional and shall only be legally binding between the Parties if agreed in writing and executed by the duly authorised signatories of each Party.

“**Mandate”** shall have the meaning ascribed to it in Clause [7](#_bookmark23) of this Consortium Agreement.

**“Needed”** means:

*For the implementation of the Project:*

Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks assigned to the recipient Party would be technically or legally impossible, significantly delayed, or require significant additional financial or human resources.

*For Exploitation of own Results:*

Access Rights are Needed if, without the grant of such Access Rights, the Exploitation of own Results would be technically or legally impossible.

“**Project Management Team**” or “**PMT**” shall have the meaning as set out in Section [6.5](#_bookmark17) of this Consortium Agreement.

“**Research Infrastructure**” or “**RI**” means facilities that provide resources and services for the research communities to conduct research and foster innovation in their fields and that are a Party to this Consortium Agreement.

**“Software”** means sequences of instructions to carry out a process in, or convertible into, a form executable by a computer and fixed in any tangible medium of expression.

“**Third Party**” means a legal entity or person which is not a party to this Consortium Agreement, including a legal entity or person only providing resources to a Party.

**“Trans-National Access”** or **“TNA**” means the access to Access Provider’s services granted by Access Providers to Parties and/or Third Parties as users following TNA calls for proposals as launched by WP2 (after the call topics were proposed by the Strategic Advisory Board and reviewed by the Executive Committee), upon the conditions as determined by the Access Provider(s) in accordance with the

European Charter of Access for Research Infrastructures1, subject to the relevant terms and conditions as set out in the Consortium Agreement and the Grant Agreement.

# Purpose

The purpose of this Consortium Agreement is to specify with respect to the Project the relationship among the Parties, in particular concerning the organisation of the work between the Parties, the management of the Project and the rights and obligations of the Parties concerning inter alia liability, Access Rights and dispute resolution.

# Entry into force, duration and termination

 **Entry into force**

An entity becomes a Party to this Consortium Agreement by signature of this Consortium Agreement by

1. duly authorised representative(s).

This Consortium Agreement shall have effect from the Effective Date identified at the beginning of this Consortium Agreement.

An entity becomes a new Party to the Consortium Agreement upon signature of the accession document (Attachment 02 of this Consortium Agreement) by the new Party and the Coordinator. Such accession shall have effect from the date identified in the accession document.

 **Duration and termination**

This Consortium Agreement shall continue in full force and effect until complete fulfilment of all obligations undertaken by the Parties under the Grant Agreement and under this Consortium Agreement.

However, this Consortium Agreement or the participation of one or more Parties to it may be terminated earlier in accordance with the terms of this Consortium Agreement.

If

* + the Grant Agreement is not signed by the Granting Authority or a Party, or
  + the Grant Agreement is terminated, or
  + a Party's participation in the Grant Agreement is terminated,

this Consortium Agreement shall automatically terminate in respect of the affected Party/ies, subject to the provisions surviving the expiration or termination under Section [3.3](#_bookmark3) of this Consortium Agreement.

 **Survival of rights and obligations**

The provisions relating to Access Rights (Section 10.4.3) Dissemination (Section 9.4) and Non- disclosure Information (Section 11.2) , for the time period mentioned therein, as well as for liability, applicable law and settlement of disputes and any other provision by its nature intended to survive

1 European Commission, Directorate-General for Research and Innovation, *European charter of access for research infrastructures : principles and guidelines for access and related services*, Publications Office, 2016, [**https://data.europa.eu/doi/10.2777/524573**](https://data.europa.eu/doi/10.2777/524573)

termination or expiration of this Consortium Agreement shall survive the expiration or termination of this Consortium Agreement.

Termination shall not affect any rights or obligations of a Party leaving the Project incurred prior to the date of termination, unless otherwise agreed between the Governing Board and the leaving Party. This includes the obligation to provide all necessary input, deliverables and documents for the period of its participation.

# Responsibilities of Parties

 **General principles**

Each Party undertakes to take part in the efficient implementation of the Project, and to cooperate, perform and fulfil, promptly and on time, all of its obligations under the Grant Agreement and this Consortium Agreement as may be reasonably required from it and in a manner of good faith as prescribed by applicable law.

Each Party undertakes to notify promptly the Granting Authority and the Governing Board simultaneously, in accordance with the governance structure of the Project, of any significant information, fact, problem or delay likely to affect the Project.

Each Party shall promptly provide all information reasonably required by a Consortium Body or by the Coordinator to carry out its tasks and shall responsibly manage the access of its employees to the EU Funding & Tenders Portal.

Each Party shall take reasonable measures to ensure the accuracy of any information or materials it supplies to the other Parties.

The Parties may, where necessary in view of the Project and this Consortium Agreement, conclude separate (JRA or TNA-) agreements to set out their specific duties, roles, and responsibilities in respect to such JRA and TNA projects. Such separate agreements may not contain provisions contradicting this Consortium Agreement or limiting the rights already granted to the Parties under this Consortium Agreement. In case of issues on interpretation of the provisions in such separate agreements, the provisions of such separate agreements will be interpreted in the light of the provisions of this Consortium Agreement.

For the avoidance of any doubt, the responsibilities and the role of the Parties with respect to the performance of clinical studies related activities shall be subject to separate agreements governing the execution of such clinical studies. Such separate agreements may not contain provisions contradicting this Consortium Agreement or limiting the rights already granted to the Parties under this Consortium Agreement. In case of issues on interpretation of the provisions in such separate agreements, the provisions of such separate agreements will be interpreted in the light of the provisions of this Consortium Agreement.

 **Breach**

In the event that the Governing Board identifies a breach by a Party of its obligations under this Consortium Agreement and/or the Grant Agreement (e.g. improper implementation of the Project), the Coordinator or, if the Coordinator is in breach of its obligations, the Party appointed by the Governing

Board, will give formal notice to such Party requiring that such breach will be remedied within 30 Days from the date of receipt of the written notice by the Coordinator or the Party (the case being).

If such breach is substantial and is not remedied within that period or is not capable of remedy, the Governing Board may decide to declare the Party to be a Defaulting Party and to decide on the consequences thereof which may include termination of its participation to the Project.

 **Involvement of Third Parties**

A Party that enters into a subcontract or otherwise involves Third Parties (including but not limited to Affiliated Entities or other participants) in the Project remains responsible for carrying out its relevant part of the Project and for such Third Party’s compliance with the provisions of this Consortium Agreement and of the Grant Agreement. Such Party has to ensure that the involvement of Third Parties does not affect the rights and obligations of the other Parties under this Consortium Agreement and the Grant Agreement.

 **Specific responsibilities regarding data protection**

Where necessary, the Parties shall cooperate in order to enable one another to fulfil legal obligations arising under applicable data protection laws and/or regulations (including the *Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data* – “GDPR” and/or relevant national data protection laws and/or internal data protection legal framework applicable to said Party/ies, within the scope of the performance and administration of the Project and of this Consortium Agreement.

Additional guidance on the management and processing of Personal Data in the scope of the Project shall be detailed in deliverable D.3.2 “Data Management Plan”.

In particular, the Parties shall, where necessary in view of the Project and this Consortium Agreement, conclude separate data processing, data sharing and/or joint controller agreement(s) before any data processing or data sharing takes place.

# Liability towards each other

 **No warranties**

In respect of any information or materials (incl. Results and Background) supplied by one Party to another under the Project, no warranty or representation of any kind is made, given or implied as to the sufficiency or fitness for purpose nor as to the absence of any infringement of any proprietary rights of Third Parties.

Therefore:

* the recipient Party shall in all cases be entirely and solely liable for the use to which it puts such information and materials, and
* no Party granting Access Rights shall be liable in case of infringement of proprietary rights of a Third Party resulting from any other Party (or its entities under the same control) exercising its Access Rights.

 **Limitations of contractual liability**

* + 1. No Party shall be responsible to any other Party for any indirect or consequential loss or similar damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts, except in case of breach of confidentiality.
    2. If a Party’s own share of the total estimated costs in the Project is >15.000 EUR at the time of the facts that incur liability, such Party’s aggregate liability towards the other Parties collectively shall be limited to once the Party’s own share of the total estimated costs of the Project as identified in Annex 2 of the Grant Agreement as may be updated by reallocations of budget to- or from that Party in accordance with the provisions of the Grant Agreement and Consortium Agreement. If a Party’s own share of the total estimated costs is < (or equal to) 15,000 EUR at the time of the facts that incur liability, said Party’s liability towards the other Parties collectively shall be limited to 15,000 EUR. For the avoidance of doubt, a Party’s ‘own’ share of the total estimated costs as referred to in this clause does not include any budgets of such Party that are identified as ‘ring-fenced’ in Table 3.1h of Annex 1 – part B to the Grant Agreement.
    3. A Party’s liability shall not be limited under either of the two foregoing paragraphs to the extent such damage was caused by a wilful act or gross negligence or to the extent that such limitation is not permitted by applicable law.

Nothing in this Consortium Agreement may be construed to limit (i) the right of any Party to bring an action for damages against any Third Party, including claims for indirect, special or consequential damages, based on any acts or omissions of such Third Party, and (ii) the liability of a Party for personal injury or death resulting from the negligence of such Party or its employees, officers, directors, agents, or representatives (as applicable).

 **Damage caused to Third Parties**

Each Party shall be solely liable for any loss, damage or injury to Third Parties resulting from the performance of the said Party’s obligations by it or on its behalf under this Consortium Agreement or from its use of Results or Background.

 **Force Majeure**

No Party shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its obligations under the Consortium Agreement by Force Majeure.

Each Party will notify the Governing Board and all Parties that are impacted of any Force Majeure without undue delay. If the consequences of Force Majeure for the Project are not overcome within 6 weeks after such notice, the transfer of tasks – if any – shall be decided by the Governing Board.


 **Export control**

No Party shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its obligations under the Consortium Agreement due to a restriction resulting from import or export laws and regulations and/or any delay of the granting or extension of the import or export license or any other governmental authorisation, provided that the Party has used its reasonable efforts to fulfil its tasks and to apply for any necessary license or authorisation properly and in time.

Each Party will notify the Governing Board of any such restriction without undue delay. If the consequences of such restriction for the Project are not overcome within 6 weeks after such notice, the transfer of tasks – if any – shall be decided by the Governing Board.

Notwithstanding the foregoing, Parties that are International Organisations may – by virtue of the privileges and immunities accorded to them by International law - be exempt from certain of such prohibitions or restrictions on imports and exports as part of their official activities.

# Governance structure



 **General structure**

The organisational structure of the consortium shall comprise the following Consortium Bodies:

* + 1. The **Governing Board (“GB”)** is the decision-making body of the consortium as set out in Section [6.2](#_bookmark9) of this Consortium Agreement.
    2. The **Coordinator** is the legal entity as set out in Section [6.3](#_bookmark13) of this Consortium Agreement acting as the intermediary between the Parties and the Granting Authority. The Coordinator shall, in addition to its responsibilities as a Party, perform the tasks assigned to it as Coordinator as described in the Grant Agreement and this Consortium Agreement.
    3. The **Executive Committee (“ExCom”)** is the supervisory body for the Project and implementation of the decisions taken by the Governing Board as set out in Sections [6.4](#_bookmark15) of this Consortium Agreement.
    4. **The Project Management Team (“PMT”)** will coordinate the day-to-day management, including the administrative, legal, financial and reporting activities to the European Commission, as set out in Sections [6.5](#_bookmark17) of this Consortium Agreement.
    5. The **Strategic Advisory Board (“StAB”)** is part of the Independent Advisory Board and provides instructions on the priority of Trans-National Access (“**TNA**”) topics for calls for proposals set out in Sections [6.6.2.1](#_bookmark19) of this Consortium Agreement.
    6. The **Scientific Advisory Board (“SciAB”)** is part of the Independent Advisory Board and provides instructions on the Joint-Research Activities (“**JRA**”) topics for calls for proposals as set out in Sections [6.6.2.2](#_bookmark20) of this Consortium Agreement.
    7. The **Ethics Advisory Board (“EthAB”)** is part of the Independent Advisory Board and monitors how the Project handles ethics issues as set out in Sections [6.6.2.3](#_bookmark21) of this Consortium Agreement.
    8. The **Security Advisory Board (“SecAB”)** is part of the Independent Advisory Board and monitors how the Project handles security issues set out in Section [6.6.2.4](#_bookmark22) of this Consortium Agreement.

 **Governing Board**

* + 1. **Members**

The Governing Board shall consist of one representative of each of the following Research Infrastructures and networks (“**RI**”) (hereinafter each referred to as “**Governing Board Member**”).

* + - * ERINHA,
      * EVA, duly represented by AMU
      * VetBioNet, duly represented by INRAE
      * Infravec, duly represented by IP
      * Sonar-Global, duly represented by IP
      * MIRRI, duly represented by Uminho
      * Transvac, duly represented by EVI
      * Instruct,
      * EuBi,
      * EU-OS
      * ECRIN
      * EATRIS
      * BBMRI
      * INFRAF
      * EMBRC
      * Elixir, duly represented by EMBL
      * EMERGEN, duly represented by ANRS, in its turn duly represented by INSERM
      * Inserm-Transfert

The Project will rely on the RIs that designed the Project to constitute the Governing Board where the RIs of the core consortium are represented and act on behalf of the other Parties. Each Governing Board Member shall be deemed to be duly mandated and authorised to deliberate, negotiate and decide on all Governing Board responsibilities on behalf of the Parties and the Parties acknowledge that they are duly represented through the participation of (at least one of) the above RIs in the Governing Board as set out in Attachment 9 List of Parties and their AP’s under the RI’s that represent them in the Governing Boardto this Consortium Agreement.

The Coordinator shall chair all meetings of the Governing Board with the assistance of the PMT, unless decided otherwise by the Governing Board (“**Chairperson of the Governing Board**”).

The Parties agree to abide by all decisions of the Governing Board.

This does not prevent the Parties from submitting a dispute for resolution in accordance with the provisions of settlement of disputes in Article 12.8 of this Consortium Agreement.

* + 1. **Representation in meetings**

Any Governing Board Member:

* should be present or represented at any meeting;
* may appoint a substitute or a proxy to attend and vote at any meeting;
* and shall participate in a cooperative manner in the meetings.
  + 1. **Responsibilities of the Governing Board**

The Governing Board shall be free to act on its own initiative to formulate proposals and take decisions in accordance with the procedures set out herein.

The following decisions shall be taken by the Governing Board:

- Content, finances and intellectual property rights regarding the Project:

* Proposals for changes to Annexes 1 and 2 of the Grant Agreement to be agreed by the Granting Authority
* Changes to the Consortium Plan;
* Subject to Clause 10.1.2 of the Consortium Agreement, Modifications or withdrawal of Background as initially provided by the Parties in Attachment 1: Background included of this Consortium Agreement (Background Included – which is added automatically to this Consortium Agreement)
* Additions to Attachment 3: List of Third Parties for simplified transfer according to Section 9.3.2. of this Consortium Agreement (List of Third Parties for simplified transfer according to Section **Error! Reference source not found.**)

Evolution of the Consortium

* Entry of a new Party to the Project and approval of the settlement on the conditions of the accession of such a new Party
* Withdrawal of a Party from the Project and the approval of the settlement on the conditions of the withdrawal
* Identification of a breach by a Party of its obligations under this Consortium Agreement or the Grant Agreement
* Declaration of a Party to be a Defaulting Party
* Remedies to be performed by a Defaulting Party
* Termination of a Defaulting Party’s participation in the consortium and measures relating thereto
* Proposal to the Granting Authority for a change of the Coordinator
* Proposal to the Granting Authority for suspension of all or part of the Project
* Proposal to the Granting Authority for termination of the Project and the Consortium Agreement Appointments

On the basis of the Grant Agreement, the appointment, if necessary, of:

* External Expert Advisors to the:
  + Strategic Advisory Board (“**StAB**”);
  + Scientific Advisory Board (“**SciAB**”); o Ethics Advisory Board (“**EthAB**”); and o Security Advisory Board (“**SecAB**”).

In the case of abolished tasks as a result of a decision of the Governing Board, Governing Board Members shall rearrange the tasks of the Parties concerned. Such rearrangement shall take into consideration any prior legitimate commitments which cannot be cancelled.

* + 1. **Preparation and organisation of meetings**
       1. Convening meetings:

The Chairperson of the Governing Board shall, with the assistance of the PMT, convene ordinary meetings of the Governing Board at least once every six months and shall also convene extraordinary meetings at any time upon written request of any Governing Board Member.

Meetings of the Governing Board can be held face-to-face at venues to be agreed or may also be held by tele- or videoconference or other telecommunication means allowing votes to be submitted verbally. In case of meetings held by tele- or videoconference or other telecommunication means, the Parties agree that these meetings may be recorded for internal Governing Board purposes upon request of one of the Governing Board members. In such case, it shall be clearly indicated at the beginning of the meeting that such meeting will be recorded, allowing the participants to reasonably object thereto

* + - 1. Notice of a meeting

The Chairperson of the Governing Board, shall, with the assistance of the PMT, give written notice of a meeting to each Governing Board Member as soon as possible and no later than 14 Days preceding an ordinary meeting and 7 Days preceding an extraordinary meeting. For the avoidance of doubt, notice of upcoming meetings of the Governing Board and their agendas will be shared through the all- [partners@isidore-project.eu](mailto:partners@isidore-project.eu) mailing list to which all Parties may sign up to by contacting the Project Management Team.

* + - 1. Sending the agenda:

The Chairperson of the Governing Board shall, with assistance of the PMT, prepare and send each Governing Board Member an agenda no later than 14 Days preceding the ordinary meeting, or 7 Days before an extraordinary meeting.

* + - 1. Adding agenda items:

Any agenda item requiring a decision by the Governing Board Members must be identified as such on the agenda.

Any Governing Board Member may add an item to the original agenda by written notice to all of the other Governing Board Members no later than 7 Days preceding the ordinary meeting and 2 Days preceding an extraordinary meeting.

During a meeting of the Governing Board, the Members present or represented can unanimously agree to add a new item to the original agenda.

* + - 1. Any experts or qualified persons may be invited by any member of the Governing Board to attend meetings of the Governing Board with a role of non-voting advisor. Prior to their first participation in a meeting of the Governing Board or their first receipt of Confidential Information, any third party expert or qualified person shall first enter into an Advisory Agreement with the Coordinator, on behalf of the Parties, in accordance with Clause [7.](#_bookmark23) This requirement to enter into an Advisory Agreement shall not apply to the extent such expert or qualified person is (i) an employee, agent, consultant, or sub- contractor of a Party which is under confidentiality obligations at least equivalent to the confidentiality obligations provided herein and which is required to assign any Intellectual Property to such Party in order for the latter to comply with its obligations under this Consortium Agreement; or (ii) a representative of a governmental or administrative agency under confidentiality obligations imposed by law or regulations.
    1. **Voting rules and quorum**
       1. In order for a Governing Board meeting to be quorate there shall be present no fewer than seventy-five (75%) percent of the Members.
       2. If the quorum is not reached, the Chairperson of the Governing Board, with assistance of the PMT, shall convene another ordinary meeting within 15 Days. In order for the Governing Board to be quorate in this new meeting there shall be present no fewer than sixty-six percent (66%) of the Members.
       3. If the quorum is not reached once more, the chairperson of the Governing Board shall with the assistance of the PMT, convene an extraordinary meeting which shall be entitled to decide if more than fifty percent (50%) of Members is present or represented.
       4. Each Governing Board Member present or represented in the meeting shall have one vote. However, a Governing Board Member which the Governing Board has declared according to Section [4.2](#_bookmark5) to be a Defaulting Party may not vote.
       5. The Governing Board will strive to reach decisions by consensus. However, if consensus cannot be reached, decisions shall be taken by a majority of sixty-six percent (66%) of the votes cast.
       6. Decisions will only be binding once the relevant part of the minutes has been accepted according to Section [6.2.8.](#_bookmark12)
    2. **Veto rights**
       1. A Governing Board Member may exercise a veto with respect to the corresponding decision or relevant part of the decision, to the extent it - can demonstrate that (i) its own work, (ii) time for performance, (iii) costs, with the exception of the re-allocation of the flexible TNA budget as set out in Section [8.1.5](#_bookmark25) of this Consortium Agreement, (iv) liabilities, (v) intellectual property rights or (vi) other legitimate interests, (vii) or that the work, time for performance, costs (with the exception of the re-allocation of the flexible TNA budget) liabilities, intellectual property rights or other legitimate interests of any of the Parties that it represents as RI, would be severely affected by a decision of the Governing Board. Such veto shall however be reasonably and duly justified by the Party exercising it.
       2. When the decision is foreseen on the original agenda, a Governing Board Member may only veto such a decision during the meeting.
       3. When a decision has been taken on a new item added to the agenda before or during the meeting, a Governing Board Member may veto such decision during the meeting or within 15 Days after receipt of the draft minutes of the meeting. Such veto shall be reasonably and duly justified by the Party exercising it.
       4. When a decision has been taken without a meeting (i.e. via circulation procedure as set out in section [6.2.7](#_bookmark11)) a Governing Board Member may veto such decision for the reasons as set out in Clause 6.2.6.1 of this Consortium Agreement within 10 Days after receipt of the written notice by the chairperson of the outcome of the vote. Such veto shall be reasonably and duly justified by the Party exercising it.
       5. In case of exercise of veto, the Governing Board Members shall make every effort to resolve the matter amicably which occasioned the veto to the general satisfaction of all Governing Board Members.
       6. A Governing Board Member may neither veto:
          1. decisions relating to its or any of the Parties that it represents as Ris’ identification to be in breach of its (or any of the Parties that it represents as Ris’) obligations nor to its identification (or the identification of any of the Parties that it represents as Ris’) as a Defaulting Party.
          2. when it (or the Party that it represents as RI) is considered as a Defaulting Party, decisions relating to its (or any of the Parties that it represents as Ris’) participation and termination in the consortium or the consequences of them
          3. allocation of the flexible TNA budget in compliance with the Consortium Plan and as set out in Section [8.1.5](#_bookmark25) of this Consortium Agreement
          4. Allocation of the JRA budget as set out in Section 8.2.5.1 of this Consortium Agreement.
       7. A Governing Board Member (or any of the Parties that it represents as RI) requesting to leave the consortium may not veto decisions relating thereto. For the avoidance of doubt this does not imply that a Party wishing to leave the Consortium can be forced to stay.
    3. **Decisions without a meeting – circulation procedure**

Any decision may also be taken without a formal Governing Board meeting if

1. the Coordinator circulates to all Governing Board Members a suggested decision in hard copy or by email with a deadline for the Governing Board Members to respond (e-mail suffice) of at least 10 Days after circulation of the suggested decision by the Coordinator; and
2. the decision is considered to be agreed if a majority of 66 % of all Governing Board Members have approved such decision.

The Chairperson of the Governing Board, shall, with the assistance of the PMT, inform all the Governing Board Members of the outcome of the vote.

The decision will be binding after the Coordinator sends a notification thereof to all Governing Board Members. The Coordinator will keep records of the votes and make them available to the Parties on request.

* + 1. **Minutes of meetings**
       1. The Chairperson of the Governing Board shall, with assistance of the PMT produce minutes of each meeting which shall be the formal record of all decisions taken. The Chairperson of the Governing Board shall with assistance of the PMT send draft minutes (e-mail suffice) to all Governing Board Members within 7 Days of the meeting.
       2. The minutes shall be considered as accepted if, within 10 Days from circulation by the Chairperson (with the assistance of the PMT), no Governing Board Member has sent an objection (e-mail suffice) to the Chairperson of the Governing Board with respect to the accuracy of the draft minutes by written notice.
       3. The Chairperson of the Governing Board, with assistance of the PMT shall make the accepted minutes available to all the Parties (e-mail suffice, or make available in shared folder), and to the Coordinator, who shall retain copies of them.

 **Coordinator**

* + 1. **Responsibilities of the Coordinator**

The Coordinator shall be the intermediary between the Parties and the Granting Authority and shall perform all tasks assigned to it as described in the Grant Agreement and in this Consortium Agreement.

In particular, the Coordinator shall be responsible for:

* monitoring compliance by the Parties with their obligations under this Consortium Agreement and the Grant Agreement
* keeping the address list of Parties and other contact persons updated and available
* collecting, reviewing to verify consistency and submitting reports, other deliverables (including financial statements and related certification) and specific requested documents to the Granting Authority
* with the assistance of the PMT; preparing the meetings, proposing decisions and preparing the agenda of Governing Board meetings, chairing the meetings, preparing the minutes of the meetings and monitoring the implementation of decisions taken at meetings
* transmitting promptly documents and information connected with the Project to any other Party concerned
* administering the financial contribution of the Granting Authority and fulfilling the financial tasks described in Section [8.2](#_bookmark26)
* providing, upon request, the Parties with official copies or originals of documents that are in the sole possession of the Coordinator when such copies or originals are necessary for the Parties to present claims.

If one or more of the Parties is late in submission of any Project deliverable as listed in Annex 2 of the Grant Agreement, the Coordinator may nevertheless submit the other Parties’ Project deliverables and all other documents required by the Grant Agreement to the Granting Authority in time.

* + 1. If the Coordinator fails in its coordination tasks, the Governing Board may propose to the Granting Authority to change the Coordinator.
    2. The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium, unless explicitly stated otherwise in the Grant Agreement or this Consortium Agreement.
    3. The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium Agreement and in the Grant Agreement.

#### Executive Committee

* + 1. **Members**

The Executive Committee shall consist of the Project’s work pack leaders and the work-pack co-leaders. The Coordinator shall chair the Executive Committee (“**Chairperson of the Executive Committee**”) .

* + 1. **Representation in Meetings**

Any Executive Committee Member:

* + - * should be present or represented at any meeting;
      * may appoint a substitute or a proxy to attend and vote at any meeting;
      * and shall participate in a cooperative manner in the meetings.
    1. **Responsibilities of the Executive Committee**

The Executive Committee shall be responsible for the preparation of decisions with respect to policies and decision making in relation to the overall management of the Project, as well as for the implementation of the decisions of the Governing Board, the day-to-day operations and the initial arbitration of any disputes between the Parties relating to the execution of the Project, including mitigating any conflicts of interest identified by any of the Parties. The Executive Committee shall be responsible for reviewing recommendations made by the StAB on TNA topics for calls for proposals, as well as the recommendations made by the SciAB on JRA topics for proposals in preparation of the respective Governing Board decisions.

* + 1. **Preparation and organisation of meetings**
       1. Convening meetings:

The Chairperson of the Executive Committee shall, with the assistance of the PMT, convene ordinary meetings of the Executive Committee at least once every 4 months and shall also convene extraordinary meetings at any time upon written request of any Executive Committee Member.

* + - 1. Notice of a meeting

The Chairperson of the Executive Committee shall with the assistance of the PMT, give written notice of a meeting to each Executive Committee Member as soon as possible and no later than 7 Days preceding a meeting.

* + - 1. Any experts or qualified persons may be invited by any member of the Executive Committee to attend meetings of the Executive Committee with a role of non-voting advisor. Prior to their first participation in a meeting of the Executive Committee or their first receipt of Confidential Information, any third-party expert or qualified person shall first enter into an Advisory Agreement with the Coordinator, on behalf of the Parties, in accordance with Clause [7.](#_bookmark23) This requirement to enter into an Advisory Agreement shall not apply to the extent such expert or qualified person is (i) an employee, agent, consultant, or sub-contractor of a Party which is under confidentiality obligations at least equivalent to the confidentiality obligations provided herein and which is required to assign any Intellectual Property to such Party in order for the latter to comply with its obligations under this Consortium Agreement; or (ii) a representative of a governmental or administrative agency under confidentiality obligations imposed by law or regulations.
    1. **Voting rules and quorum**
       1. In order for an Executive Committee meeting to be quorate there shall be present no fewer than seventy-five (75) percent of the Members.
       2. If the quorum is not reached, the Chairperson of the Executive Committee, with assistance of the PMT shall convene another ordinary meeting within 15 Days. In order for the Executive Committee to be quorate in this new meeting, there shall be present no fewer than sixty-six percent (66%) of the Members of the Executive Committee.
       3. If the quorum is not reached once more, the Chairperson of the Executive Committee shall with the assistance of the PMT, convene an extraordinary meeting which shall be entitled to decide if fifty percent (50%) of Members is present or represented.
       4. Each Executive Committee Member present or represented in the meeting shall have one vote.
       5. The Executive Committee will strive to reach a decision by consensus. However, if consensus cannot be reached decisions shall be taken by a majority of 66 % of the votes cast.
    2. **Executive Committee decisions without a meeting – circulation procedure**

Decisions may be taken by the Executive Committee outside of an Executive Committee meeting with the application of the procedure as set out in Section [6.2.7](#_bookmark11) of this Consortium Agreement.

 **Project Management Team (“PMT”)**

* + 1. The PMT will coordinate the day-to-day management, including the administrative, legal, financial and reporting activities to the European Commission.
    2. The PMT will be composed of representatives of the Coordinator and Inserm -Transfert.

 **Independent Advisory Boards**

* + 1. **Boards**

A strategic Advisory Board (StAB), Scientific Advisory Board (SciAB), Ethics Advisory Board (EthAB) and a Security Advisory Board (SecAB) will be appointed and steered by the Governing Board. These independent Advisory Boards shall assist and facilitate the decisions made by the Governing Board and are composed of external experts (and the case being representatives of the Parties).

* + 1. **Responsibilities**
       1. The Strategic Advisory Board (“**StAB”)** is the advisory board to provide advice on the priority of Trans-National Access (“TNA”) topics for calls for proposals. The StAB will make recommendations on TNA topics for calls for proposals based on major trends and priorities in the field of epidemic-prone pathogens.
       2. The Scientific Advisory Board (“**SciAB**”) is the advisory board intended to represent the User communities and will provide advice on the Joint-Research Activities (“JRA”) topics for calls for proposals to improve or extend the ISIDORe catalogue of services.
       3. The Ethics Advisory Board (“**EthAB**”) is the advisory board composed of minimum 3 (three) experts in clinical studies, animal welfare, and data protection that monitors how the Project handles ethics issues. The EthAB will monitor and report on the Project’s compliance with all relevant ethical regulations and standards
       4. The Security Advisory Board (“**SecAB**”) is the advisory board composed of up to 5 (five) experts that monitors how the Project handles security issues. The SecAB reviews the project deliverables, evaluates the sensitivity of the information that they contain and, if necessary, proposes timely measures for preventing the misuse of such information. The SecAB will take all necessary measures for the protection of such sensitive information through the whole duration of the project

 **Non-disclosure agreements**

The Coordinator will ensure that no later than 30 Days after their nomination or before any Confidential Information will be exchanged/disclosed, whichever date is earlier, any third party expert or qualified person shall first enter into an Advisory Agreement in accordance with Clause [7](#_bookmark23) of this Consortium Agreement. This requirement to enter into an Advisory Agreement does not apply to the extent such expert or qualified person is (i) an employee, agent, consultant, or Sub-Contractor of a Party which is under confidentiality obligations at least equivalent to the confidentiality obligations provided herein and which is required to assign any intellectual property to such Party in order for the latter to comply with its obligations under this Consortium Agreement; (ii) a representative of a governmental or administrative agency under confidentiality obligations imposed by law or regulations or (iii) a member to the Scientific Advisory Board with whom a non-disclosure agreement has already been entered into before the last date of signature of this Consortium Agreement.

# Mandate

7.1 To facilitate the work of the Governing Board and Executive Committee, and by way of exception to Section [6.3.3](#_bookmark14) of this Consortium Agreement, to allow for an easier engagement in discussions with Third Parties in fulfilment of their obligations under this Consortium Agreement, the Parties hereby give the following Mandate to the Coordinator to act for and on behalf of the Parties and to take the following legal acts and measures as it deems necessary for the implementation of the Project, provided that it acts in compliance with the applicable laws and regulations and the provisions of the Grant Agreement and this Consortium Agreement:

7.1.1 negotiate and conclude a one-sided confidential disclosure agreement (“**one-sided CDA**”), materially in the form as attached to this Consortium Agreement in

Attachment 4: Contract under mandate: One-Sided CDA with a Third Party regarding disclosure of this Consortium Agreement and disclosure of relevant Confidential information in order to engage in discussions with such specific Third Party that has expressed an interest in (i) providing independent advice to any of the various governance bodies in the Project as such, (ii) acceding to the project in compliance with the Grant Agreement and this Consortium Agreement, or (iii) a collaboration between the Project and such specific Third Party, other projects or other Third Party collaborations; provided, however, that the Governing Board members have been informed at least one week in advance about the engagement in discussions with such Third Party by prior written notice (enclosing the CDA proposed for signature, detailing the types of Confidential Information to be disclosed and the purpose of disclosure) from the Coordinator (e-mail suffice), potentially with the assistance of the PMT and have not objected to the conclusion of such CDA in writing to the Coordinator within ten (10) Days after receipt of such notification (e-mail for notification suffice). The template CDA is enclosed in

Attachment 4: Contract under mandate: One-Sided CDA.

7.1.2. negotiate and conclude a two-sided confidential disclosure agreement (“**Two-sided CDA**”), materially in the form as attached to this Consortium Agreement in Attachment 5 with a Third Party regarding disclosure of this Consortium Agreement and disclosure of relevant Confidential information, in order to engage in discussions with such specific Third Party that has expressed an interest in (i) providing independent advice to any of the various governance bodies in the Project as such, (ii) acceding to the project in compliance with the Grant Agreement and this Consortium Agreement, or (iii) a collaboration between the Project and such specific Third Party, other projects or other Third Party collaborations; provided, however, that the Governing Board members have been informed at least one week in advance about the engagement in discussions with such Third Party by prior written notice (enclosing the CDA proposed for signature, detailing the types of Confidential Information to be disclosed and received and the purpose of disclosure) from the Coordinator (e-mail suffice) potentially with the assistance of the PMT and has not objected to the conclusion of such CDA in writing to the Coordinator within ten (10) Days after receipt such notification (e-mail suffice). The template CDA is enclosed in Attachment 5: Contract under Mandate: two-sided CDA.

7.1.3 negotiation and conclusion of an advisory agreement materially in the form attached hereto in Attachment 6: Contract under Mandate: Advisory Agreement (“**Advisory Agreement**”) or a similar agreement providing an appropriate level of protection in light of the specific situation and/or advisor, with the experts and qualified persons for which an advisory agreement may be executed in accordance with Section 6.7 of this Consortium Agreement, or with any external advisors being invited to participate in meetings of any of the Project’s governance bodies as set out in Sections [6.4.4.](#_bookmark16)3 and

6.2.4.5 of this Consortium Agreement.

* + 1. conclude the accession document as set out in Attachment 2 to this Consortium Agreement with an acceding Party after approval of such accession by the Governing Board.
    2. Any material changes to the terms and conditions of the agreements as provided in Attachment 4,5 and 6 require the prior written approval of all Governing Board Members. For the avoidance of doubt, the mandate as provided under this clause does not include the mandate for the Coordinator to impose any additional obligations on the Parties in the contracts referred to in this Clause without the prior consent of the Parties.
  1. The Parties will receive a copy of each executed agreement for their files.
  2. The Mandate shall remain in force until (i) the Project end date or preliminary termination of the Project, (ii) with respect to such leaving Party until this Party leaves the Project pursuant to this Consortium Agreement, or (iii) with respect to such revoking Party, until the Mandate is revoked by a Party by written notice to the Coordinator. For the avoidance of doubt, in case one or more Parties leave the Project or revoke the Mandate, the Mandate will remain in force for each other Party, and any agreements entered into prior to such Party leaving the Project or revoking its Mandate shall remain in full force and effect even for the leaving and/or revoking Party.

# Financial provisions

 **General Principles**

* + 1. **Distribution of Financial Contribution**

The financial contribution of the Granting Authority to the Project shall be distributed by the Coordinator or, in accordance with Section [8.2.2,](#_bookmark27) by the RI’s, according to:

* + The provisions of the Grant Agreement
  + The Consortium Plan
  + the approval of reports by the Granting Authority, and
  + the provisions of payment in Section [8.2](#_bookmark26) of this Consortium Agreement.
    1. A Party shall be funded only for its tasks carried out in accordance with the Consortium Plan.
    2. **Justifying Costs**

In accordance with its own usual accounting and management principles and practices, each Party shall be solely responsible for justifying its costs (and those of its Affiliated Entities, if any) with respect to the Project towards the Granting Authority. Neither the Coordinator nor any of the other Parties shall be in any way liable or responsible for such justification of costs towards the Granting Authority.

* + 1. **Funding Principles**

A Party that spends less than its allocated share of the budget as set out in the Consortium Plan or – in case of reimbursement via unit costs – implements less units than foreseen in the Consortium Plan will be funded in accordance with its units/actual duly justified eligible costs only.

A Party that spends more than its allocated share of the budget as set out in the Consortium Plan will be funded only in respect of duly justified eligible costs up to an amount not exceeding that share as set out in the Consortium Plan.

* + 1. **Budget Flexibility for TNA service provision budget**

In accordance with the Consortium Plan and Article 5.5. of the Grant Agreement, Parties acknowledge and agree that the budget breakdown as included in the Consortium Plan that is allocated for TNA service provision (the “**TNA Budget**”) is provisional and may be adjusted by decision of the Governing Board in accordance with the needs of the Project by transfers between parties and budget categories.

Such possible re-allocations of the TNA Budget between Parties, or between the RI’s that hold such funds for Parties in accordance with and as detailed in Attachment 8: List of RIs that hold funding for the APs who will contribute to their respective TNA Work Packages for the provision of the services as identified in Table 3.1k of Annex 1 to the Grant Agreement. of this Consortium Agreement and in accordance with the Grant Agreement, will be implemented by the Coordinator after decision of the Governing Board. The Governing Board will ensure that such transfers of TNA Budget between Parties, which could impact a Party’s provisionally received unspent funding, will be considered as an exceptional measure that can be applied only if such TNA Budget cannot be sourced by the contingency fund for the provision of services, as specified in the Consortium Plan, which is held by the Coordinator.

In preparation of any reporting period to the Granting Authority, the Executive Committee will aim to prepare the necessary documents that allow for a detailed review of the TNA Budget by the Governing Board for the Governing Board’s further decision.

* + 1. **Excess payments**

A Party has received excess payment

* + - 1. if the payment received exceeds the amount declared or
      2. if a Party has received payments but, within the last year of the Project, its real Project costs fall significantly behind the costs it would be entitled to according to the Consortium Plan.

In case a Party has received excess payment, the Party has to inform the Coordinator or, if applicable, the Party having made the excess payment and return the relevant amount to the Coordinator or, if applicable, the Party having made the excess payment without undue delay. The Coordinator will also follow-up on this and announce this to the relevant Party upon becoming aware Without limiting the obligations of the Parties to notify the Coordinator or, if applicable, the Party having made the excess payment in this regard, the Coordinator or, if applicable, the Party having made the excess payment may also notify a Party in case the Coordinator notices that a Party has received excess payment. In case no refund takes place within 60 Days upon request for return of excess payment from the Coordinator or, if applicable, the Party having made the excess payment, the Governing Board may identify this as a breach of Party of its obligations under this Consortium Agreement or the Grant Agreement in accordance with Articles 4.2 and 6.2.3 of this Consortium Agreement.

Amounts which are not refunded by a breaching Party and which are not due to the Granting Authority, shall be apportioned by the Coordinator to the remaining Parties pro rata according to their share of total costs of the Project as identified in the Consortium Budget , until recovery from the breaching Party is possible.

* + 1. **Revenue**

In case a Party earns any revenue that is deductible from the total funding as set out in the Consortium Plan, the deduction is only directed toward the Party earning such revenue. The other Parties’ financial share of the budget shall not be affected by one Party’s revenue. In case the relevant revenue is more than the allocated share of the Party as set out in the Consortium Plan, the Party shall reimburse the funding reduction suffered by other Parties.

* + 1. **Financial Consequences of the termination of the participation of a Party**

A Party leaving the consortium shall refund to the Coordinator any payments it has received except the amount of contribution accepted by the Granting Authority or another contributor.

In addition, a Defaulting Party shall, within the limits specified in Section [5.2](#_bookmark7) of this Consortium Agreement, bear any reasonable and justifiable additional costs occurring to the other Parties in order to perform the leaving Party´s task and necessary additional efforts to fulfil them as a consequence of the Party leaving the consortium. The Governing Board should agree on a procedure regarding additional costs which are not covered by the Defaulting Party or the Mutual Insurance Mechanism. Should the Governing Board be unable to come to an alternative agreement within a reasonable period of time, any such additional costs shall be apportioned by the Coordinator to the remaining Parties pro rata according to their share of total costs of the Project as identified in the Consortium Budget, and shall be transferred promptly to the Coordinator until recovery from the Defaulting Party is possible.

 **Payments**

* + 1. Payments to Parties are mainly the task of the Coordinator. In particular, the Coordinator shall:
       - notify the Party concerned promptly of the date and composition of the amount transferred to its bank account, giving the relevant references
       - perform diligently its tasks in the proper administration of any funds and in maintaining financial accounts
       - undertake to keep the Granting Authority’s financial contribution to the Project separated from its normal business accounts, its own assets and property, except if the Coordinator is a Public Body or is not entitled to do so due to statutory legislation.

With reference to Article 22 of the Grant Agreement, no Party shall before the end of the Project receive more than its allocated share of the maximum grant amount less the amounts retained by the Granting Authority for the Mutual Insurance Mechanism and for the final payment.

* + 1. Subject to the provisions of this Consortium Agreement, the Coordinator may transfer funding to RI’s that will hold such funding on behalf of certain AP’s that have agreed to having their funding held by these RI’s as set out in Attachment 8**: List of RIs that hold funding for the APs who will contribute to their respective TNA Work Packages for the provision of the services as identified in Table 3.1k of Annex 1 to the Grant Agreement.** . In such case, the RI’s holding funding on behalf of AP’s shall respect the obligations that apply to the Coordinator *mutatis mutandis* regarding payment of this funding as set out in this Section 8.
    2. **Distribution of funds from the Granting Authority to the Coordinator**

Subject to the provisions of Section 8.2.2, Payments to Parties are the task of the Coordinator. Allocation of funds shall be in line with the provisions of the Grant Agreement (including the Consortium Plan).

Funding for costs accepted by the Granting Authority will be first transferred to the Coordinator, upon which the Coordinator will transfer the funds to the Party or RI concerned in accordance with the provisions of the Consortium Agreement and the Grant Agreement. In that perspective the Granting Authority will transfer to the Coordinator:

* 80% of the total grant amount as of the start of the Project, minus 5% which is held as the mutual insurance mechanism contribution. (the “**Prefinance Amount**”);
* Up to 10% of the total grant amount as interim payment after the interim reports for months 1 to 18 of the Project are submitted (“**Interim Amount**”); and
* Any remaining unpaid balance of the total grant amount as final payment once the final reports of the Project are submitted (“**Final Amount**”)
  + 1. **Distribution of funds from the Coordinator to the Parties/RIs**

The total grant amount of each Party consists of a (flexible) TNA Budget, a JRA Budget (if any) (as defined below) and a Consortium Related Activities budget (if any). Any budget allocations not related to a TNA - or JRA Budget allocation, will be considered as Consortium Related Activities budget allocations. The distribution of Consortium Related Activities funding (if any) will follow the same distribution principles as set out below for the distribution of the funding related to TNA services.

***Funding related to TNA services – TNA Budget***

* + - 1. The subsequent transfer of the parts of the Prefinance Amount, the Interim Amount and the Final Amount to the relevant Parties and/or RIs will for the TNA Budget be subject to the budget flexibility principle as set out in Section [8.1.5](#_bookmark25) of this Consortium Agreement and in accordance with Article 22.1 and Article 7 of the Grant Agreement and following the payment schedule set out in Sections [8.2.4.3](#_bookmark28) and [0](#_bookmark29) of this Consortium Agreement below.
      2. The Coordinator may, for the TNA Projects, transfer the TNA related funding for certain Parties (as APs) via the RI representing them and that can hold such funding for the APs it represents according to the scheme as set out in Attachment 8: List of RIs that hold funding for the APs who will contribute to their respective TNA Work Packages for the provision of the services as identified in Table 3.1k of Annex 1 to the Grant Agreement.
      3. **For Parties with an initial Budget of ≥15,000.00 euro (as set out in the Consortium Plan):**

|  |  |
| --- | --- |
| **Amount** | **Timing** |
| **Prefinancing:**  70 % of the concerned Party’s prefinancing amount. | Amount will be transferred by the Coordinator to such Party upon receipt by the Coordinator of the Prefinance Amount from the Granting Authority |
| **Interim payment:**  Amount equal to interim payment received by the Coordinator from the Granting Authority for that respective party (if any). | Amount will be transferred by the Coordinator to such Party upon receipt by the Coordinator of the Interim Amount from the Granting Authority. |
| **Final payment:**  Amount equal to the approved total cost of the TNAservices provided by the Party, less any payments already made to the Party regarding these services. . | Amount will be transferred by the Coordinator to such Party upon receipt by the Coordinator of the Final Amount from the Granting Authority . |

* + - 1. **For Parties with an initial Budget of <15,000.00 euro (as set out in the Consortium Plan):**

Parties agree that in light of the flexible budget principles for TNA services as set out in the Grant Agreement and Section [8.1.5](#_bookmark25) of this Consortium Agreement and in order to further minimize the likelihood that Parties would need to return unspent funding which they would already have received, the Coordinator or the RIs as set out in Attachment 8: List of RIs that hold funding for the APs who will contribute to their respective TNA Work Packages for the provision of the services as identified in Table 3.1k of Annex 1 to the Grant Agreement. of this Consortium Agreement, shall in first instance retain the amounts for Parties with an initial grant amount of <15,000.00 euro.

The Coordinator will only transfer such Parties their TNA Budget, or via the RIs representing them, once those concerned Parties’ TNA services are requested by a user in accordance with following payment schedule:

|  |  |
| --- | --- |
| **Amount** | **Timing** |
| **Prefinancing:**  80 % of the estimated costs of the accepted service requests (“**Prefinanced Cost for TNA Services**”) | Amount will be transferred by the Coordinator or via the RI representing them, to such Party, upon valid request of the Party. |
| **Interim payments:**  Amount equal to the interim payment received in relation to these services by the Coordinator from the Granting Authority for that Party (if any). | Amount will be transferred by the Coordinator or via the RI representing them to such Party after receipt by the Coordinator of the Interim Amount from the Granting Authority (or- the case being- upon receipt by the RI of such amount by the Coordinator) And upon valid request of the Party. |
| **Final payments:**  Amount equal to the total approved cost of the services provided by the Party less any payments already made to the Party regarding these services.. | Amount will be transferred by the Coordinator or via the RI representing them, to such Party upon receipt of the final payment by the Coordinator of the final amount from the Granting Authority (or- the case being- upon receipt by the RI of such amount by the Coordinator). |

Notwithstanding the above payment schedule, a Party can request to the Party holding the funds 100% of the costs of the delivered services. Such request, in lieu of the above payment schedule, to be granted at the discretion of the Party holding the funds.

Again, notwithstanding the above payment schedule, also the Parties with an initial grant amount of

<15,000.00 euro, may submit a written request to the Coordinator to receive their initial TNA Budget in accordance with the schedule as set out in Section [8.2.4.3](#_bookmark28) of this Consortium Agreement. Acceptance of such request will not be unduly withheld by the Coordinator.

In the event that the request is upheld, the requesting Party can no longer request costs for services according to the schedule in 8.2.4.4 and must instead follow the payment schedule in 8.2.4.3

* + 1. ***Funding related to Joint Research Activities (JRA)– JRA Budget***
       1. Funding for the performance of JRA (“**JRA Budget**”) by the Parties will be held by the Coordinator until the SciAB has been consulted on a gap analysis of the tools and methods offered by the ISIDORe catalogue of services, resulting in recommendations by the SciAB as to research priorities and concomitant resource allocation that will allow expansion and/or upgrade of support services as needed most by the users of ISIDORe’s catalogue of services. This gap analysis and recommendations as performed by the SciAB are foreseen to be provided around the 10th month of the Project and will be submitted as a deliverable (as specified in the Consortium Plan) to the Executive Committee for validation. This analysis will then result in internal calls for JRA proposals launched by WP2. The proposals will be selected upon independent peer review and will result in budget allocations approved by the Governing Board for the division of such JRA Budget to the concerned Parties.
       2. Such payments for JRA services will be transferred by the Coordinator to the relevant Parties as follows:

|  |  |
| --- | --- |
| **Prefinancing:**  70 % of the estimated costs of the selected JRA to be provided by the Party concerned (“**Prefinanced Cost for JRA**”) | Amount will be transferred by the Coordinator or via the RI representing them, to such Party, upon approval of the payment schedule by the Governing Board in accordance with Section 8.2.4 of this Consortium Agreement. |
| **Interim payments:**  Amount equal to interim payment received by the Coordinator from the granting authority for that reporting period in relation to the JRA services. | Amount will be transferred by the Coordinator or via the RI representing them to such Party upon receipt by the Coordinator of the Interim amount from the Granting Authority (or- the case being- upon receipt by the RI of such amount by the Coordinator). . |
| **Final payments:**  Amount equal to the total approved cost of the selected JRA provided by the Party less any payments already made to the Party regarding these services. | Amount will be transferred by the Coordinator or via the RI representing them to such Party upon receipt of the final payment by the Coordinator of the final amount from the Granting Authority (or- the case being- upon receipt by the RI of such amount by the Coordinator). |

* + 1. The Coordinator, or the RI representing the Party upon instruction by the Coordinator following Governing Board decision, is entitled to withhold any payment due to a Party identified by the Governing Board to be in breach of its obligations under this Consortium Agreement or the Grant Agreement or to a Party which has not yet signed this Consortium Agreement.
    2. The Coordinator is entitled to recover any payments already paid to a Defaulting Party except the costs already claimed by the Defaulting Party and accepted by the Granting Authority. The Coordinator is equally entitled to withhold payments to a Party when this is suggested by or agreed with the Granting Authority.

# Results

 **Ownership of Results**

Results are owned by the Party that generates them.

However, ownership of output generated by Third Party users using the services or materials of APs in or generated by a Party in the course of performing a service for a Third Party in the framework of TNA services, shall be governed by a separate agreement to be concluded between the respective Party/ies providing the TNA service and such Third Party users in which ownership of such output can be assigned to such Third Party user.

 **Joint ownership**

Joint ownership is governed by the Grant Agreement Article 16.4 and its Annex 5, Section Ownership of Results, with the following additions:

The joint owners must agree — in writing — on the allocation and terms of exercise of their joint ownership (‘joint Ownership Agreement’), to ensure compliance with their obligations under this Agreement.

Unless otherwise agreed in writing by the joint owners:

* + each of the joint owners shall be entitled to use their jointly owned Results for internal, non- commercial research and teaching activities on a royalty-free basis, and without requiring the prior consent of the other joint owner(s).
  + each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant non-exclusive licenses to Third Parties (without any right to sub-license), if the other joint owners are given: (a) at least forty-five (45) Days advance notice before start of the Exploitation or entering into any binding agreement with Third Parties for the granting of such licenses; and

1. Fair and Reasonable compensation.

The joint owners shall agree on all protection measures and the division of related cost in advance.

 **Transfer of Results**

* + 1. Each Party may transfer ownership of its own Results, including its share in jointly owned Results (subject to the provisions of the Joint Ownership Agreement concluded between them, if any), following the procedures of the Grant Agreement Article 16.4 and its Annex 5, Section Transfer and licensing of results, sub-section “Transfer of ownership”.
    2. Each Party may identify specific Third Parties it intends to transfer the ownership of its Results to in Attachment 3**: List of Third Parties for simplified transfer according to Section 9.3.2.** of this Consortium Agreement. The other Parties hereby waive their right to prior notice and their right to object to such a transfer to listed Third Parties according to the Grant Agreement Article 16.4 and its Annex 5, Section Transfer of licensing of results, sub-section “Transfer of ownership”, 3rd paragraph.

The transferring Party shall, however in such case, at the time of the transfer, inform the other Parties of such transfer and shall ensure that the rights of the other Parties under the Consortium Agreement and the Grant Agreement will not be affected by such transfer. Any addition to Attachment (3) after signature of this Consortium Agreement requires a decision of the Governing Board.

* + 1. The Parties recognise that in the framework of a merger or an acquisition of an important part of its assets, it may be impossible under applicable EU and national laws on mergers and acquisitions for a Party to give at least 45 Days prior notice for the transfer as foreseen in the Grant Agreement. The transferring Party shall ensure that the rights of the other Parties under the Consortium Agreement and the Grant Agreement will not be affected by such transfer and shall inform the Parties of such transfer as soon as they are allowed to do so under applicable EU and national laws.
    2. The obligations above apply only for as long as other Parties still have – or still may request – Access Rights to the Results.

 **Dissemination**

* + 1. For the avoidance of doubt, the confidentiality obligations set out in Clause [11](#_bookmark38) of this Consortium Agreement shall apply to all dissemination activities described in this Section [9.4](#_bookmark32) of this Consortium Agreement as far as Confidential Information is involved.
    2. **Dissemination of own (including jointly owned) Results**
       1. During the Project and for a period of 1 year after the end of the Project, the dissemination of own Results by one or several Parties including but not restricted to publications and presentations, shall be governed by the procedure of Article 17.4 of the Grant Agreement and its Annex 5, Section Dissemination, subject to the following provisions.

Prior notice (e-mail suffice) of any planned publication shall be given to the other Parties at least 20 Days before the publication. Any objection to the planned publication shall be made in accordance with the Grant Agreement by written notice (e-mail suffice) to the Coordinator and to the Party or Parties proposing the dissemination within 15 Days after receipt of such notice. If no objection is made within the time limit stated above, the publication is permitted. As an exception to the 20 Days’ notice period as set out above, the delay for submission prior to the presentation shall be reduced to 15 Days for the following communications: poster presentations, slides and abstracts for oral presentations at scientific meetings. The term for objection to such communications will be 10 Days after receipt of such notice. There will be no prior notice required for press releases, short news items for a website, blog and online social network contributions when these reference or report on previously approved publications.

* + - 1. An objection is justified if
         1. the protection of the objecting Party’s Results or Background would be adversely affected, or
         2. the objecting Party’s legitimate interests in relation to its Results or Background would be significantly harmed, or
         3. the proposed publication includes Confidential Information of the objecting Party. The objection has to include a precise request for necessary modifications.
      2. If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting Party shall not unreasonably continue the opposition if appropriate measures are taken following the discussion.
      3. The objecting Party can request a publication delay of not more than 90 Days from the time it raises such an objection. After 90 Days the publication is permitted, provided that the objections of the objecting Party have been addressed.
    1. **Cooperation obligations**

The Parties undertake to cooperate to allow the timely submission, examination, publication and defence of any dissertation or thesis for a degree that includes their Results or Background subject to the confidentiality and publication provisions agreed in this Consortium Agreement.

* + 1. **Use of names, logos or trademarks**

Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising, publicity or otherwise the name of the Parties or any of their logos or trademarks without their prior written approval.

* + 1. **Dissemination of another Party’s unpublished Results or Background**

A Party shall not include in any dissemination activity another Party’s Results or Background or Confidential Information without obtaining the owning Party’s prior written approval, unless they are already legitimately made public.

# Access Rights

 **Background included**

* + 1. In Attachment 1**: Background included** of this Consortium Agreement, the Parties identify and agree on the Background for the Project and, where relevant, inform each other that Access to specific Background is subject to legal restrictions or limits.

Background provided by the Parties after signature of the Consortium Agreement will be added automatically to Attachment 1 without the need for a formal Consortium Agreement amendment.

Anything not identified in Attachment 1: Background included shall not be the object of Access Right obligations regarding Background.

* + 1. Any Party may add additional Background to Attachment 1**: Background included** during the Project provided they give written notice to the other Parties. However, approval of the Governing Board is needed should a Party wish to otherwise modify (e.g. reduce their Background contributed) or withdraw its Background as is listed in Attachment 1**: Background included**.
    2. Each Party remains the sole owner of its Background. Nothing contained in this Consortium Agreement shall affect any property rights of a Party to its own Background. Unless where indicated in the Consortium Agreement (e.g. on Access Rights), nothing in this Consortium Agreement shall be interpreted as granting a Party any right or license to the other Party’s Background.

 **General Principles**

* + 1. Each Party shall implement its tasks in accordance with the Consortium Plan and shall bear sole responsibility for ensuring that its acts within the Project do not infringe Third Party property rights without prejudice of the provisions of Clause 5.1**.**
    2. Any Access Rights granted exclude any rights to sublicense unless expressly stated otherwise. Access Rights shall be free of any administrative transfer costs. Access Rights are granted on a non- exclusive basis.
    3. Results and Background shall be used only for the purposes for which Access Rights to it have been granted.
    4. All requests for Access Rights shall be made in writing. The granting of Access Rights may be made conditional on the acceptance of specific conditions aimed at ensuring that these rights will be used only for the intended purpose and that appropriate confidentiality obligations are in place.
    5. The requesting Party must show that the Access Rights are Needed. Each Party shall take appropriate measures to ensure that it can grant Access Rights to fulfil its obligations under the Grant Agreement and this Consortium Agreement notwithstanding any rights of its employees or any Third Party that it engages to perform work on its behalf in the Project.
    6. Access Rights under Sections 10.3 (Access Rights to Results and Background for implementation) and 10.4.1.2 (Access Rights to Results for internal, non-commercial research and teaching activities) and which are provided on Royalty-free conditions, are hereby requested in writing by the Parties by means of signature of the Consortium Agreement. Such Access Rights are hereby granted by the respective Party by means of signature of the Consortium Agreement.
    7. Additional or deviating Access Rights may be agreed upon by the relevant Parties in the context of a JRA project. Such Access rights may in no way impact Access Rights of other Parties as already provided for under this Consortium Agreement and shall be set out in the applicable JRA project agreement, of which a template is included in Attachment 7 **: JRA project template agreement.**to this Consortium Agreement.

 **Access Rights for implementation**

Access Rights to Results and Background Needed for the performance of the own work of a Party under the Project shall be granted on a royalty-free basis, unless otherwise agreed for Background in Attachment 1: Background included to this Consortium Agreement.

 **Access Rights for Exploitation**

* + 1. **Access Rights to Results**
       1. Access Rights to Results if Needed for Exploitation of a Party’s own Results shall be granted on Fair and Reasonable conditions.
       2. Access rights to Results for internal, non-commercial, research and for teaching activities shall be granted on a royalty-free basis.
    2. **Access Rights to Background**

Access Rights to Background if Needed for Exploitation of a Party’s own Results, shall be granted on Fair and Reasonable conditions.

* + 1. A request for Access Rights may be made up to twelve months after the end of the Project or, in the case of Section [10.7.2.1.2,](#_bookmark37) after the termination of the requesting Party’s participation in the Project.

 **Access Rights for Entities under the same Control**

Entities under the same Control have Access Rights under the conditions of the Grant Agreement Article

16.4 and its Annex 5, Section “Access rights to results and background”, sub-section “Access rights for entities under the same control”.

Such Access Rights must be requested by the Entity under the same Control from the Party that holds the Background or Results. Alternatively, the Party granting the Access Rights may individually agree with the Party requesting the Access Rights to have the Access Rights include the right to sublicense to the latter’s Entity under the same Control. Access Rights to an Entity under the same Control shall be granted on Fair and Reasonable conditions and upon written bilateral agreement.

Entities under the same Control which obtain Access Rights in return fulfil all confidentiality obligations accepted by the Parties under the Grant Agreement or this Consortium Agreement as if such entities were Parties.

Access Rights may be refused to Entities under the same Control if such granting is contrary to the legitimate interests of the Party which owns the Background or the Results.

Access Rights granted to any Entity under the same Control are subject to the continuation of the Access Rights of the Party with whom it is under the same control, and shall automatically terminate upon termination of the Access Rights granted to such Party.

Upon cessation of the status as an Entity under the same Control, any Access Rights granted to such former Entity under the same Control shall lapse.

Further arrangements with Entities under the same Control may be negotiated in separate agreements.

 **Additional Access Rights**

The Parties agree to negotiate in good faith any such additional Access Rights to Results as might be asked for by any Party, upon adequate financial condition to be agreed upon.

 **Access Rights for Parties entering or leaving the consortium**

* + 1. **New Parties entering the consortium**

As regards Results developed before the accession of the new Party, the new Party will be granted Access Rights on the conditions applying for Access Rights to Background.

* + 1. **Parties leaving the consortium**
       1. Access Rights granted to a leaving Party
          1. Defaulting Party

Access Rights granted to a Defaulting Party and such Party’s right to request Access Rights shall cease immediately upon receipt by the Defaulting Party of the formal notice of the decision of the Governing Board to terminate its participation in the consortium.

* + - * 1. Non-defaulting Party

A non-defaulting Party leaving voluntarily and with the Governing Board’s consent shall have Access Rights to the Results developed until the date of the termination of its participation.

It may request Access Rights within the period of time specified in Section [10.4.3](#_bookmark35) of this Consortium Agreement.

* + - 1. Access Rights to be granted by any leaving Party

Any Party leaving the Project shall continue to grant Access Rights pursuant to the Grant Agreement and this Consortium Agreement as if it had remained a Party for the whole duration of the Project.

 **Specific Provisions for Access Rights to Software**

For the avoidance of doubt, the general provisions for Access Rights provided for in this Section [9.4.5](#_bookmark33) are applicable also to Software.

Parties’ Access Rights to Software do not include any right to receive source code or object code ported to a certain hardware platform or any right to receive respective Software documentation in any particular form or detail, but only as available from the Party granting the Access Rights.

# Non-disclosure of information

 All information, data, documents or other material in whatever form or mode of communication, which is disclosed by a Party (the “Disclosing Party”) to any other Party (the “Recipient”) in connection with the Project during its implementation and which has been explicitly marked as “confidential” at the time of disclosure, or when disclosed orally has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 Days from oral disclosure at the latest as confidential information by the Disclosing Party, is “Confidential Information”.

 The Recipients hereby undertake in addition and without prejudice to any commitment on non- disclosure under the Grant Agreement, for a period of 5 years after the end of the Project:

* + not to use Confidential Information otherwise than for the purpose for which it was disclosed;
  + not to disclose Confidential Information without the prior written consent by the Disclosing Party, other than to its Entities Under the Same Control to the extent (i) they need to know the Confidential Information in order for the Receiving Party to exercise its rights of perform its obligations under this Consortium Agreement or Grant Agreement and (ii) they are bound by obligations of confidentiality at least equivalent to those set forth herein;
  + to ensure that internal distribution of Confidential Information by a Recipient shall take place on a strict need-to-know basis; and
  + to return to the Disclosing Party, or destroy, on request all Confidential Information that has been disclosed to the Recipients including all copies thereof and to delete all information stored in a machine-readable form to the extent practically possible. The Recipients may keep a copy to the extent it is required to keep, archive or store such Confidential Information because of compliance with applicable laws and regulations or for the proof of on-going obligations provided that the Recipient complies with the confidentiality obligations herein contained with respect to such copy.

 The Recipients shall be responsible for the fulfilment of the above obligations on the part of their employees or Third Parties involved in the Project and shall ensure that they remain so obliged, as far as legally possible, during and after the end of the Project and/or after the termination of the contractual relationship with the employee or Third Party.

 The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can show that:

* + the Confidential Information has become or becomes publicly available by means other than a breach of the Recipient’s confidentiality obligations;
  + the Disclosing Party subsequently informs the Recipient that the Confidential Information is no longer confidential;
  + the Confidential Information is communicated to the Recipient without any obligation of confidentiality by a Third Party who is to the best knowledge of the Recipient in lawful possession thereof and under no obligation of confidentiality to the Disclosing Party;
  + the disclosure or communication of the Confidential Information is foreseen by provisions of the Grant Agreement;
  + the Confidential Information, at any time, was developed by the Recipient completely independently of any such disclosure by the Disclosing Party;
  + the Confidential Information was already known to the Recipient prior to disclosure, or
  + the Recipient is required to disclose the Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order of any competent jurisdiction, subject to the provision Section **Error! Reference source not found.** hereunder.

 The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within the scope of the Project as with its own confidential and/or proprietary information, but in no case less than reasonable care

 Each Recipient shall promptly inform the relevant Disclosing Party by written notice of any unauthorised disclosure, misappropriation or misuse of Confidential Information after it becomes aware of such unauthorised disclosure, misappropriation or misuse.

 If any Recipient becomes aware that it will be required, or is likely to be required, to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, it shall, to the extent it is lawfully able to do so, prior to any such disclosure

* + Promptly ,notify the Disclosing Party of this fact or where the Recipient Party is prohibited by applicable law or the governmental body from notifying the Disclosing Party of such request, so notify the Disclosing Party promptly upon the lapse, termination, removal or modification of such prohibition;
  + consult with the Disclosing Party regarding the Recipient Party’s response to the demand or request by such governmental body;
  + cooperate with the Disclosing Party’s reasonable instructions to protect the confidentiality of the information.
  + to the extent permissible by law, seek to contest, limit or challenge the demand or request, and request such governmental body to redirect the relevant request for disclosure directly to the Disclosing Party;
  + provide the Disclosing Party a true, correct and complete copy of the Recipient Party’s response to such demand or request; and
  + keep the Disclosing Party informed of all developments and communications with the governmental body upon the Disclosing Party’s request.

# Miscellaneous

 **Attachments, inconsistencies and severability**

This Consortium Agreement consists of this core text and:

* + Attachment 1 (Background included)
  + Attachment 2 (Accession document)
  + Attachment 3 (List of Third Parties for simplified transfer according to Section **Error! Reference source not found.**)
  + Attachment 4 (Contract under Mandate – one way CDA
  + Attachment 5 (Contract under Mandate – two-way CDA)
  + Attachment 6 (Contract under Mandate – advisory agreement)
  + Attachment 7 (JRA project template Agreement)
  + Attachment 8 (List of RIs that hold funding for the APs who will contribute to their respective TNA Work Packages for the provision of the services as identified in Table 3.1k of Annex 1 to the Grant Agreement.)
  + Attachment 9 (List of Parties and their APs under the RIs that represent them in the Governing Board)

In case the terms of this Consortium Agreement are in conflict with the terms of the Grant Agreement, the terms of the latter shall prevail. In case of conflicts between the attachments and the core text of this Consortium Agreement, the latter shall prevail.

Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Consortium Agreement. In such a case, the Parties concerned shall be entitled to request that a valid and practicable provision be negotiated that fulfils the purpose of the original provision.

 **No representation, partnership or agency**

Except as otherwise provided in this Consortium Agreement, no Party shall be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium. Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping or any other kind of formal business grouping or entity between the Parties.

 **Formal and written notices**

Any notice to be given under this Consortium Agreement shall be addressed to the recipients as listed in the most current address list kept by the Coordinator.

Any change of persons or contact details shall be immediately communicated to the Coordinator by written notice (e-mail suffice). The Coordinator shall confirm receipt of the requested change(s) by replying to such request (e-mail suffice). The address list shall be accessible to all Parties.

Formal notices:

If it is required in this Consortium Agreement (e.g. Sections [4.2,](#_bookmark5) [10.7.2.1.1,](#_bookmark36) and [12.4](#_bookmark40) of this Consortium Agreement) that a formal notice, consent or approval shall be given, such notice shall be signed by an authorised representative of a Party and shall either be served personally or sent by e-mail with recorded delivery with acknowledgement of receipt.

Written notice:

Where written notice is required by this Consortium Agreement, this is fulfilled also by other means of communication such as e-mail.

 **Assignment and amendments**

Except as set out in Section [9.3](#_bookmark31) of this Consortium Agreement, no rights or obligations of the Parties arising from this Consortium Agreement may be assigned or transferred, in whole or in part, to any Third Party without the other Parties’ prior formal approval.

Amendments and modifications to the text of this Consortium Agreement not explicitly listed in Section

[6.2.3](#_bookmark10) of this Consortium Agreement require a separate written agreement to be signed between all Parties.

 **Mandatory national law**

Nothing in this Consortium Agreement shall be deemed to require a Party to breach any mandatory statutory law under which the Party is operating.

In case a Party is obliged under its national law to publish the text of this Consortium Agreement in an official register or official journal, the Party shall be allowed to do so provided that all personal data and Appendix 1 on Background are excluded.

 **Language**

This Consortium Agreement is drawn up in English, which language shall govern all documents, notices, meetings, arbitral proceedings and processes relative thereto.

 **Applicable law**

This Consortium Agreement shall be construed in accordance with and governed by the laws of Belgium excluding its conflict of law provisions.

Nothing in this Consortium Agreement may be interpreted as a waiver of the privileges or immunities of International Organisations, as accorded by applicable treaty or international law. Any references to any sets of rules, including, but not limited to, national laws, statutes, regulations, guidelines, shall, with respect to International Organisations, be understood to refer to those sets of rules only to the extent these rules can apply to them according to applicable treaty or international law to which they are subject.

 **Settlement of disputes**

The Parties shall endeavour to settle their disputes amicably.

Subject to clause 12.7, second paragraph, of this Consortium Agreement, any dispute, controversy or claim arising under, out of or relating to this Consortium Agreement and any subsequent amendments of this Consortium Agreement, including, without limitation, its formation, validity, binding effect, interpretation, performance, breach or termination, as well as non-contractual claims, may be submitted if all parties involved agree, to mediation in accordance with the WIPO Mediation Rules. The place of mediation shall be Brussels unless otherwise agreed upon. The language to be used in the mediation shall be English unless otherwise agreed upon.

In case (i) Parties do not agree to submit their dispute to mediation in accordance with the paragraph above, or (ii) if, and to the extent that, any such dispute, controversy or claim has not been settled pursuant to the mediation within 60 Days of the commencement of the mediation, it shall, upon the filing of a Request for Arbitration by either Party, be referred to and finally determined by arbitration in accordance with the WIPO Expedited Arbitration Rules by a single arbitrator. Alternatively, if, before the expiration of the said period of 60 Days, either Party fails to participate or to continue to participate in the mediation, the dispute, controversy or claim shall, upon the filing of a Request for Arbitration by the other Party, be referred to and finally determined by arbitration in accordance with the WIPO Expedited Arbitration Rules by a single arbitrator. The place of arbitration shall be Brussels unless otherwise agreed upon. The language to be used in the arbitral proceedings shall be English unless otherwise agreed upon.

The award of the arbitration will be final and binding upon the Parties.

Subject to clause 12.7, second paragraph, of this Consortium Agreement, in case a Party can demonstrate that, due to its nature of public entity, it is not allowed by its national law to submit its disputes to arbitration, the courts of Brussels shall have the exclusive jurisdiction with regards to disputes concerning such Party. Should any dispute, controversy or claim arise between such Party and

an International Organisation, the Parties will undertake to resolve such dispute in a way and by means acceptable and applicable to such Parties involved.

Subject to clause 12.7, second paragraph, of this Consortium Agreement, nothing in this Consortium Agreement shall limit the Parties' right to seek injunctive relief in any applicable competent court. In case of any dispute, controversy or claim, to which an International Organisation is a party, Parties recognize that they will have to consider Emergency Relief Proceedings in accordance with Article 49 of the WIPO Expedited Arbitration Rules.

# Signatures

The Parties agree to execute this Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format) , and agree this shall constitute a valid and enforceable agreement between the Parties. The present Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g. , scan in PDF format)**.**

The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written.

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 1

EUROPEAN RESEARCH INFRASTRUCTURE ON HIGHLY PATHOGENIC AGENTS, with legal

address at Rue Du Trône 98/B4, Brussels 1050, Belgium. (“ERINHA” or the “Coordinator”);

Signature

Name

Title

Date

Director General

27/02/2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

**Party 2**

**UNIVERSITE D'AIX MARSEILLE,** with legal address at 58 Boulevard Charles Livon, Marseille 13284, France **("AMU");**

Signature

Name Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a ha ndwritten signature (e.g. scan in PDF format}, and agree this shall constitute a va lid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic vers ion which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., sca n in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned author ised representatives in separate signature pages on the day and year indicated in the s ignature .

**Party** 3

**INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET**

**L'ENVIRONNEMENT ,** with legal address at 147 Rue De L'universite, Paris Cedex 07 75007 , France

**" INRAE");**

Signature

Name

Title

Date

DocuSign Envelope ID: 92AE6348-7AB0-4759-8DOA-DA6525BE4D2C

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 4

INSTITUT PASTEUR, a French non-profit foundation with charitable status pursuant to a decree dated of June 4th, 1887, located at 25-28 rue du Docteur Roux, 75724 Paris Cedex 15, France, VAT FR 65 775 684 897, represented by xxx, Vice-President Senior Executive, duly authorized ("IP") acting in its own name and on behalf of the Centre National pour la Recherche Scientifique

(CNRS), a public scientific and technical research establishment, with headquarters at 3 rue Michel­ Ange, 75794 Paris Cedex 16, with regards to the Laboratory "Genetique Moleculaire des Virus a ARN",

headed by xxx, which is part of the mixed research unit UMR3569 - Universite Paris Cite and the laboratory "Genetics and Genomics of Insect Vectors" which is part of the mixed research unitUMR2000 - Paris 6 , in accordance with the mandate resulting from the framework agreement currently in force;

Signature

DocuSigned by:

9

Name

xxx

Title

Vi ce-Presi dent

Date

23 mars 202 3

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 5

EUROPEAN VACCINE INITIATIVE EWIV, with legal address at Vossstrasse 2 Geb 4040, Heidelberg 69115, Germany (“EVI”);

xSignature

Name

Title

EVI Executive Director

Date

20-04-2023

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 6

INSTRUCT-ERIC, with legal address at Oxford House, Parkway Court, John Smith Drive, Oxford OX4 2JY, United Kingdom (“INSTRUCT”);

Signature

Name

Title Professor

Date 28th February 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

**Party 7**

**EURO-BIOIMAGING ERIC,** with legajaddrss7at Pl 123, Turku 20521, Finland **("EURO- BIOIMAGING"**

Signature

Name

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 8**

**EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY**

**EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM ,** established in Robert-Rossle-Str. 10, Berlin 13125, Germany **("EU-OS" or "EU-OPENSCREEN ERIC");**

Signature Name

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 9

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK, with legal address at 5

Rue Watt, Paris 75013, France ("ECRIN");

Signature Name

Title

Date

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 10

EATRIS ERIC, with legal address at De Boelelaan 1118, Amsterdam 1081 HZ, Netherlands(EATRIS );

Signature

Title

Date

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 11

BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM,

with legal address at Neue Stiftingtalstrasse 2/B/6, Graz 8010, Austria (""BBMRI"); Signature

Name

Title Director General

Date 17.03.2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwrit.ten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceab le agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 12**

**INFRAFRONTIER GMBH,** with legal address Germany **("INFRAFRONTIER ");**

at lngolstadter Landstrasse 1, Neuherberg 85764,

*f*

Signature

Name

Title

Date

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 13**

**EUROPEAN MARINE BIOLOGICAL RESOURCE CENTRE EUROPEAN RESEARCH**

**INFRASTRUCTURE CONSORTIUM,** with legal address at 4 Place Jussieu, Paris 75005, France

**("EMBRC") ;**

Name

Title Executive Director

Date *2710212023*

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format) , and agree this shall constitute a valid and enforceable agreement between the Parties. The present Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g. , scan in PDF format).

The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written.

Party 14 (signature 1 of 2)

**EUROPEAN MOLECULAR BIOLOGY LABORATORY** as part of - and mandated by the ELIXIR Consortium with legal address at Wellcome Genome Campus Hinxton, Cambridgeshire, CB10 1S , nited Kingdom

Signature

Name

Title

Date

Signature of the Consortium Agreement for the Integrated Services for Infectious

Disease Outbreak Research Project ("ISIOORe") Grant Agreement No.: 101046133

The Parties agree to execute this Agreement by way of a scanned or digitized image of a handwritten signature (e.g.scan in PDF format) • and agree this shall constitute a valid and enforceable agreement between the Parties. The present Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g. , scan in PDF format).

The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year ftrSt above written.

Party 14

EUROPEAN MOLECULAR BIOLOGY LABORATORY, an International Organization with legal address at Meyerhofstrasse 1, Heidelberg 69117, Germany, ("EMBL" or "IEIO")

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 15

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, with legal address at Rue

De Tolbiac 101, Paris 75654, France (“INSERM”);

Signature

Name

Title

Date

Directeur ANRS | MIE

11 mai 2023

64 / 259

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreemen t for the Integrated Services for Infectious Disease Outbreak Research Proje ct ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

**Party 16**

**UNIVERSIDADE DO MINHO,** with legal address at Largo Do Paco, Braga 4704 553, Portugal

**("UMIN**HO");

Signature x

Name

Title Vice-Rector for Research and Innovation

Date 15th of December, 2023

65 / 259

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 17**

**INSERM TRANSFERT SA,** with legal address at Rue Watt 7, Paris 75013, France ("IT");

Signature

Name

Title

Date

66 / 259

**Signature ·of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 18**

**FOLKHALSOMYNDIGHETEN ,** with legal address at Nobels Vag 18, Solna 171 82, Sweden **(FOHM");**

Signature

Name

Title

Date

67 *I L59*

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (11 ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 19**

**INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE,** with legal address at Avenida Padre Cruz,

Lisboa 1649-016, Portugal **("INSA");**

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe" )**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 20**

**NEMZETI NEPEGESZSEGUGYI KOZPONT,** established in ALBERT FLORIAN UT 2-6, BUDAPEST 1097, Hungary **("NNK");**

Signature

Name

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe" )**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g.,scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 21**

**ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC),** an institution

organized in accordance with public law of the Netherlands (article 1.13,2 WHW), with principal place of business at Dr. Molewaterplein 40, 3015GD Rotterdam,. The Netherlands, and registered with the national Chamber of Commerce with number 24485070, legally represented by Prof dr S. Sleijfer, in his capacity of Dean and Member of the Board of Directors of "Erasmus University Medical Center Rotterdam("EMC");

Signature

Name


Title

Date



Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project

Grant Agreement No.: 101046133



Party 22

KATHOLIEKE UNIVERSITEIT LEUVEN, for the purposes of this Agreement represented by KU Leuven Research & Development, with legal address at Oude Markt 1 KUL

71 / 259

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 23**

**MEDIZINISCHE UNIVERSITAT GRAZ,** with legal address at Neu Austria **("MUG");**

Signature

Name

10 Graz,

Title

Date

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format}, and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 24

BERNHARD-NOCHT-I NSTITUT FLIER TROPENMEDIZIN, with legal address at Bernhard Nocht Strasse 74, Hamburg 20359, Germany ("BNI");

Signature

Name

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 25**

**CHARITE - UNIVERSITAETSMEDIZIN BERLIN,** with legal address at Chariteplatz 1, Berlin 10117, Germany **("CUB");**

Signature

Name

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 26

DEPARTMENT OF HEALTH, with legal address at Quarry House, Quarry Hill, Leeds LS2 7UE, United Kingdom (“DH”);

Signature

Name

Title

Date

Senior Business Development Manager

14 March 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 27**

**UNIVERZA V LJUBWANI,** with legal address at Kongresni Trg 12, Ljubljana 1000, Slovenia **("UL);**

Signature:

Name:

Title:

Rector

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 28

BIOMEDICINSKE CENTRUM SLOVENSKEJ AKADEMIE VIED, VEREJNA VYSKUMNA INSTITUCIA,

with legal address at Dubravska Cesta 9, Bratislava 845 05 , Slovakia ("BMC SAV");

Signature Name

77 *I*

259

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 29**

**UNIVERSITAT BASEL,** with legal address at Petersplatz 1, Basel 4051, Switzerland **("UNIBAS");**

Vice President for Research

Date

78 *I* 259

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe" )**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceab le agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 30**

**ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI ISTITUTO DI**

**RICOVERO E CURA A CARATTERE SCIENTIFICO,** with legal address at Via Portuense, 292, ROMA 00149, Italy **("INMI");**

Signature

Name

ISTITUTO N

Title

00149 ROMA ·VIA PORTUENSE, 292

79 *I* 259

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 31**

**The State of the Netherlands, represented by it's Minister of Health, Welfare and Sport, on behalf of the Minister represented by Professor Johannes Brug, Director-General of the National Institute for Public Health and the Environment (RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU),** with legal address at Antonie Van Leeuwenhoeklaan 9, Bilthoven 3721 MA, Netherlands **("RIVM");**

Name

Title Directeur-generaal

Date 06/06/23

80 *I* 259

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISiDO Re Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 32**

**PHILIPPS UNIVERSITAET MARBURG,** with legal address at Biegenstrasse 10, Marburg 35032, Germany **("UMR");** *7*

Signature

Name

Acknowledged and agreed

79 I 136

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 33

THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS, with legal

address at Area 1A, Nobel House, Smith Square 17, LONDON SW1P 3JR, United Kingdom, acting through the Animal and Plant Health Agency (APHA), Addlestone, Surrey, United Kingdom, (“DEFRA”);

Signature

Name

Title

Date

Director of Scientific Services

20/03/2023

82 / 259

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for lnfectios Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of cl handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties.The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format).The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 34**

**FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT,**

with legal address at Sudufer 10, Geifswald-lnsel Rierns 17493, !3ermany **("FLI");**

Signature

Name

Title

81 / 154

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 35

THE PIRBRIGHT INSTITUTE LBG, with legal address at Ash Road, Pirbright, Woking GU24 0NF, United Kingdom (“TPI”);

Signature

2nd March 2023

Name

Title

Director of Finance & Company Secretary

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 37

ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE, with legal address at Viale Dell Universita 10, Legnaro 35020, Italy ("IZSVE");

· Signature Name

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature {e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature {e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 38**

**LEIBNIZ-INSTITUT DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UNO**

**ZELLKULTUREN GMBH,** with legal address at lnhoffenstrasse 7b, Braunschweig 38124, Germany

**("DSMZ");**

Scientific Director

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this JSJDORe Consortium Agreement to be duly signed by the under.signed authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 39

JULIUS-KUHN·INSTITUT BUNDESFORSCHUNGSINSTITUT FUR KULTURPFLANZEN, with legal address at ERWIN-BAUR-STRASSE 27, QUEDLINBURG 06484, Germany (JKI");

Name

Title

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this fSIOORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 40**

**AGRICULTURAL RESEARCH COUNCIL INSTITUTE FOR SOIL CLIMATE AND WATER,** with legal

elvedere Street 600, Pretoria 0001, South Africa **("ARC");**

Name

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 41**

**STICHTING WAGENINGEN RESEARCH,** more specifically its institute Wageningen Bioveterinary Research with legal address at Houtribweg 39, LELYSTAD 8221 RA,, Netherlands **("WR");**

Signature

Name

Title Managing Director

Date 25 April202

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 42

MOREDUN RESEARCH INSTITUTE, with legal address at Pentlands Science Park, Bush Loan, PENICUIK EH26 0PZ, United Kingdom (“MRI”);

Signature

Name

Title

Date

Chief Operating Officer

19th May 2023

ISIDORe Consortium Agreement

*f*

Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")** .

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present lSIDORe Consortium Agreement is made in an electronic version which ·is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF · format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 43**

**AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS M.P.,** with legal

--

address at Calle Serrano 117, Madrid 28006, Spain **("CSIC");**

1 Title: Vice-president for International Affairs


By Delegation from the President (Resolution published on the Spanish Official Journal dated 28/01/2021)

..











Projects Office Coordinator

20/04/2023

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 45**

**EIDGENOESSISCHES DEPARTEMENT DES INNERN,** with legal address at lnselgasse 1, BERN 3003, Switzerland (MEDl-IVI");

Signature

Name

Title

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

Party 46

PANSTWOWY INSTYTUT WETERYNARYJNY - PANSTWOWY INSTYTUT BADAWCZY , with legal

address at Partyzantow 57, PULAWY 24100, Poland ("PIWET");

Signature

!

Name:

Title: Professor

Date: 10/03/2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 47**

**AARHUS UNIVERSITET,** with legal address at NORDRE RINGGADE 1, AARHUS C 8000, Denmark

**("AU");**

Signature

Name

Date

DocuSign EnvelopeID:A5AE29C5-DAA6-4E 11-AF04-4A785731 B62F

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 48**

**AGENCE NATIONALE DE SECURITE SANITAIRE DE L'ALIMENTATION DE L'ENVIRONNEMENT**

**ET DU TRAVAIL,** with legal address at 14 Rue Pierre et Marie Curie, Maisons Alfort 94700, France

**("ANSES");**

Signature

Name

Title

Date 24/03/2023

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 49

THE UNIVERSITY COURT OF EDINBURGH, with legal address at Old College, South Bridge, Edinburgh EHB 9YL, United Kingdom ("UEDIN );

Signature

Name

### Title Solicitor.Head of Research Contracts

Date Aug 28, 2023

Adobe Acrobat Sign Transaction Number: CBJCHBCAABAAU1xlBXIY3woX3Ei 9MrrRtPbPybtljqDn

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signatur e (e.g. scan in PDF format), and agree this shall constitute a va lid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format).The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 51**

**NOLDUS INFORMATION TECHNOLOGY BV,** with legal address at NIEUWE KANAAL 5, WAGENINGEN 6709 PA, Netherlands **("NOLDUS");**

Signature

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed ..the undersigned authorised representatives in separate signature pages on the day and year indicated in the signa ure.

**Party 52**

**STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER,** with legal address at Lange Kleiweg 161, Rijswijk Zh 2288 GJ, Netherlands **("BPRC");**

Name

Title

..

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDPRe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties.The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 53

HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH, with legal address at

lnhoffenstrasse 7, Braunschweig 38124, Germany ("HZI");

Signature

Name

Title Scientific Director Legal Affairs and Licenses

Date ''

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 54**

**INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA,** with legal address at Avenida Da Republica Quinta Do Marques, Oeiras 2781-901, Portugal **("IBET");**

Signatur

Name

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 55

STATENS SERUM INSTITUT, with legal address at Artillerivej 5, 2300 Copenhagen S., Denmark (“SSI”);

Signature: Name:

Title: CEO

Date: May 9th, 2023

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 56

UNIVERSITA DEGLI STUDI DISIENA, with legal address at Via Banchi Di Sotto 55, Siena 53100, Italy ("UNISI");

Signature

Name

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version wh ich is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 57**

**VACCINE FORMULATION INSTITUTE(CH)LTD,** with legal address at Rue du Champ-Blanchod 4, Plan Les Quates 1228, Switzerland **("VFI");**

Signature

Name

Title

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 58**

**COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES,** with legal address

at Rue Leblanc 25, Paris 15 75015, France **("CEA");**

Signature

Name

Title

Date **1 5 MARS 2023**

107 / 259

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 59

ACADEMISCH ZIEKENHUIS LEIDEN, with legal address at ALBINUSDREEF 2, LEIDEN 2333 ZA,

Netherlands (“LUMC”);

Signature

Name

Title

Managing director

Date 20-03-2023

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 60

STICHTING AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT, with legal

address at Paasheuvelweg 25 Tower C4, Amsterdam 1105 BP, Netherlands (“AIGHD”);

Signature

Name

Title

Date

General Manager

13 March 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISJDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g.,scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 61**

**STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG,** with

legal address at OTTERSTRAAT 118-124, UTRECHT 3500 BN, Netherlands **("NIVEL.);**

Signature

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 62**

**MEDIZINISCHE UNIVERSITAET WIEN,** with legal address at SPITALGASSE 23, WIEN 1090, Austria

**("MUW");**

Title

Vice Rector for Research and Innovation

Date

03.03.2023



Signature of the Consortium Agreement for the Integrated Services for



Grant Agreement No.: 101046133

## 13 Signatures

The Parties agree to execute this Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format) , and agree this shall constitute a valid and enforceable agreement between the Parties. The present Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g. , scan in PDF format).

The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written.

Party 63

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

Signature

Name

Title  Date

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 64

BRAC JANES P GRANT SCHOOL OF PUBLIC HEALTH, BRAC UNIVERSITY, with legal address at

6th floor Medona tower, 28 Mohakhali Commercial Area, Bir Uttom A K Khandakar Road, Dhaka- 1213, Bangladesh (“BRAC”);

Signature Name

Title Dean and Professor

Date March 15, 2023



**Signature of the Consortium 'Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signatue (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party 'via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned. authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 65**

**UNIVERSITY COLLEGE LONDON,** with legal address at Gower Street, London WC1E 6BT, United Kingdom **("UCL")·**

I ----

Name'..

Title: Head of European Contract Management, European Research & Innovation Office (ERIO)

. Date: 01/03/2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format)**.** The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 66**

**CENTRE REGIONAL DE RECHERCHE ET DE FORMATION A LA PRISE EN CHARGE CLINIQUE**

**DU VIH SIDA ET MALADIES ASSOCIEES DE DAKAR CRCF**, with legal address at Chnu De Fann, Avenue Cheikh Anta Diop, Dakar 18524, Senegal (“**CRCF**”) ;

Signature Name

Title

Date

General secretary

01/06/2023

DocuSign EnvelopeID: 1A2D73F4-DDOD-4EOO-B4E1-73CA9D24FOF7

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 67**

**VIB VZW,** with legal address at Rijvisschestraat 120,Zwijnaarde - Gent 9052, Belgium **("VIB VZW');**

Signature

Name

Title managing director

Date 03 March 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISiDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned **authorised representatives in separate signature pages on the day and year indicated in the signature.**

**Party 68**

**UNIVERSITE DE LIEGE,** with legal address at PLACE DU 20 AOUT 7, LIEGE 4000, Belgium

**('ULIEGE");**

Signature

03/03/2023

**Signature of the Cons ortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handw ritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties.The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format) . The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 69**

**MASARYKOVA UNIVERZITA ,** with legal address at Zerotinovo namesti 9, BRNO 601 77, Czechia

**("MU");**

Signature

Name

Title Director of the Research and Development Office

Date **0 *7* -03- 2023**

116 *I* .

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an elect ronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 70**

**BIOTECHNOLOGICKY USTAV AV CR** WI, with legal address at Prumyslova 595, Vestec 252 50, Czechia **("IBT");**

Signature

.

Title:

Date: 06. 03. 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties.The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 71**

**JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN,** established in Theodor W

Adorno Platz 1, Frankfurt Am Main 60629, Germany **("GUF");**

Signature

Name

Title

.

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 72**

**OULUN YLIOPISTO,** with legal address at Pentti Kaiteran Katu 1, Oulu 90014, Finland **("UOULU");**

Director, Biocenter Oulu Research Infrastructure Services Date

Research Funding Specialist



ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 73

ITA-SUOMEN YLIOPISTO, with legal address at Yliopistonranta 1e, Kuopio 70211, Finland (“UEF”);

Signature

Name

Title

Date

Dean of the Faculty of Science, Forestry and Technology

Kuopio 21.3.2023

ISIDORe Consortium Agreement Execution copy



**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Pa rties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a ha ndwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortiu m Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a ha ndwritten signatu re (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives i n separate signature pages on the day and year indicated i n the signature.

**Party 74**

**HELSINGIN YLIOPISTO,** with legal address at Yliopistonkatu 3, Helsingin Yliopisto 00014, Finland

**("UH");**

Date:

Signature:

Name:

Title: Vice-Rector, University of Helsinki

Date

Signature: Name:

Title: Principal Investigator, Faculty of Biological and Environmental Sciences, University of Helsinki

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 75**

**CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE,** a French Economic Interest

Group (Groupement d'lnteret Economique), organized under the laws of France, registred under the n° SIRET 38111246500020, with legal address at Rue Laurent Fries 1, BP 10142, lllkirch 67404, cedex, France **("CERBM")**

Signature

Name

Title Director of GIE CERBM

Date March 8th 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 76**

**CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS,** with legal address at Rue Michel Ange 3, Paris 75794 , France **("CNRS");**

Title

Date **2 7 MARS *1013***

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 77

WEIZMANN INSTITUTE OF SCIENCE, with legal address at Herzl Street 234, Rehovot 7610001, Israel ("WEIZMANN");

Signature

16:27:49 +02'00'

Name

Title Head of Research Grants and Projects office

Date

Signature

.

Name

Title Head of Projects Branch,Finance Division

Date

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreem nt between the Parties. The presentJ?lDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISlDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 78

CONSORZIO INTERUNIVERSITARI O RISONANZE MAGNETICHE DI METALLO PROTEINE, with

legal address at Piazza San Marco 4, Firenze 50121, Italy ("CIRMMP");

Signature

Name

Title Member of the Board of Directors of CIRMMP

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signatur e pages on the day and year indicated in the signatur e.

**Party 79**

**STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK**

**ZIEKENHUIS ,** with legal address at Plesmanlaan 121, Amsterdam 1066 CX, Netherlands **("NKI");**

Name

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format)**.** The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 80**

**UNIVERSITEIT LEIDEN**, with legal address at Rapenburg 70, Leiden 2311 Ez, Netherlands (“**ULEI**”);

Signature

Name

Title

Date

Executive Director Faculty of Science Leiden University

15 May 2023

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIOORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 81

UNIVERSITEIT UTRECHT, with legal address at Hei ("UU");

Sign

rglaan 8, Utrecht 3584 CS, Netherlands

Nam

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electron ic vers ion which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

**Party 82**

**CHEMICKY USTAV SLOVENSKEJ AKADEMIE VIED,** with legal address at DUBRAVSKA CESTA 9, BRATISLAVA 845, Slovakia **("IC SAS");**

Signature Name

Title

Date

131 I 259

DocuSign Envelope ID: 0226EOE2-AB7B-4939-9806-76F4778DC962

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 83**

**UNIVERSITY OF LEEDS,** with legal address at Woodhouse Lane, Leeds LS2 9JT, United Kingdom

**("UNIVLEEDS");**

Signature

A61 F1A5B4DFB404 ...

28 February 2023

Name

Title Head of Research Ops and Reporti ng

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 84**

**DIAMOND LIGHT SOURCE LIMITED,** incorporated and registered in England and Wales with company number 04375679 , with legal address at Diamond House, Harwell Science & Innovation Campus Chilton, Didcot, Oxfordshire, OX11 ODE, United Kingdom **("Diamond");**

Signature

Name

Title



ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 85

THE ROSALIND FRANKLIN INSTITUTE, with legal address at Building R113, Rutherford Appleton Laboratory, Harwell, Didcot OX11 0FA, United Kingdom (“RFI”);

Signature

Name

Title

Date

Chief Operating Officer

16 March 2023

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 86**

**ROUMEN TSANEV INSTITUTE OF MOLECULAR BIOLOGY BULGARIAN ACADEMY OF**

**SCIENCES ,** with legaladdress at Acad G. Bonchev 21, SOFIA 1113, Bulgaria **("IMB BAS");**

Signature

Name Title

Date

135/ 259

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 87**

**USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA**

**INSTITUCE,** with legal address at VIDENSKA 1083, PRAHA 4 142 20, Czechia **("IMG CAS");**

Signature Name

Title

Date

f53)

136 / 259

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 88

156. ABO AKADEMI, with legal address at Domkyrkotorget 3, ABO 20500, Finland (“ABO”);

Signature

Name

Title

135 / 204

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 89**

**DEBRECENI EGYETEM,** with legal address at Egyetem Ter 1, Debrecen 4032, Hungary **("UD");**

Signature


Name

Title

Date

**·**

138 *I* 259



Director of Department Biomedical Sciences CNR

07/14/23

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 91

UNIVERSITA DEGLI STUDI DI TORINO, with legal address at Via Giuseppe Verdi 8, Torino 10124, Italy (“UNITO”);

Signature

Name

Title

Date

Director of Department

07/03/2023

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 92**

**ELETTRA - SINCROTRONE TRIESTE SCPA,** with legal address at Ss 14 Km 163.5 Area Science Park, Basovizza Trieste 34149, Italy **("ELETTRA");**

Signature Name

Title Chief Executive Officer

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 93

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM, with legal address at GEERT

Grooteplein 10 Zuid, Nijmegen 6525 GA, Netherlands (“RADBOUDUMC”);

Signature:

Date: 28-02-2023

Head of department of medical microbiology

Signature:

Date: 01-03-2023

Director of Valorisation / Technology transfer

Signature:

TTO# A22-1358

Date: 28-02-2023

Principal Investigator

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 94

UNIVERSITAIR MEDISCH CENTRUM UTRECHT, with legal address at Heidelberglaan 100, Utrecht 3584 CX, Netherlands (“UMCU”);

Name

Title

Date

Chair and Medical Scientific Manager dLAB

07/03/2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present JSJDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this JSJDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

**Party 95**

**UNIVERSITETET I OSLO,** with legal address at Problemveien 5-7, Oslo 0316, Norway **("UiO");**

Title

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 96**

**TURUN YLIOPISTO,** with legal address at Yliopistonmakl, Turku 20014, Finland **("UTU");**

Signature

Name

Title Vice Rector

Date

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 97

VIENNA BIOCENTER CORE FACILITES GMBH, with legal address at Dr Bohr Gasse 3, Wien 1030, Austria (“VBCF”);

Signature

Name

Title

Managing Director, Vienna BioCenter Core Facilities GmbH

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 98**

**INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC,** with legal address at Rua Alfredo Allen 208, Porto 4200 135, Portugal **("IBMC");**

Signature

Name

Title

Date

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 99

FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS

INNOVADORES EN ANDALUCIA, with legal address at Avda Del Conocimiento 3, Armilla Granada 18100, Spain (“MEDI”);

Signature

Name

Title

Date

Scientific Director

March 10, 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g.,scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 100**

**INSTYTUT CHEMll BIOORGANICZNEJ POLSKIEJ AKADEMll NAUK,** with legal address at Noskowskiego 12-14, Poznan 61 704, Poland, represented by the Director of the Institute Prof. Dr. Marek Figlerowicz; **("IBCH");**

Signature

Name

Title

Date

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 101

DANMARKS TEKNISKE UNIVERSITET, with legal address at Anker Engelundsvej 1 Bygning 101 A, Kgs Lyngby 2800, Denmark (“DTU”);

Signature

Name

Title

Date

Professor, Head of Department

13 March 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 102**

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

**Party 103**

**FORSCHUNGSVERBUND BERLIN EV,** Leibniz-Forschungsinstitut fuer Molekulare Pharmakologie, with legal address at Rudower Chaussee 17, Berlin 12489, Germany, jointly represented by the Director of the Institute Prof. Dr. Volker Haucke and the Managing Director Dr. Nicole MOnnich **("FMP");**

Signature

Name

Title Director FMP Managing Director FVB

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISiDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 104**

**FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.,**

with legal address at Hansastrasse 27c, MOnchen 80686, Germany acting as legal entity for and on behalf of its Fraunhofer institute ITMP **("Fraunhofer ");**

Signature

Name

Title

Date

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe ")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwr itten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 105**

**UNIVERZITA PALACKEHO V OLOMOUCI,** with legal address at Krizkovskeho 8, Olomouc 771 47, Czechia **("UP");**

Signature

Name

154 / ,

ISIDORe Consorllum Agreement Execution copy

Signature of the Cons ortium Agreement for the Integrated Servic es for Infectious Disease Outbreak Researc h Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized Image of a handwritten signature (e.g. scan In PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement Is made in an electronic version which is signed by each Party via a scanned or digitized Image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year Indicated In the signature.

Signature

Name

Title Senior Legal Adviser, FIA-UIB

Date 2023-04-18

Read and approved by Department of Biomedicine:

155 / 259

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe" )**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 107**

**SINTEF AS,** with legal address at Strindvegen 4, Trondheim 7034, Norway **(" SINTEF");**

Signature

Name

*.*

Title Research Director

Date 17 March 2023

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 108

INSTYTUT BIOCHEMll IBIOFIZYKI POLSKIEJ AKADEMll NAUK, with legal address at Pawinskiego Sa, Warszawa 02 106, Poland ("IBB PAN");

Signature

Name

Title Prof.

Date 18.04.2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format).The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned author ised representatives in separate signature pages on the day and year indicated in the signature.

**Party 110**

**WARSZAWSKI UNIWERSYTET MEDYCZNY,** Department of Plant Sciences with legal address at UI. Zwirki IWigury 61, Warszawa 02 091, Poland **("MUWa");**

Signature

Name

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 111**

**FONDAZIONE PER L'ISTITUTO DI RICERCA IN BIOMEDICINA,** with legal address at VIA Francesco Chiesa 5, Bellinzona 6500, Switzerland **("IRB");**

Signature

Title IRB President ; IRB Director

Date March 1, 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe" )**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic vers ion which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

**Party 112**

**JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH,** with legal address at Leonhardstrasse 59 , Graz 8010 , Austria **("JR");**

Signature

Name

Title



**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe"}**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature .

**Party 113**

**IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON ,** with legal address at Soranou Efesiou 4, AthinA 115 27, Greece **("BRFAA");**

Name

Date

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe"}

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. sca n in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 114

SWISS CLINICAL TRIAL ORGANISATION, with legal address at Effingerstrasse 35, Bern 3008, Switzerland ("SCTO");

Title PRESIDENT SCTO

Signature

Name

Title MANAGING DIRECTOR SCTO

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 116**

**UNIVERZITA PAVLA JOZEFA SAFARIKA V KOSICIACH,** with legal address at Srobarova 2, Kosice 04180, Slovakia **("UPJS");**

Signature

Name

Title **rector**

Date **18.4.2023**

164 / 259

**Signature of the Consortium Agreement for the Integrated Services for Infectious isease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 117**

**UNIVERSIDADE NOVA DE LISBOA,** with legal address at Campus De Campolide, Lisboa 1099 085 , Portugal **("UNL");**

Signature

Name

Title

Date

165 / 259

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Patties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Patty 118

AL HF, with legal address at OLAV KYRRES GATE 17, TRONDHEIM 7006, Norway

Name

Title . .....

07/03/2023

Date

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., sca n in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 119

ISTITUTO SUPERIORE DI SANITA', with legal address at Viale Regina Elena 299, ROMA 00161, Italy ("ISS");

Signature

Name

Title

President

oate

167 *I* 259

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 120

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK, a body incorporated

under Charter with its place of address at at Western Road, Cork, Ireland (“UCC”);

Signature

Name

Title

Date

Director of Research Support and Policy

9th March 2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 121**

**KKS-NETZWERK EV -NETZWERK DER KOORDINIERUNGSZENTREN FUR KLINISCHE STUDIEN,**

with legal address at Alt-Moabit 96 A, Berlin 10559, Germany **("KKSN");**

Signature Name

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe" )**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 122**

**PECSI TUDOMANYEGYETEM - UNIVERSITY OF PECS,** with legal address at Vasvari Pal Utca 4, Pees 7622, Hungary **(" UPecs");**

Signature

Name

Title

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 123**

**NARODOWY INSTYTUT KARDIOLOGll STEFANA KARDYNALA WYSZVNSKIEGO -PANSTWOWY**

**INSTYTUT BADAWCZV,** with legal address at UI. Alpejska 42, Warszawa 04 628, Poland **("NIKARD.);**

Signature

Name

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 124**

**AIBILI ASSOCIACAO PARA INVESTIGACAO BIOMEDICA E INNOVACAO EM LUZ E IMAGEM,**

established in Azinhaga de Santa Comba, Celas, COIMBRA 3000 548, Portugal **("AIBILI");**

Signature

Name

Title President

I I

!

**Signture of the Consortium Agreement for the Integrated Services for**

\

**Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 125**

**FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PAZ,**

with legal address at PASEO DE LA CASTELLANA 261, MADRID 28046, Spain **("FIBHULP");**

Signature


Name

Title











Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 127

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES, with legal address at Avenida Prof Egas Moniz, Lisboa 1649 028, Portugal ("iMM );

(

Name

Title Executive Director and Vice- Director

Date 17.03.2023

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 128**

**OSLO UNIVERSITETSSYKEHUS HF,** with legal address at KIRKEVEIEN 166 TARNBYGGET , OSLO 0450 , Norway **{OUH");**

Signature

Name

DocuSign Envelope ID: 0711AF39-2EEF-41B6-9BD0-317FAB8D20EC

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 129

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA, with legal

address at Passeig Vall D Hebron 119-129 Edificio De Recerca, Barcelona 08035, Spain (VHIR");

Signature

Name


Title Di rector

Date











President of Directive Board Member of Directive Board

6 March 2023 6 March 2023

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 131

STAZIONE ZOOLOGICA ANTON DOHRN, with legal address at Villa Comunale, NAPOLI 80121, Italy (“SZN”);

Signature Name:

Title: President

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 132

ASSISTANCE PUBLJQUE HOPITAUX DE PARIS, with legal address at 55 BOULEVARD DIDEROT, PARIS 75012, FRANCE ("APHP");

Signature

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 133**

**HOSPICES CIVILS DE LYON,** with legal address at QUAI DES CELESTINS 3, LYON 69002, France

**("HCL");**

179 / 257

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 135

UNIVERSITY OF GLASGOW, with legal address at University Avenue, Glasgow G12 Bqq, United Kingdom ("UG");

Signature

Name

Title Date

183 / 259

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. sca n in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agree ment to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 136**

**INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT ,** witfl legal address at in Boulevard De Dunkerque 44 Cs 90009, Marseille 13572, France **("IRD);** ' • "

Signature

Name

Title

Date

184 / 259



ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreeme nt No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electron ic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 137

INSTITUT PASTEUR DE NOUVELLE-CALEDONI E, secondary establishment of lnstitut Pasteur, with legal address at AVENUE PAUL DOUMER 11 CENTRE VILLE, NOUMEA 98845, New Caledonia, represented by its director duly autorised by delegation of the General Director of lnstitut Pasteur ("IPNC");

Signature

Name

Title

Date

185 / 259

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g.,scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 138**

**UNIVERZITA KARLOVA,** with legal address at OVOCNY TRH 560/5, PRAHA 1, 11636, Czechia

**("CU");**

Signature

Name:

Title: Dean of the Faculty of Science, Charles University

Date **1 6 -03- 2023**

186 / 259

ISIDORe Consortium Agreement Execution copy

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 139

CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR

LEDEVELOPPEMENT - C.I.R.A.D. EPIC, with legal address at Rue Scheffer 42, Paris 75016, France (“CIRAD”);

Signature

Name

Title

Date

25/05/2023



Managing Director of the Max Planck Institute for Infection Biology

16 March 2023

Signature of the Conaortium Agreement for the Integrated Service•for lnfectioua Diana• Outllraak RN•arch Praj•ct ("ISIDOR•")

###### Grant Agreement No.:101046133

1he Parties asree ta execull! this ISIDORe can-aum Ajp'eement by W1tf of 11 scanned or dl8'tlzed lmap of a hanct.wltten sllllature (e.g. scan In PDF format), and 11ree U1ls shall collltltute a valld and enforceable asreement between the Parties. The pn!Se'lt ISIDORe Consortium Aareement ia made in an electronic wersion ldl ts slllled by sch Party vii a llGlnned or dl&ltlzed lmlllll! of a handwritten sljpiature [11.41-, SCll'I In PDF format).The Parties have caused this ISIDORe Conronlum Asreernent ta be dulv signed by the undetll&ned

authorlaed repretentlltl11e& In separate sllllaturePliSonthedayandyear Indicated In thes11nat11re.



IDRYllA TECHNOLOGIAS KAI EREVNAS, wtth legal addreea at N Pl.Ura 811' 100, lralclelo 70013,

GI.-('FORIH');



Nlme

Tiiie

ISIDORt1 Co11sor11um Agruement Exocullon copy

Signature of the Consortium Agreement for the Integra ted Services for Infectiou s Disease Outbreak Researc h Projec t ("ISIOOR e")

Grant Agreement No.. 101046133

The Parties agreelo execule thisISIDORe Consortium Agreemt>nt by way of ;i scanned or d1g111zed image of a handwritten signature (e.g scan in PDF formal), and agree this sh<ill constitute a valid and enforceable agreemenl bt!lween the Parties.The presenl ISIDORe Consortium Agreement 1s made in an electronic version "<h1ch Is signed by each Party via a scanned or d1g11lzed Image of a handvmnen signature (e.g., scan m PDF format). he Parl1es have caused this ISIDORe Consor tium Agreement to be duly signed by the undersigned authomed representatives in separate signalure pages on hc day and year lnd1catcd in the signature.

Party 143

UNIVERZITET U NOVO SAOU, POLJOPRIVREONI FAKULTET NOVI SAD w1lh legal address al

Trg Dos11eja Obradov1ca 8 N v1 Sad 21000 Serbm ( FANS")

S1gna1ure

Nam

Title

0l·03- ZOZ3

189

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe" )**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 145**

**INSTITUT PASTEUR DE DAKAR ,** with legal address at Avenue Pasteur 36, Dakar, Senegal **("IP Dakar");**

Signature

Name

Title

Date

192 / 259

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 146**

**UNIVERSITE DES SCIENCES DES TECHNIQUES ET DES TECHNOLOGIES DE BAMAKO,** with

legal address at in Quartier ACI 2000 Rue 405 Porte 359, Bamako Bp1805, Mali **(USTTB");**

Signature

Name:

Title: RECTOR

Date

193 / 259

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 147**

**WAGENINGEN UNIVERSITY,** Department of Plant Sciences, with legal address at Droevendaalsesteeg 1, Wageningen 6708 PB, Netherlands **("WU");**

Signature

Title Director Operations

Date 27-03-2023

194 *I* 259

ISIDORe Consortium Agreement Execution copy

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. ·scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each **Party** via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 148**

**MINISTERE DE LA SANTE ET DE L'HYGIENE PUBLIQUE,** with legal address at, 10278

Ouagadougou, Burkina Faso **("INS**

\*

Signature

Name

Title


Date O 4 SEP 2023


195 /











Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 150

CENTRO AGRICOLTURA E AMBIENTE GIORGIO NICOLI SRL, with legal address at Via Sant' Agata 835 , Crevalcore 40014, Italy ("CAA");

Signature

Name

Title Legale Rappresentante

Date 28/03/2023

197 / 259

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format)**.** The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 151**

**TROPIQ HEALTH SCIENCES**, with legal address at Transistorweg 5 2e Verdiepin, Nijmegen 6534 at, Netherlands (“**TROPIQ**”);

Title

Date

##### CEO CFO

##### March 13th 2023 March 13th 2023

198 / 259

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 152

AVIA-GIS NV, with legal address at Risschotlei 33, Zoersel2980, Belgium (MAvia");

Signature

Name

Title

Date

**Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")**

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this JSIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

**Party 153**

**HITS GGMBH,** with legal address at Schloss Wolfsbrunnenweg 35, Heidelberg 69118, Germany

**("HITS");**

Signature

Title

Date

ISIDORe Consortium Agreement

•Ref. Ares(2023)2386598- 03/04/2023

With qualified electronic signa.ture(s)

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project ("ISIDORe")

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 154

JRC - JOINT RESEARCH CENTRE- EUROPEAN COMMISSION, with legal address at Rue de la Loi 200, Brussels 1049, Belgium ("JRC").

Signature

Name

Title

Signature of the Consortium Agreement for the Integrated Services for Infectious Disease Outbreak Research Project (“ISIDORe”)

Grant Agreement No.: 101046133

The Parties agree to execute this ISIDORe Consortium Agreement by way of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format), and agree this shall constitute a valid and enforceable agreement between the Parties. The present ISIDORe Consortium Agreement is made in an electronic version which is signed by each Party via a scanned or digitized image of a handwritten signature (e.g., scan in PDF format). The Parties have caused this ISIDORe Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages on the day and year indicated in the signature.

Party 155

SCUOLA UNIVERSITARIA PROFESSIONALE DELLA SVIZZERA ITALIANA with legal address at

Stabile Le Gerre, Via Pobiette 11, 6928 Manno, Switzerland, (“SUPSI”)

Signature Signature

Name

Title

Director

Director

Department of Environment Constructions and Design

Research,Development and Knowledge Transfer

Dr. Dr.

Date

13th March 2023

15.03.2023

# Attachment 1: Background included

According to the Grant Agreement (Article 16.1) Background is defined as “data, know-how or information (…) that is (…) needed to implement the Action or exploit the Results”. Because of this need, Access Rights have to be granted in principle, but Parties must identify and agree amongst them on the Background for the Project. This is the purpose of this attachment.

For the entities listed in the table below, it is agreed between the Parties that, to the best of their knowledge, at the time of signature of the Consortium Agreement, no data, know-how or information is currently needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article

16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement.

Following entities currently have no Background to contribute:

|  |  |
| --- | --- |
| **PARTY NUMBER** | **PARTY NAME** |
| 1 | EUROPEAN RESEARCH INFRASTRUCTURE ON HIGHLY PATHOGENIC AGENTS (ERINHA) |
| 3 | INRAE |
| 4 | INSTITUT PASTEUR |
| 5 | EUROPEAN VACCINE INITIATIVE EWIV (EVI), |
| 7 | EURO-BIOIMAGING ERIC |
| 8 | EU-OPENSCREEN ERIC |
| 9 | EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN) |
| 10 | EATRIS ERIC |
| 12 | INFRAFRONTIER GMBH |
| 14 | EUROPEAN MOLECLAR BIOLOGY LABORATORY (EMBL) |
| 15 | INSERM |
| 16 | UNIVERSIDADE DO MINHO |
| 17 | INSERM-TRANSFERT |
| 18 | FOLKHALSOMYNDIGHETEN |
| 19 | INSTITUTO NACIONAL DE SAÚDE DOUTOR RICARDO JORGE (INSA), |
| 20 | NEMZETI NEPEGESZSEGUGYI KOZPONT (NNK), |
| 21 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC), |
| 22 | KATHOLIEKE UNIVERSITEIT LEUVEN |
| 23 | MEDICAL UNIVERSITY OF GRAZ |
| 24 | BNI |
| 25 | CHARITÉ |
| 26 | DEPARTMENT OF HEALTH (DH) |
| 28 | BIOMEDICINSKE CENTRUM SLOVENSKEJ AKADEMIE VIED, VEREJNA VYSKUMNA INSTITUCIA |
| 29 | UNIVERSITAT BASEL |
| 30 | ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI IRCCS |
| 31 | RIVM |
| 35 | THE PIRBRIGHT INSTITUTE |
| 37 | ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE (IZSVe), |
| 38 | LEIBNIZ-INSTITUT DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GMBH (DSMZ), |
| 40 | AGRICULTURAL RESEARCH COUNCIL INSTITUTE FOR SOIL CLIMATE AND WATER (ARC), |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 41 | STICHTING RESEARCH | WAGENINGEN | | RESEARCH | | | - | WAGENINGEN | | | BIOVETERINARY | | |
| 42 | MRI | | | | | | | | | | | | |
| 43 | CSIC | | | | | | | | | | | | |
| 44 | INSTITUT DE RECERCA I TECNOLOGIA AGROALIMENTÀRIES (IRTA), | | | | | | | | | | | | |
| 45 | EDI-IVI | | | | | | | | | | | | |
| 47 | AARHUS UNIVERSITY, | | | | | | | | | | | | |
| 49 | THE UNIVERSITY OF EDINBURGH (UEDIN), | | | | | | | | | | | | |
| 51 | NOLDUS | | | | | | | | | | | | |
| 52 | STICHTING BIOMEDICAL PRIMATE RESEARCH CENTRE (BPRC), | | | | | | | | | | | | |
| 54 | iBET | | | | | | | | | | | | |
| 56 | UNIVERSITA DEGLI STUDI DI SIENA (UNISI) | | | | | | | | | | | | |
| 59 | ACADEMISCH ZIEKENHUIS LEIDEN (LUMC), | | | | | | | | | | | | |
| 60 | STICHTING AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT, | | | | | | | | | | | | |
| 61 | STICHTING NEDERLANDS GEZONDHEIDSZORG (NIVEL) | | | INSTITUUT  , | | | VOOR | | ONDERZOEK | | | VAN | DE |
| 62 | MEDIZINISCHE UNIVERSITAET WIEN, | | | | | | | | | | | | |
| 63 | THE CHANCELLOR, OXFORD, | | MASTERS | | AND | SCHOLARS | | | OF | THE | UNIVERSITY | | OF |
| 64 | BRAC UNIVERSITY | | | | | | | | | | | | |
| 65 | UNIVERSITY COLLEGE LONDON (UCL), | | | | | | | | | | | | |
| 66 | CENTRE REGIONAL DE RECHERCHE ET DE FORMATION A LA PRISE EN CHARGE CLINIQUE DU VIH SIDA ET MALADIES ASSOCIEES DE DAKAR CRCF (CRCF), | | | | | | | | | | | | |
| 67 | VIB VZW | | | | | | | | | | | | |
| 68 | UNIVERSITE DE LIEGE | | | | | | | | | | | | |
| 69 | MASARYK UNIVERSITY | | | | | | | | | | | | |
| 71 | JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN (GUF) | | | | | | | | | | | | |
| 72 | UNIVERSITY OF OULU | | | | | | | | | | | | |
| 73 | UNIVERSITY OF EASTERN FINLAND | | | | | | | | | | | | |
| 74 | HELSINGIN YLIOPISTO | | | | | | | | | | | | |
| 76 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), | | | | | | | | | | | | |
| 77 | WEIZMANN INSTITUTE | | | | | | | | | | | | |
| 78 | CIRMMP | | | | | | | | | | | | |
| 79 | STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NKI), | | | | | | | | | | | | |
| 80 | UNIVERSITEIT LEIDEN | | | | | | | | | | | | |
| 81 | UNIVERSITEIT UTRECHT | | | | | | | | | | | | |
| 83 | UNIVERSITY OF LEEDS, | | | | | | | | | | | | |
| 84 | DIAMOND LIGHT SOURCE LTD | | | | | | | | | | | | |
| 85 | ROSALIND FRANKLIN INSTITUTE, | | | | | | | | | | | | |
| 86 | ROUMEN TSANEV INSTITUTE OF MOLECULAR BIOLOGY BULGARIAN ACADEMY OF SCIENCES (IMB BAS), | | | | | | | | | | | | |
| 88 | ABO AKADEMI | | | | | | | | | | | | |
| 89 | UNIVERSITY OF DEBRECEN, | | | | | | | | | | | | |
| 90 | CONSIGLIO NAZIONALE DELLE RICERCHE | | | | | | | | | | | | |
| 91 | UNITO – UNIVERSITA’ DEGLI STUDI DI TORINO | | | | | | | | | | | | |
| 92 | ELETTRA | | | | | | | | | | | | |
| 93 | RADBOUDUMC | | | | | | | | | | | | |
| 96 | TURUN YLIOPISTO, | | | | | | | | | | | | |
| 98 | INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC (IBMC), | | | | | | | | | | | | |
| 100 | INSTYTUT CHEMII BIOORGANICZNEJ POLSKIEJ AKADEMII NAUK (IBCH), | | | | | | | | | | | | |
| 101 | DANMARKS TEKNISKE UNIVERSITET | | | | | | | | | | | | |
| 102 | LATVIJAS ORGANISKAS SINTEZES INSTITUTS, | | | | | | | | | | | | |
| 103 | FORSCHUNGSVERBUND BERLIN E.V., LEIBNIZ-FORSCHUNGSINSTITUT FUER MOLEKULARE PHARMAKOLOGIE (FMP) | | | | | | | | | | | | |
| 104 | FRAUNHOFER-GESELLSCHAFT FORSCHUNG E.V. | | | | ZUR | FÖRDERUN | | | G DER | | ANGEWANDTEN | | |
| 105 | UNIVERZITA PALACKEHO V OLOMOUCI (UP) | | | | | | | | | | | | |
| 106 | UNIVERSITY OF BERGEN | | | | | | | | | | | | |

|  |  |
| --- | --- |
| 107 | SINTEF AS |
| 108 | INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS, POLISH ACADEMY OF SCIENCES, |
| 109 | NARODOWY INSTYTUT ONKOLOGII IM. MARII SKLODOWSKIEJ-CURIE - PANSTWOWY INSTYTUT BADAWCZY (MSCNRIO), |
| 110 | MEDICAL UNIVERSITY OF WARSAW |
| 111 | FONDAZIONE PER L’ISTITUTO DI RICERCA IN BIOMEDICINA (IRB), |
| 113 | IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON (BRFAA) |
| 114 | SWISS CLINICAL TRIAL ORGANISATION, |
| 116 | PAVOL JOZEF ŠAFARIK UNIVERSITY IN KOŠICE |
| 117 | UNIVERSIDADE NOVA DE LISBOA (UNL), |
| 118 | ST OLAVS HOSPITAL HF |
| 119 | ISTITUTO SUPERIORE DI SANITA’ (ISS), |
| 120 | UNIVERSITY COLLEGE CORK (UCC) |
| 121 | NETZWERK DER KOORDINIERUNGSZENTREN FÜR KLINISCHE STUDIEN (KKS-  Network, KKSN) |
| 122 | UNIVERSITY OF PÉCS, |
| 123 | NARODOWY INSTYTUT KARDIOLOGII STEFANA KARDYNALA WYSZYNSKIEGO - PANSTWOWY INSTYTUT BADAWCZY (NIKARD |
| 124 | AIBILI, |
| 125 | FIBHULP |
| 126 | INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL (IGTP) |
| 127 | INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES, |
| 128 | OSLO UNIVERSITETSSYKEHUS HF (OUH), |
| 129 | FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (VHIR), |
| 130 | CENTRO DE CIÊNCIAS DO MAR DO ALGARVE (CCMAR), |
| 131 | STAZIONE ZOOLOGICA ANTON DOHRN (SZN), |
| 132 | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (APHP) |
| 134 | MEDITERRANEE INFECTION, |
| 135 | UNIVERSITY OF GLASGOW |
| 138 | UNIVERZITA KARLOVA, |
| 139 | CIRAD |
| 140 | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (IMPERIAL) |
| 141 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV (MPG) |
| 142 | FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS (FORTH |
| 145 | INSTITUT PASTEUR DE DAKAR, |
| 146 | UNIVERSITE DES SCIENCES DES TECHNIQUES ET DES TECHNOLOGIES DE BAMAKO (USTTB), |
| 147 | WAGENINGEN UNIVERSITY |
| 148 | MINISTERE DE LA SANTE (CNFRP), |
| 149 | POLOGGB, |
| 150 | CENTRO AGRICOLTURA E AMBIENTE GIORGIO NICOLI SRL (CAA), |
| 153 | HITS |
| 154 | JOINT RESEARCH CENTRE (JRC) |
| 155 | SCUOLA UNIVERSITARIA PROFESSIONALE DELLA SVIZZERA ITALIANA |

It is agreed between the Parties that, to the best of their knowledge, the following Background is hereby identified and agreed upon for the Project for the Parties listed below. Specific limitations and/or conditions, shall be as mentioned hereunder:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **N°** | **Party abbreviation** | **Describe Background** | **Specific restrictions and/or conditions for implementation (Article 16.4 Grant Agreement and its Annex 5, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the Action”)** | **Specific restrictions and/or conditions for Exploitation (Article 16.4 Grant Agreement and its Annex 5, Section “Access rights to results and background”, sub-section “Access rights for exploiting the results”)** |
| **2** | AMU |  |  |  |
| **6** | **INSTRUCT-ERIC** |  |  |  |
| **11** | **BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI- ERIC** |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | BBMRI-ERIC ELSI Services | ELSI Knowledge Base: open access platform | ELSI Knowledge Base: open access platform |
| **13** | **EUROPEAN MARINE BIOLOGICAL RESOURCE CENTRE EUROPEAN RESEARCH INFRASTRUCTURE (EMBRC – ERIC),** |  |  |  |
| **27** | UNIVERZA V LJUBLJANI |  |  |  |
| **32** | **UMR** |  |  |  |
| **33** | **ANIMAL AND PLANT HEALTH AGENCY** |  |  |  |
| **34** | **FRIEDRICH-LOEFFLER- INSTITUT -**  **BUNDESFORSCHUNGSI** |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **NSTITUT FUER TIERGESUNDHEIT** |  |  |  |
| **36** | **COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO)**, |  |  |  |
|  |  |  |
|  |  |  |
| **39** | **JULIUS KUEHN INSTITUTE, FEDERAL RESEARCH CENTRE FOR CULTIVATED PLANTS (JKI)**, |  |  |  |
| **46** | **PIWet** |  |  |  |
|  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Animal models | No | No |
| **48** | **ANSES** |  |  |  |
|  |  |  |
| **50** | **InSCREENeX (ISX),** |  |  |  |
| **53** | **HZI** |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| **55** | **SSI** |  |  |  |
| **57** | **VACCINE FORMULATION INSTITUTE (VFI)**, |  |  |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **58** | **CEA**, |  | | |  |  |
|  |  |  |  |  |
| **70** | **INSTITUTE OF BIOTECHNOLOGY OF THE CZECH ACADEMY OF SCIENCES (IBT)**, |  | | |  |  |
| **75** | **CERBM / CBI / IGBMC** |  | | |  |  |
| **82** | **CHEMICKY USTAV SLOVENSKEJ AKADEMIE VIED** |  | | |  |  |
| **87** | **USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE** |  | | |  |  |
| **94** | **UNIVERSITY MEDICAL CENTER UTRECHT (UMCU),** |  | | |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **95** | **UNIVERSITY OF OSLO** |  |  |  |
|  |  |  |
|  |  |  |
| **97** | **VIENNA BIOCENTER CORE FACILITIES GMBH**, |  |  |  |
| **99** | **FUNDACION CENTRO DE EXCELENCIA EN**  **INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA** (**MEDI** |  |  |  |
|  |  |  |
| **112** | **JOANNEUM RESEARCH FORSCHUNGSGESELLS CHAFT MBH** |  |  |  |
|  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |
|  |  |  |
| **133** | **HCL** |  |  |  |
|  |  |  |
| **136** | **INSTITUT DE**  **RECHERCHE POUR LE DÉVELOPPEMENT** |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **137** | **INSTITUT PASTEUR DE NOUVELLE-CALÉDONIE** |  |  |  |
|  |  |  |
|  |  |  |
| **143** | **UNIVERZITET U NOVOM SADU, POLJOPRIVREDNI FAKULTET NOVI SAD (FANS)** |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |
|  |  |  |
| **151** | **TROPIQ HEALTH SCIENCES B.V** |  |  |  |
| **152** | **AVIA-GIS** |  |  |  |
|  |  |  |

# Attachment 2: Accession document

**ACCESSION of a new Party to ISIDORe Consortium Agreement, version [… , YY YY-MM-DD]**

[OFFICIAL NAME OF THE NEW PARTY AS IDENTIFIED IN THE Grant Agreement]

hereby consents to become a Party to the Consortium Agreement identified above and accepts all the rights and obligations of a Party starting [date].

ERINHA, as Coordinator, hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new Party] to the consortium starting [date].

This Accession document has been done in 2 originals to be duly signed by the undersigned authorised representatives.

[Date and Place]

[INSERT NAME OF THE NEW PARTY]

Signature(s) Name(s) Title(s)

[Date and Place] ERINHA

Signature

Name

Title Director General

# Attachment 3: List of Third Parties for simplified transfer according to Section 9.3.2.

|  |
| --- |
| **Partner 65: UCL**  UCL Business Ltd, The Network Building, 97 Tottenham Court Road, London, W1T 4TP |
| **Partner 77: WEIZMANN**   1. Yeda Research and Development Company Ltd., Technology Transfer Arm of the Weizmann Institute of Science, of P.O. Box 95, Rehovot 76100022. 2. xxx |
| **Partner 79: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS:**  STICHTING ONCODE INSTITUTE (“Oncode”), a foundation incorporated under the laws of the Netherlands, with its registered office at Jaarbeursplein 6, 3521AL, Utrecht, and registered with the chamber of commerce with number 69303010. Oncode will act as the exclusive valorisation partner for the intellectual property and know how developed by the research group of Dr. Anastassis Perrakis in the Project. |

# Attachment 4: Contract under mandate: One-Sided CDA

**[THIS IS A TEMPLATE CDA PROPOSED FOR THE ISIDORE PROJECT, WHOSE MEMBERS HAVE APPROVED THE SUBSTANTIVE PROVISIONS AND AUTHORISED ITS SIGNATURE ON THEIR BEHALF.**

**ANY MATERIAL CHANGES THAT COULD I MPAC T THE PARTI E S’ RIGHTS AND OBLIGATION UNDER THE CONSORTIUM AGREEMENT SHOULD NOT BE MADE WITHOUT ADDITIONAL APPROVALS, WHICH MAY CAUSE A DELAY.]**

**CONFIDENTIAL DISCLOSURE AGREEMENT (ONE WAY)**

**THIS CONFIDENTIAL DISCLOSURE AGREEMENT** (this “**Agreement**”) is made and entered into as of the [insert date] (the “**Effective Date**”), by and between:

ISIDORe Consortium Members, as defined below and listed in Exhibit 1;

and

***[insert Recipient’s name and Recipient’s address; if Recipient is anot her consortium insert: “[Y] Consortium Members, as defined below and listed in* Exhibit *2”]*** (“**Recipient**”)

**WHEREAS,**

1. The parties intend to disclose/receive confidential information for the purpose of facilitating discussions between the ISIDORe Consortium Members and the Recipient;
2. The ISIDORe Consortium Members have formed a consortium under Horizon Europe (“HE”) for the purpose of establishing the project called “the Integrated Services for Infectious Diseases Outbreak Research Project” (HE Grant Agreement No. 101046133) (the “**ISIDORe Project**”) and are parties to the ISIDORe Consortium Agreement, as defined below;
3. The ISIDORe Consortium Members have authorized ERINHA (the “**Mandate Holder**”) to execute this Agreement on behalf of the ISIDORe Consortium Members.

***[Delete Sections (D) if not applicable:]***

1. The [Y] Consortium Members of the project called “[title of Consortium]” (the “[Y] Project”) and are parties to the [Y] Consortium Agreement, as defined below,
2. The [Y] Consortium Members have authorized [name of authorized company or institution] (the “[Y] Mandate Holder”), to execute this Agreement on behalf of the [Y] Consortium Members.

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the parties hereto agree as follows:

1. **DEFINITIONS**

“**Entity under the same Control**” shall mean any legal entity that is under the direct or indirect control of a party, under the same direct or indirect control as a party, or is directly or indirectly controlling a party, control taking any of the following forms: (a) the direct or indirect holding of more than 50% of the nominal value of the issued share capital in the legal entity concerned, or of a majority of the voting rights of the shareholders or associates of that entity; (b) the direct or indirect holding, in fact or in law, of decision-making powers in the legal entity concerned.

“**Confidential Information”** shall mean any and all information that is disclosed on or after the Effective Date whether orally or in written, electronic or other tangible form by any of the ISIDORe Consortium Members (each referred to as a “Disclosing Party” and collectively as the “Disclosing Parties”) to any Recipient that relates to the ISIDORe Project.

“**ISIDORe Consortium Members**” shall mean the parties to the ISIDORe Consortium Agreement effective as of *[…]* (“**ISIDORe Consortium Agreement**”) as listed at Exhibit 1.

***[Delete if not applicable:***

“[Y] Consortium Members” shall mean the parties to the Consortium Agreement for *[title of Consortium]*

effective as of *[*

*]* (“*[Y]* Consortium Agreement”) as listed at Exhibit 2. *]*

1. **PURPOSE OF DISCLOSURE**

The Confidential Information is being disclosed to the Recipient for the purpose of facilitating discussions between ISIDORe Consortium Members and the Recipient [**CHECK THE APPROPRIATE BOX**]:

* in order to engage in discussions regarding the providing of independent advice to ***[insert the applicable****:* “the ***[specify committee]*** committee of the ISIDORe Project ”; *or* “the various committees in the ISIDORe Project” or “the consortium of the ISIDORe Project as such”*]*;
* in order to engage in discussions regarding the accession of the Recipient to the ISIDORe

Project consortium in compliance with the ISIDORe Consortium Agreement;

* in order to engage in discussions regarding a collaboration between the **ISIDORe Project**

consortium and the Recipient; (the “**Purpose**”).

1. **MAINTENANCE OF CONFIDENTIALITY; NON-USE OBLIGATIONS**

* Each Disclosing Party’s Confidential Information shall be kept confidential by the Recipient and, except as otherwise permitted herein, shall not be disclosed by the Recipient to any Third Party without first obtaining the Disclosing Party’s prior written consent to such disclosure. The Recipient shall protect the Confidential Information in the same manner it protects its own confidential information of a similar nature, which shall be at least a reasonable standard of care. Recipient may disclose the Confidential Information only to its officers, employees, consultants and/or Entities under the same Control on a need-to-know basis, provided that the Recipient will have executed or shall execute appropriate written agreements with its employees, consultants and Entities under the same Control sufficient to enable compliance

with all the provisions of this Agreement with respect to the Confidential Information. The Recipient shall be liable for any damage caused by or resulting from any unauthorized disclosure of the Confidential Information by the Recipient’s employees, consultants or Entities under the same Control.

* The Confidential Information shall not be utilized by the Recipient, except for the Purpose permitted herein, without first obtaining the Disclosing Party’s prior written consent to such use.

1. **EXCLUDED INFORMATION**

Subject to applicable data protection legislation providing otherwise, Confidential Information shall not include any information which:

* at the time of disclosure is in the public domain;
* after disclosure becomes part of the public domain, except through breach of this Agreement by Recipient;
* Recipient can demonstrate by reasonable proof was in Recipient’s or any of its Entities under the same Control’ possession prior to the time of disclosure by a Disclosing Party hereunder, and was not acquired directly or indirectly from a Disclosing Party;
* Recipient can demonstrate by reasonable proof was developed by or on behalf of Recipient or its Entities under the same Control independent of and without reference to the Confidential Information; or
* becomes available to Recipient or its Entities under the same Control from a Third Party who did not acquire such information directly or indirectly from a Disclosing Party and who is not otherwise prohibited from disclosing such information.

Confidential Information shall not be deemed to be or have become public knowledge merely because any part of such Confidential Information is embodied in general disclosures or because individual features, components or combinations thereof are known or become known to the public.

1. **NOTIFICATION OF MANDATORY DISCLOSURE**
   1. Recipient may disclose that portion of Confidential Information that is required by law to be disclosed, provided that, to the extent practicable, the Disclosing Party is first given advance notice of the required disclosure and an adequate opportunity to seek appropriate legal relief to prevent such disclosure or limit use and further disclosure of the Confidential Information. Recipient shall cooperate with the Disclosing Party in seeking an appropriate relief or remedy and shall use reasonable efforts to secure confidential treatment of any Confidential Information disclosed.
   2. If, in the absence of such legal relief or other remedy, the Recipient is nonetheless required to disclose any part of the Confidential Information, the Recipient may disclose such Confidential Information without liability hereunder, provided that the Recipient shall furnish only such portion of the Confidential Information which the Recipient is legally required to

disclose. For the avoidance of any doubt, if the Recipient is required to disclose Confidential Information pursuant to the Recipient’s obligations under the provisions of any applicable law or regulation in any other applicable jurisdiction, the Recipient shall in all instances seek to apply the exemptions under that applicable law or regulation. The disclosure of personal data shall furthermore be subject to the provisions of applicable data protection legislation.

1. **TERM**

This Agreement shall come into effect on the Effective Date. It may be terminated with respect to further disclosures upon thirty (30) days’ prior written notice. This Agreement shall cover Confidential Information disclosed within a period of two (2) years from the effective date. After such period, the obligations accrued under this Agreement shall survive for a period of five (5) years.

1. **NO OTHER OBLIGATION; NO LICENSE**

This Agreement shall not be construed, by implication or otherwise, as an obligation to enter into any further agreement relating to the Confidential Information or as the grant of a license or other ownership rights other than to use the Confidential Information for the Purpose. Confidential Information disclosed by a Disclosing Party to the Recipient, as well as any right which could result from such Confidential Information, remains the exclusive property of that Disclosing Party.

1. **NO REPRESENTATION OR WARRANTY**

The Recipient acknowledges and agrees that Confidential Information is provided as is. A Disclosing Party makes no representations or warranties either express or implied with respect to the Confidential Information and specifically disclaims any implied warranty of non- infringement or merchantability, satisfactory quality or fitness for purpose. The Disclosing Party will not be liable (save in respect of any fraudulent representations) for any losses, costs, claims, damages or expenses suffered or incurred by the Recipient as a result of the Recipient doing or omitting to do anything in reliance upon the Disclosing Party's Confidential Information.

1. **RETURN OF CONFIDENTIAL INFORMATION**

At the request of the Disclosing Party or, at the latest, on completion of the Purpose, and in the absence of any further written agreement between the parties, the Recipient shall cease all use of the Confidential Information and shall promptly return to each Disclosing Party all of its Confidential Information which is in tangible form, except that the Recipient shall be permitted to retain one (1) copy of the Confidential Information so that any continuing obligations may be determined. The return of the Confidential Information will not affect Recipient’s obligation to observe the confidentiality and non-use obligations set out in this Agreement. The provisions of this clause 9 shall not apply to copies of electronically exchanged Confidential Information or copies thereof which must be stored by the Recipient according to the provisions of mandatory applicable law.

1. **NO PUBLICITY**

Subject to clause 5, the parties shall not directly or indirectly cause or permit (a) the oral or written release of any public statement referring to the existence or terms of this Agreement, or

(b) any use of the other parties’ name, logo or trademarks, without the other parties’ prior written consent.

1. **RIGHTS OF THIRD PARTIES**

Each ISIDORe Consortium Member shall have a right to enforce the terms of this Agreement.

1. **ASSIGNMENT**

This Agreement shall not be assigned by the Recipient without the prior written consent of the Disclosing Parties, whose consent may be withheld at the Disclosing Parties’ sole discretion, and any purported assignment without such consent shall be void.

1. **SEVERABILITY**

Should any provision of this Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Agreement. In such a case, the parties concerned shall be entitled to request that a valid and practicable provision be negotiated that fulfils the purpose of the original provision.

1. **ENTIRE AGREEMENT; AMENDMENTS; WAIVER**

This Agreement contains the entire understanding between the parties hereto with respect to the subject matter contained herein and supersedes all prior written or oral communications, negotiations, understandings or agreements of any kind with respect to such subject matter. No amendment or modification of this Agreement shall be effective except by a written instrument referring to this Agreement and signed by authorized representatives of both parties. Failure by a party to enforce any rights under this Agreement shall not be construed as a waiver of such rights nor operate as a waiver in other instances.

1. **GOVERNING LAW; HEADINGS**

This Agreement shall be governed by and construed in accordance with the laws of Belgium, without giving effect to any of its conflict of laws principles. The headings in this Agreement are for convenience of reference only and shall not affect its interpretation.

The parties hereto have caused this Agreement to be executed in their own name and in case of the Mandate Holder in addition in the name and on behalf of their respective Consortium Members as their duly authorized representative. The parties explicitly agree to execute this Agreement by way of an electronic signature [by using Adobe Sign] and agree this shall constitute a valid and enforceable agreement between the parties. The present Agreement is made in an electronic version which shall be electronically signed by each party. Each party hereby acknowledges receipt of the e-signed Agreement, electronically signed for approval by the parties.

|  |  |  |
| --- | --- | --- |
| ***[name of authorized company or institution]*** | ***[Recipient, as the case may be:*** |  |
| (**ISIDORe Mandate Holder** ) | *„****name of authorized company institution****;” ]* | ***or*** |

Name: Name:

Function: Function:

Place:

Place:

Date:

Date:

***[Add further signature lines for further signatures on behalf of signing entities, if requested by such signing entities]***

**EXHIBIT 1**

***[list names and addresses of ISIDORe Consortium Members]***

**Attachment 5: Contract under Mandate: two-sided CDA**

THIS IS A TEMPLATE CDA PROPOSED FOR THE ISIDORe PROJECT, WHOSE MEMBERS HAVE APPROVED THE SUBSTANTIVE PROVISIONS AND AUTHORISED ITS SIGNATURE ON THEIR BEHALF.

THE DEFINITION OF CONFIDENTIAL INFORMATION OF THE CONTRACT PARTNER NEEDS THE APPROVAL OF THE GOVERNING BOARD.

ANY MATERIAL CHANGES THAT COULD IMPACT THE RIGHTS AND OBLIGATIONS OF THE

PARTI E S’ UND ER TH E CONSORTIU M AGR EE MENT SHOULD NOT BE MADE WITHOUT GOVERNING BOARD APPROVAL, WHICH MAY CAUSE A DELAY.

**CONFIDENTIAL DISCLOSURE AGREEMENT (TWO WAY)**

**THIS CONFIDENTIAL DISCLOSURE AGREEMENT** (this “**Agreement**”) is made and entered into as of the ***[insert date]*** (the “**Effective Date**”), by and between:

ISIDORe Consortium Members, as defined below and listed in Exhibit 1;

and

***[insert R ecipient´s n ame and Recip ient’s addre ss; if Recipi ent is another consortium ins ert: “[Y] Consortium Members, as defined below and listed in* Exhibit *2”]*** (“**Contract Partner**”)

**WHEREAS,**

1. The parties intend to disclose/receive confidential information for the purpose of facilitating discussions between the ISIDORe Consortium Members and the Contract Partner;
2. The ISIDORe Consortium Members have formed a consortium under Horizon Europe (“**HE**”) for the purpose of establishing the project called “***[title of Consortium]*”** (HE Grant Agreement No*.* 101046133) (the “**ISIDORe Project**”) and are parties to the ISIDORe Consortium Agreement, as defined below;
3. The ISIDORe Consortium Members have authorized **ERINHA** (the **ISIDORe Mandate Holder**”), to execute this Agreement on behalf of the ISIDORe Consortium Members.

***[Delete Sections (D) and (E) if not applicable:]***

1. The ***[Y]*** Consortium Members have formed a consortium for the purpose of establishing the project called **“*[title of Consortium]***” (the “***[Y]* Project**”) and are parties to the ***[Y]*** Consortium Agreement, as defined below;
2. The ***[Y]*** Consortium Members have authorized ***[name of authorized company or institution]*** (the “***[Y]* Mandate Holder**”), to execute this Agreement on behalf of the ***[Y]*** Consortium Members.

**NOW, THEREFORE**, in consideration of the premises and mutual covenants contained herein, the parties hereto agree as follows:

* 1. **DEFINITIONS**

c) “**Entities under the same Control**” shall mean any legal entity that is under the direct or indirect control of a party, under the same direct or indirect control as a party, or is directly or indirectly controlling a party, control taking any of the following forms: (a) the direct or indirect holding of more than 50% of the nominal value of the issued share capital in the legal entity concerned, or of a majority of the voting rights of the shareholders or associates of that entity; (b) the direct or indirect holding, in fact or in law, of decision-making powers in the legal entity concerned.

1. “**Confidential Information**” shall mean any and all information that is disclosed on or after the Effective Date whether orally or in written, electronic or other tangible form by any of the ISIDORe Consortium Members, on the one hand, or by the Contract Partner, on the other hand (each referred to as a “**Disclosing Party**” and collectively as the “**Disclosing Parties**”) under this Agreement for the Purpose, to the ISIDORe Consortium Members, on the one hand, or to the Contract Partner, on the other hand (each referred to as a “**Recipient**” and collectively as the “**Recipients**”). In case of the ISIDORe Consortium Members, Confidential Information shall be limited to comprise any of their information that relates to the ISIDORe Action. In case of Contract Partner, Confidential Information shall be limited to comprise ***[to be inserted.].*** Personal Data processed in view of the Purpose (as defined below) shall also be deemed Confidential Information.“ ISIDORe **Consortium Members**” shall mean the parties to the Consortium Agreement for ***[title of Consortium]*** effective as of *[…]* (“**ISIDORe Consortium Agreement**”) as listed at Exhibit 1.

***[Delete if not applicable:]***

1. “***[Y]* Consortium Members**” shall mean the parties to the Consortium Agreement for ***[title of Consortium]*** effective as of *[…]* (“ ***[Y]* Consortium Agreement**”) as listed at Exhibit 2.
   1. **PURPOSE OF DISCLOSURE**

The Confidential Information is being disclosed for the purpose of facilitating discussions between ISIDORe Consortium Members and Contract Partner [CHECK THE APPROPRIATE BOX]:

* in order to engage in discussions regarding the provision of providing independent advice to  ***[insert the applicable:*** “the ***[specify committee]*** committee of the ISIDORe Action”; *or* “any of the various committees in the ISIDORe Project” or “the consortium of the ISIDORe ***Project*** as such”;
* in order to engage in discussions regarding the accession of the Contract Partner to the ISIDORe Project consortium in compliance with the ISIDORe Consortium Agreement;
* in order to engage in discussions regarding a collaboration between the ISIDORe Project consortium and the Contract Partner;

(the “**Purpose**”).

* 1. **MAINTENANCE OF CONFIDENTIALITY; NON-USE OBLIGATIONS**
     1. Each Disclosing Party’s Confidential Information shall be kept confidential by each Recipient and, except as otherwise permitted herein, shall not be disclosed by the Recipient to any Third Party without first obtaining the Disclosing Party’s prior written consent to such disclosure. Each Recipient shall protect the Confidential Information in the same manner it protects its own confidential information of a similar nature, which shall be at least a reasonable standard of care. Each Recipient may disclose the Confidential Information only to its officers, employees, consultants and/or Entities under the same Control on a need-to-know basis, provided that it imposes on them restrictions on disclosure and use equivalent to those set forth herein. Each Recipient shall be liable for any damage caused by or resulting from any unauthorized disclosure of the Confidential Information by the Recipient’s employees, consultants or Entities under the same Control.
     2. The Confidential Information shall not be utilized by the Recipient, except for the Purpose permitted herein, without first obtaining the Disclosing Party’s prior written consent to such use.
  2. **EXCLUDED INFORMATION**

Subject to applicable data protection legislation providing otherwise, Confidential Information shall not include any information which:

* + 1. at the time of disclosure is in the public domain;
    2. after disclosure becomes part of the public domain, except through breach of this Agreement by Recipient;
    3. Recipient can demonstrate by reasonable proof was in Recipient’s or any of its Entities under the same Control’ possession prior to the time of disclosure by a Disclosing Party hereunder, and was not acquired directly or indirectly from a Disclosing Party;
    4. Recipient can demonstrate by reasonable proof was developed by or on behalf of Recipient or its Entities under the same Control independent of and without reference to the Confidential Information; or
    5. becomes available to Recipient or its Entities under the same Control from a Third Party who did not acquire such information directly or indirectly from a Disclosing Party and who is not otherwise prohibited from disclosing such information.

Confidential Information shall not be deemed to be or have become public knowledge merely because any part of such Confidential Information is embodied in general disclosures or because individual features, components or combinations thereof are known or become known to the public.

* 1. **NOTIFICATION OF MANDATORY DISCLOSURE**
     1. Each Recipient may disclose that portion of Confidential Information that is required by law to be disclosed, provided that, to the extent practicable, the Disclosing Party is first given advance notice of the required disclosure and an adequate opportunity to seek appropriate legal relief to prevent such disclosure or limit use and further disclosure of the Confidential Information. Each Recipient shall cooperate with the Disclosing Party in seeking an appropriate relief or remedy and shall use reasonable efforts to secure confidential treatment of any Confidential Information disclosed.
     2. If, in the absence of such legal relief or other remedy, a Recipient is nonetheless required to disclose any part of the Confidential Information, Recipient may disclose such Confidential Information without liability hereunder, provided that, Recipient shall furnish only such portion of the Confidential Information which Recipient is legally required to disclose. For the avoidance of any doubt, if a Recipient is required to disclose Confidential Information pursuant to Recipient’s obligations under any applicable law or regulation in any other applicable jurisdiction, Recipient shall in all instances seek to apply the exemptions under the applicable law or regulation . The disclosure of personal data shall be subject to the applicable data protection legislation.
  2. **TERM**

This Agreement shall come into effect on the effective date. It may be terminated with respect to further disclosures upon thirty (30) days’ prior written notice. This Agreement shall cover Confidential Information disclosed within a period of two (2) years from the effective date. After such period, the obligations accrued under this Agreement shall survive for a period of five (5) years after the end of the ISIDORe Project.

***[Delete if not applicable:]***

*[For the avoidance of doubt, in the event a ISIDORe Consortium Member is also a [Y] Consortium Member, such ISIDORe Consortium Member, respectively [Y] Consortium Member shall only be obligated to hold Confidential Information disclosed under the present Agreement confidential for the confidentiality term to which it is bound under the ISIDORe Consortium Agreement respectively the [Y] Consortium Agreement, whichever is longer, for the same Confidential Information*

* 1. **NO OTHER OBLIGATION; NO LICENSE**

This Agreement shall not be construed, by implication or otherwise, as an obligation to enter into any further agreement relating to the Confidential Information or as the grant of a license or other ownership rights other than to use the Confidential Information for the Purpose. Confidential Information disclosed by a Disclosing Party to a Recipient, as well as any right which could result from such Confidential Information, remains the exclusive property of that Disclosing Party.

* 1. **NO REPRESENTATION OR WARRANTY**

The Recipient acknowledges and agrees that Confidential Information is provided as is. A Disclosing Party makes no representations or warranties either express or implied with respect to the Confidential Information and specifically disclaims any implied warranty of non- infringement or merchantability, satisfactory quality or fitness for purpose. The Disclosing Party will not be liable (save in respect of any fraudulent representations) for any losses, costs, claims, damages or expenses suffered or incurred by the Recipient as a result of the Recipient doing or omitting to do anything in reliance upon the Disclosing Party's Confidential Information.

* 1. **RETURN OF CONFIDENTIAL INFORMATION**

At the request of the Disclosing Party or, at the latest, on completion of the Purpose, and in the absence of any further written agreement between the parties, each Recipient shall cease all use of the Confidential Information and shall promptly return to each Disclosing Party all of its Confidential Information which is in tangible form, except that each Recipient shall be permitted to retain one (1) copy of the Confidential Information so that any continuing obligations may be determined. The return of the Confidential Information will not affect Recipient’s obligation to observe the confidentiality and non-use obligations set out in this Agreement. The provisions of this clause 9 shall not apply to copies of electronically exchanged Confidential Information or copies thereof which must be stored by Recipient according to the provisions of mandatory applicable law. The provisions of this clause shall not apply to copies of electronically exchanged Confidential Information made as a matter of routine information technology backup and to Confidential Information or copies thereof which must be stored by the Receiving Party according to provisions of mandatory law.

* 1. **NO PUBLICITY**

Subject to clause 5, the parties shall not directly or indirectly cause or permit (a) the oral or written release of any public statement referring to the existence or terms of this Agreement, or

(b) any use of the other parties’ name, logo or trademarks, without the other parties’ prior written consent.

* 1. **RIGHTS OF THIRD PARTIES**

Each ISIDORe Consortium Member shall have a right to enforce the terms of this Agreement**.  *[Delete if not applicable:*** Each ***[Y]*** Consortium Member shall have a right to enforce the terms of this Agreement.]

* 1. **ASSIGNMENT**

This Agreement shall not be assigned by Contract Partner without the prior written consent of the ISIDORe Consortium Members, whose consent may be withheld at the ISIDORe Consortium Members’ sole discretion, and any purported assignment without such consent shall be void.

* 1. **SEVERABILITY**

Should any provision of this Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Agreement. In such a case, the parties concerned shall be entitled to request that a valid and practicable provision be negotiated that fulfils the purpose of the original provision.

* 1. **ENTIRE AGREEMENT; AMENDMENTS; WAIVER**

This Agreement contains the entire understanding between the parties hereto with respect to the subject matter contained herein and supersedes all prior written or oral communications, negotiations, understandings or agreements of any kind with respect to such subject matter. No amendment or modification of this Agreement shall be effective except by a written instrument referring to this Agreement and signed by authorized representatives of both parties. Failure by a party to enforce any rights under this Agreement shall not be construed as a waiver of such rights nor operate as a waiver in other instances.

* 1. **GOVERNING LAW; HEADINGS**

This Agreement shall be governed by and construed in accordance with the laws of Belgium, without giving effect to any of its conflict of laws principles. The headings in this Agreement are for convenience of reference only and shall not affect its interpretation.

REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK

The parties hereto have caused this Agreement to be executed in their own name and in case of the Mandate Holder in addition in the name and on behalf of their respective Consortium Members as their duly authorized representative. The parties explicitly agree to execute this Agreement by way of an electronic signature by using Adobe Sign and agree this shall constitute a valid and enforceable agreement between the parties. The present Agreement is made in an electronic version which shall be electronically signed by each party. Each party hereby acknowledges receipt of the e-signed Agreement, electronically signed for approval by the parties.

|  |  |  |
| --- | --- | --- |
| ***ERINHA*** | ***[Recipient, as the case may be:*** |  |
| (ISIDORe Mandate Holder) | ***“name of authorized com p any***  ***inst it u t ion ”* ]** | ***o r*** |

Name: Name:

Function: Function:

Place:

Place:

Date:

Date:

***[Add further signature lines for further signatures on behalf of signing entities, if requested by such signing entities]***

**EXHIBIT 1**

***[list names and addresses of ISIDORe Consortium Members]***

***[Delete if not applicable:]***

**EXHIBIT 2**

***[list names and addresses of [Y] Consortium Members]***

**Attachment 6: Contract under Mandate: Advisory Agreement**

**Advisory Agreement**

between ISIDORe Consortium Members as listed in Appendix 1

* hereinafter jointly referred to as “**Consortium**” –

and ***[Name and private address of consultant]***

* hereinafter referred to as “**Advisor**” –

**WHEREAS,**

1. The Consortium has been formed for the purpose of establishing the project called **“**ISIDORe” (HE Grant Agreement No. *[ …]*) (the “**Project**”). It consists of the parties listed in Exhibit 1 hereto (collectively the “**Parties**”), including ERINHA acting as the “**Coordinator**”. The Parties are parties to a Consortium Agreement for *[title of Consortium]* effective as of *[…]* (the “**Consortium Agreement**”).
2. Subject to the Consortium Agreement, a ***[insert name of committee]*** is established to ***[insert short description of the role of the committee]*.**
3. Advisor, who is employed by ***[name and address of employer]***, has extensive experience, scientific and/or industrial prominence and leadership in the field of ***[field of expertise]*** relating to the Project.
4. The Consortium is interested to have the Advisor to be part of the ***[insert name of committee].***
5. Each Party has authorized the Coordinator to execute this Advisory Agreement on its behalf.

***[Alternative in c ase of “o n the spot/one time con s ultancy”:***

1. *Advisor, who is employed by* ***[name and address of employer],*** *has extensive experience, scientific and/or industrial prominence and leadership in the field of* ***[field of expertise]*** *relating to the Project.*
2. *The Consortium is interested to have the advice of the Advisor be brought into the Project.*
3. *Each Party has authorized the Coordinator to execute this Advisory Agreement on its behalf.*

Therefore, it is agreed as follows:

* 1. **SUBJECT MATTER OF THE AGREEMENT**
  2. Advisor shall provide consultative and advisory services to the Consortium according to the terms and conditions of the Consortium Agreement and this Agreement as set forth below (hereinafter referred to as the “**Services**”):

*[In case Advisor is to be a member of a committee:*

*The Advisor agrees to be a member of the [insert name of committee] in accordance with the Consortium Agreement.]*

*The Advisor shall [insert precise description of services, e.g., providing expert interpretation, analysis and opinion on scientific data/information, project management, attending meetings etc., including preparation and timelines tasks, e.g.: “be available for [time needed] and shall, on request by* ***[committee to be inserted],*** *provide and/or approve reports or meeting minutes as agreed upon.]*

Further details of the Services will be agreed between the parties.

* 1. ***[Insert for healthcare professionals, otherwise delete]*** For the term of this Agreement Advisor agrees to declare in an appropriate way that he/she is an advisor to the Consortium whenever he/she writes or speaks in public about a topic that is the subject matter of this Agreement or any other issue relating to the Project.
  2. **COMPENSATION**
     1. The Parties agree that the Advisor shall not be compensated for the performance of the Services.
     2. ***[Insert Party who reimburses below costs]*** will, in compliance with the applicable laws, regulations and codices, offer to pay for reasonable travel expenses and hospitality, such as flights (business class airfare for intercontinental flights and economy class airfare for intracontinental flights), train travel, accommodation (up to 4-star rating), work related meals and transportation. In addition, Advisor shall be reimbursed by ***[insert Party who reimburses costs]*** for other reasonable travel expenses actually incurred by Advisor in connection with providing the Services, subject to the receipt of invoices or receipts. Costs for meals and drinks are not considered as travel expenses.
     3. Any payments will be made by ***[insert Party who reimburses costs]*** within 90 days to an account nominated by the Advisor previously in writing upon receipt of a correct invoice (i) complying with applicable legal and tax requirements and (ii) containing the original receipts. Further details will be agreed between the parties. Advisor acknowledges and agrees that the amounts paid will be reported to the members of the Consortium as well as the country to which the amount is paid.
     4. Advisor shall be responsible for all other taxes payable on account of payments made hereunder.
     5. Advisor agrees that the Consortium (by stating Advisor’s private information) may store, process and publish any payments made by the Consortium under this Agreement, if such disclosure is required by statutory or internal regulation or any binding Code of Conduct.
  3. **CONFIDENTIALITY, ARCHIVING, DATA PROTECTION**
     1. Advisor undertakes to hold in strict confidence any information, in particular without limitation scientific, technical or commercial information relating to the business, products or research of the Consortium, which becomes known to Advisor during the course of this collaboration, together with any information regarding the Project and all results of the cooperation with the Consortium, to use such information and results only for the purposes of this Agreement, and not to disclose such information or results to any Third Party without a prior written consent of the Consortium. The foregoing restrictions on use and disclosure will not apply to any of such information which: (a) at the time of receipt by Advisor is available to the public; or (b) becomes public knowledge other than by an act or omission on the part of Advisor; or (c) which Advisor can prove was known to Advisor before the date of its disclosure to Advisor by the Consortium; or (d) is legally acquired by Advisor from a Third Party not bound to Consortium or any of its Parties by any express or implied obligation of secrecy, or (e) Advisor can prove was developed independently by him/her without reference to or use of the information.
     2. Furthermore, Advisor may disclose such information to the extent that such disclosure is required to comply with law or an enforceable judicial order, provided, however, that Advisor shall give reasonable advance notice to the Consortium and on request, shall cooperate with the Consortium to seek a protective order or other appropriate remedy. The Advisor will use his/her reasonable efforts to secure confidential treatment of any such information that will be disclosed.
     3. Information shall not be deemed to be or have become public knowledge merely because any part of such Information is embodied in general disclosures or because individual features, components or combinations thereof are known or become known to the public.
     4. Advisor agrees to duly preserve all information and documentation provided to Advisor and to ensure that no third parties gain access thereto. Any documentation provided must be returned to the Consortium at Consortium’s request during the term of this Agreement, and shall be returned to the Consortium, or shall be destroyed promptly by the Advisor issuing a certification of such destruction upon request of the Consortium, upon termination of the Consortium Agreement. .
     5. This confidentiality and non-use obligation shall remain in effect for five (5) years after the Project expires or is terminated. ***[To be checked if this is in line with the Consortium Agreement]***

In the event the performance of Services or the preparation thereof requires Advisor to use or process any personal data, Advisor agrees to use such personal data only for the Services provided hereunder and in compliance with applicable data protection laws, and therefore the Advisor shall:

* + - 1. process the personal data exclusively in the name of and in accordance with the documented instructions (in so far needed under the applicable legislation) of the controller, including with regard to the transfer of personal data to a third country unless required to do so by applicable law to which the Advisor as processor is subject; in such a case, the Advisor shall inform the controller of that legal requirement before processing, unless that law prohibits such information on important grounds of public interest
      2. not acquire any rights with respect to the personal data;
      3. ensure that its employees dealing with the processing of personal data are obliged to data secrecy in writing and that they are informed about the applicable obligations under the Data Protection Legislation and applicable contractual provisions regarding data protection and that they will act in accordance with those obligations and provisions
      4. take all reasonable technical and organizational measures necessary to protect the personal data against unauthorized or unlawful processing and against accidental loss, destruction of or damage to such personal data that: (a) are able to ensure the ongoing confidentiality, integrity, availability and resilience of processing systems and services (b) where appropriate result in pseudonymisation and/or encryption of personal data; (c) are able to restore the availability and access to the personal data in a timely manner in the event of a physical or technical incident; and (d) include a process for regularly testing, assessing and evaluating the effectiveness of technical and organizational measures for ensuring the security of the processing.
      5. assist the controller insofar as this is possible, for the fulfilment of the controller's obligation to respond to requests for exercising the data subject's rights taking into account the nature of the processing;
      6. assist the controller, upon its request, in ensuring compliance with the obligations relating to the security of the processing data breach notifications, data protection impact assessment and prior consultation to the data protection authority, taking into account the nature of the processing of the personal data and the information available to the Advisor;
      7. obtain the controller’s prior written specific authorization prior to engaging another processor on which it shall impose the same data protection obligations as set out herein by way of a contract or other legal act and, if this new processor fails to fulfil its data protection obligations, it shall remain fully liable to the controller for the performance of new processor’s obligations;
      8. return or delete at the choice of the controller (and subject to the provisions of the Consortium Agreement) all the personal data to the controller after the end of the provision of services relating to processing, and delete existing copies (unless applicable law requires storage of the personal data);
      9. process the personal data exclusively in the EEA; otherwise, the controller’s written consent will be required as well as appropriate safeguards (e.g., EU model clauses);
      10. make available to the controller all information necessary to demonstrate compliance with the obligations laid down in this section 3.5; and
      11. allow for and contribute to audits, including inspections, conducted by the controller or another auditor mandated by the controller during the implementation of the Agreement and for seven (7) years after the completion of the Agreement.
    1. [The personal data that will be processed in view of clause 3.5 of this Agreement are [**DESCRIPTION of the Type of Personal Data**]**.** The categories of the data subjects to which the personal data relate that are processed are [**DESCRIPTION**]**.** The nature and the purpose of the processing of the personal data are as follows: [**DESCRIPTION**]]**.**
    2. In section 3.5 data protection terminology including “personal data”, “processing”, “data subject” and “data protection authority” shall have the meaning given to it in the General Data Protection Regulation (Regulation (EU) 2016/679) or any other applicable data protection legislation
  1. **RIGHTS TO RESULTS**

In case that results are generated by Advisor including intellectual property rights relating thereto (collectively “**Results**”) Advisor shall promptly disclose any Results to the Coordinator in writing. All rights, title and interest in any Results will be owned exclusively by the Parties in equal shares, and Advisor shall assign (or cause to be assigned) and does hereby assign fully to each of the Parties in equal shares all rights, title and interest in and to any Results, without payment of any additional compensation to Advisor. At a Parties’ request and expense, Advisor shall also reasonably assist such Party in obtaining, perfecting, or defending such Party’s rights, title, and interest in any Results, including, without limitation, the drafting, filing and prosecution of any patent applications. As between the Parties, such results shall be deemed to be Results and rights thereto shall be exploited and shared pursuant to the terms of the Consortium Agreement. With regard to any copyrights, Advisor consents to the right to reproduce, modify and use all copyrightable works designed or made by the Advisor by each of the Parties.

* 1. **COMPLIANCE**
     1. The Parties declare that this Agreement is in no way associated with any business or sales activities between the parties hereto and in particular Advisor is by no means obligated to prescribe, recommend or purchase any goods from the Consortium.
     2. Advisor agrees to comply with all applicable laws and regulations in the performance of the Services pursuant to this Agreement.
     3. Advisor represents and warrants that: (a) Advisor has received all necessary approvals in connection with entering into this Agreement and performing the Services to be provided hereunder; (b) compliance with the terms of this Agreement and performance of the Services do not and will not breach or conflict with (i) any other agreement or arrangement, to which Advisor is a party, or (ii) any statutory or internal regulations Advisor is subject to; (c) compliance with the terms of this Agreement and performance of the Services do not and will not breach any agreement to keep in confidence information acquired in confidence or in trust; and (d) during performance of the Services, Advisor will not disclose to Consortium, or induce Consortium to use, any information belonging to a Third Party.
     4. Advisor further represents and warrants that he/she has fully informed the management of his/her medical agency/institution or other employer, or any other organizations or authorities, if necessary, about the execution and content of this Agreement and that he/she has obtained the necessary written approvals of such employer that are required for the performance of this Agreement*.* ***[The medical agency/institution or other employer may confirm that it has no objections to Advisor entering into this Agreement, through an authorized***

***repre sentativ e’s signatur e at the pla ce indi cated b elow.]***

* + 1. The Advisor represents that in performing the Services he has not and he will not use in any capacity the services of anyone debarred, disqualified, blacklisted or banned or under investigations or threat of investigations by any regulatory authority for debarment, disqualification, blacklisting or any similar regulatory action in any jurisdiction anywhere in the world. Furthermore, the Advisor represents and warrants that neither he, nor its employees, agents, representatives or permitted sub-contractors have been debarred, disqualified, blacklisted or banned by any regulatory authority, nor that they are currently to the best of his

knowledge, the subject of such a debarment, disqualification, blacklisting or banning proceeding. During the term of this Advisory Agreement, the Advisor shall promptly notify the Coordinator should the Advisor, any of its employees, agents, representatives or permitted sub- contractors become subject of such debarment, disqualification, blacklisting or banning proceeding.

[FOR US:

Advisor hereby represents that Advisor is not an employee of the U.S. Department of Health

and Hu man Serv ices, Nat iona l Instit utes of He alt h (“NIH”) and tha t Adv isor shall imm ediate ly notify if he/she becomes an employee of NIH at any time during the term of this Agreement. In such case, the Consortium has the right to terminate this Agreement with immediate effect.

Advisor agrees to comply with all applicable federal, state and local laws and regulations in the performance of the Services pursuant to this Agreement, including, without limitation, laws related to fraud, abuse, privacy, discrimination, disabilities, samples, confidentiality, false claims and prohibition of kickbacks. Without limiting the generality of the foregoing, each party to this Agreement certifies that such party shall not violate the U.S. Anti-Kickback Statute (42 U.S.C § 1320a-7b (b)) with respect to the performance of this Agreement.

Without prejudice to the generality of section above, Advisor further agrees to comply with all applicable U.S. federal, state and local laws and regulations relating to the privacy of patient health information, including, but not limited to, the Standards for Individually Identifiable Health

Inform ation, 4 5 C.F.R . §§ 1 60 an d 1 64 (th e “HIP AA Privacy Regula tion”) prom ulg a ted p urs uant to the Health Insurance Portability and Accountability Act of 1996. If Advisor deems it necessary in the performance of the Services under this Agreement to disclose to the Consortium the

“Protected He alt h I nform at ion” (as such term is used in t he HI PA A Privacy Re g ulat io n) of a patient, then, in advance of any such disclosure, Advisor shall obtain a written authorization executed by such patient for the use and disclosure of such Protected Health Information in accordance with the HIPAA Privacy Regulation.]

* 1. **TERM**
     1. This Agreement comes into force upon signature by the parties and continues effective until all parties’ obligations pursuant to Section 1 and 2 hereof have been fulfilled **[or specific date].**
     2. Notwithstanding Section 6.1, this Agreement may be terminated in full by the Coordinator on behalf of all the Parties, at any time and with immediate effect
     3. The terms set forth in Sections 3, 4, 6.3 and 7.1 shall survive any termination or expiration of this Agreement.
  2. **MISCELLANEOUS**
     1. Advisor shall not use any name, logos or trade names or product trademarks owned by a member of the Consortium, as such in any public announcement, press release or other public document without prior written consent of the Consortium and/or the member of the Consortium that owns the name, logos or trade names or product trademarks.
     2. Advisor shall be deemed for all purposes to be an independent contractor. Advisor shall not have the authority to enter into agreements or make any representations on behalf of or otherwise bind the Consortium.
     3. This Agreement contains the entire agreement between the Advisor and the Consortium. Any amendments to this Agreement shall be made in writing. If any provision of this Agreement is or becomes invalid or unenforceable, this shall not affect the remaining provisions hereof. The parties shall in this case replace the invalid or unenforceable provision with a provision that is as close as possible to the economic effect of the invalid or unenforceable provision.
     4. Each Party is intended to be a Third Party beneficiary with the ability to enforce the terms of the Agreement in its own name and as if it was a party to this Agreement.
     5. This Agreement shall be construed, controlled and interpreted by the laws of Belgium, regardless of its conflict of laws provisions. Exclusive place of jurisdiction shall be Brussels.

REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK

The parties hereto have caused this Agreement to be executed in their own name and in case of the Mandate Holder in addition in the name and on behalf of their respective Consortium Members as their duly authorized representative. The parties explicitly agree to execute this Agreement by way of an electronic signature by using Adobe Sign and agree this shall constitute a valid and enforceable agreement between the parties. The present Agreement is made in an electronic version which shall be electronically signed by each party. Each party hereby acknowledges receipt of the e-signed Agreement, electronically signed for approval by the parties.

***ERINHA [Advisor]***

(**Mandate Holder**)

Name: Name:

Function: Function

Place:

Place:

Date:

Date:

**Acknowledged and agreed**

***[Party responsible for reimbursement of costs]***

Name: Function:

Place:

Date:

Approval of Employer: ***[Insert name of employer]***

We have read the foregoing Advisory Agreement between the Consortium and ***[Insert name of advisor]***

and approve the content and the conclusion of such Agreement:

Name:

Place/Date:

Signature/Seal:

***[Add further signature lines for further signatures on behalf of signing entity, if requested by such signing entity]***

**EXHIBIT 1**

***[list names and addresses of Consortium Parties]***

# Attachment 7 : JRA project template agreement.

The JRA project template agreement will automatically become part of this consortium agreement, without the necessity of a formal consortium agreement amendment, upon approval of the template by the Governing Board.

# Attachment 8: List of RIs that hold funding for the APs who will contribute to their respective TNA Work Packages for the provision of the services as identified in Table 3.1k of Annex 1 to the Grant Agreement.

|  |  |
| --- | --- |
| RI | Holding Budget For: |
| Transvac, duly represented by EVI (Party 5) | 1. STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER 2. HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 3. INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA 4. STATENS SERUM INSTITUT 5. UNIVERSITA DEGLI STUDI DI SIENA 6. VACCINE FORMULATION INSTITUTE(CH)LTD 7. COMMISSARIAT A L’ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES 8. ACADEMISCH ZIEKENHUIS LEIDEN |
| 6 INSTRUCT | 14 EUROPEAN MOLECULAR BIOLOGY LABORATORY  43 AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS  63 THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD.   1. VIB VZW 2. UNIVERSITE DE LIEGE 3. MASARYKOVA UNIVERZITA 4. BIOTECHNOLOGICKY USTAV AV CR VVI 5. JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN 6. OULUN YLIOPISTO 7. ITA-SUOMEN YLIOPISTO 8. HELSINGIN YLIOPISTO 9. CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE 10. CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 11. WEIZMANN INSTITUTE OF SCIENCE 12. CONSORZIO INTERUNIVERSITARIO RISONANZE MAGNETICHE DI METALLO PROTEINE 13. STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS 14. UNIVERSITEIT LEIDEN 15. UNIVERSITEIT UTRECHT 16. CHEMICKY USTAV SLOVENSKEJ AKADEMIE VIED83 UNIVERSITY OF LEEDS 17. DIAMOND LIGHT SOURCE LIMITED 18. THE ROSALIND FRANKLIN INSTITUTE |
| 7 Eu-Bi | 14 EUROPEAN MOLECULAR BIOLOGY LABORATORY  21 ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM  43 AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS  76 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS  80 UNIVERSITEIT LEIDEN  86 ROUMEN TSANEV INSTITUTE OF MOLECULAR BIOLOGY BULGARIAN ACADEMY OF SCIENCES |

|  |  |
| --- | --- |
|  | 1. USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE 2. ABO AKADEMI 3. DEBRECENI EGYETEM 4. CONSIGLIO NAZIONALE DELLE RICERCHE 5. UNIVERSITA DEGLI STUDI DI TORINO 6. ELETTRA - SINCROTRONE TRIESTE SCPA 7. STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM 8. UNIVERSITAIR MEDISCH CENTRUM UTRECHT 9. UNIVERSITETET I OSLO 10. TURUN YLIOPISTO 11. VIENNA BIOCENTER CORE FACILITES GMBH 12. INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC |
| 8 EU-OS | **EU-OS APs**:  43 AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS  53 HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH  74 HELSINGIN YLIOPISTO  87 USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE  95 UNIVERSITETET I OSLO   1. FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA 2. INSTYTUT CHEMII BIOORGANICZNEJ POLSKIEJ AKADEMII NAUK 3. DANMARKS TEKNISKE UNIVERSITET 4. LATVIJAS ORGANISKAS SINTEZES INSTITUTS 5. FORSCHUNGSVERBUND BERLIN EV 6. FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V 7. UNIVERZITA PALACKEHO V OLOMOUCI 8. UNIVERSITETET I BERGEN 9. SINTEF AS 10. INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK   **APs which have no existing legal link to EU-OS:**   1. NARODOWY INSTYTUT ONKOLOGII IM. MARII SKLODOWSKIEJ-CURIE - PANSTWOWY INSTYTUT BADAWCZY 2. WARSZAWSKI UNIWERSYTET MEDYCZNY 3. FONDAZIONE PER L'ISTITUTO DI RICERCA IN BIOMEDICINA 4. JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH 5. IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON |
| 10 EATRIS | 54 INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA  74 HELSINGIN YLIOPISTO  95 UNIVERSITETET I OSLO  119 ISTITUTO SUPERIORE DI SANITA   1. AIBILI ASSOCIACAO PARA INVESTIGACAO BIOMEDICA E INNOVACAO EM LUZ E IMAGEM 2. FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PAZ |

|  |  |
| --- | --- |
|  | 1. INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL 2. INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 3. OSLO UNIVERSITETSSYKEHUS HF 4. FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA |
| BBMRI | BBMRI is holding budget for their APs which are providers of purchased services, not beneficiaries of the grant |

# Attachment 9 List of Parties and their AP’s under the RI’s that represent them in the Governing Board

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Party** | **Research Institute / Network** | **Name of access provider / installation** | | **Installation Country code** | **Budget held by RI (Y/N)** |
| AMU | EVA | 1 | AMU1 | FR | N |
| AMU | EVA | 2 | AMU2 | FR | N |
| AMU | EVA | 3 | AMU3 | FR | N |
| AMU | EVA | 4 | AMU4 | FR | N |
| INRAE-PFIE | VetBioNet | 1 | PFIE | FR | N |
| INRAE-IERP | VetBioNet | 2 | IERP | FR | N |
| INRAE-APEX | VetBioNet | 3 | APEX | FR | N |
| INRAE-ISP | VetBioNet | 4 | ISP | FR | N |
| INRAE-VIM | VetBioNet | 5 | VIM-BMP | FR | N |
| INRAE-VIM | VetBioNet | 6 | VIM-IIP | FR | N |
| INRAE-VIRO | VetBioNet | 7 | VIRO | FR | N |
| INRAE-IVPC | VetBioNet | 8 | IVPC lab | FR | N |
| INRAE-IVPC | VetBioNet | 9 | IVPC lab | FR | N |
| IP | EVA | 1 | IP1 | FR | N |
| IP | EVA | 2 | IP2 | FR | N |
| IP | EVA | 3 | IP3 | FR | N |
| IP | EVA | 4 | IP4 | FR | N |
| IP | MIRRI | 1 | BSoC1 | FR | N |
| IP | MIRRI | 2 | BSoC2 | FR | N |
| IP | MIRRI | 3 | Bqct sqc | FR | N |
| IP | MIRRI | 4 | MALDI | FR | N |
| IP | EMERGEN | 1 | Sequence | FR | N |
| IP | Infravec | 1 | Vectors | FR | N |
| IP | Infravec | 2 | Infection | FR | N |
| IP | Infravec | 3 | Cell lines | FR | N |
| IP | Infravec | 1 | Vectors | FR | N |
| IP | Infravec | 1 | Vectors | FR | N |
| IP | Sonar-Global | 1 | VA | FR | N |
| IP | Sonar-Global | 2 | CS | FR | N |
| IP | Sonar-Global | 3 | CSII | FR | N |
| IP | Sonar-Global | 4 | Outbreak | FR | N |
| IP | Sonar-Global | 5 | Outbreak II | FR | N |
| IP | Sonar-Global | 6 | FA | FR | N |
| EVI | Transvac | 1 | RA | DE | Y |
| EU-OS | EU-OPENSCREEN | 1 | CCMF | DE | Y |
| ECRIN | ECRIN | 1 | ECRIN | FR | N |
| EATRIS | EATRIS |  | EATRIS | NL | Y |
| EMBL | Instruct | 1 | GR HTX | FR | Y |
| EMBL | Instruct | 1 | SPC | DE | Y |
| EMBL | Instruct | 2 | Beam | DE | Y |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| EMBL | Instruct | 1 | HD | DE | Y |
| EMBL | Euro-Bioimaging | 1 | LM | IO | Y |
| EMBL | Euro-Bioimaging | 2 | EM | IO | Y |
| INSERM | ERINHA | 1 | BSL4 | FR | N |
| INSERM | Infrafrontier | 1 | MC | FR | N |
| INSERM | Infrafrontier | 2 | BSL3 | FR | N |
| INSERM | Infrafrontier | 3 | Variant | FR | N |
| FoHM | ERINHA | 1 | BSL4 | SE | N |
| INSA | ERINHA | 1 | BSL3 | PT | N |
| NNK | ERINHA | 1 | BSL4 | HU | N |
| EMC | ERINHA | 1 | BSL3 | NL | N |
| EMC | Euro-Bioimaging | 2 | Data st | NL | Y |
| KUL | ERINHA | 1 | Caps-It | BE | N |
| KUL | EMBRC | 3 | LMB | BE | N |
| MUG | ERINHA | 1 | BSL3 | AT | N |
| BNI | EVA | 5 | BNI-1 | DE | N |
| BNI | EVA | 6 | BNI-2 | DE | N |
| CUB | EVA | 1 | CUB-1 | DE | N |
| CUB | EVA | 2 | CUB-2 | DE | N |
| DH | EVA | 1 | DH-1 | UK | N |
| DH | EVA | 2 | DH-2 | UK | N |
| DH | EVA | 1 | RR | UK | N |
| UL | EVA | 1 | UL-1 | SI | N |
| UL | EVA | 2 | UL-2 | SI | N |
| UL | EVA | 3 | UL-3 | SI | N |
| BMC SAV | EVA | 1 | SAV-1 | SK | N |
| BMC SAV | EVA | 2 | SAV-2 | SK | N |
| UNIBAS | EVA | 1 | UNI-1 | CH | N |
| UNIBAS | EVA | 2 | UNI-2 | CH | N |
| INMI | EVA | 1 | INMI-1 | IT | N |
| INMI | EVA | 2 | INMI-2 | IT | N |
| INMI | EVA | 3 | INMI-3 | IT | N |
| RIVM | EVA | 1 | RIVM-1 | NL | N |
| RIVM | EVA | 2 | RIVM-2 | NL | N |
| RIVM | EVA | 3 | RIVM-3 | NL | N |
| DEFRA | EVA | 1 | DEFRA1 | UK | N |
| DEFRA | EVA | 2 | DEFRA2 | UK | N |
| DEFRA | VetBioNet | 1 | APHA1 265 | UK | N |
| DEFRA | VetBioNet | 2 | APHA2 268 | UK | N |
| DEFRA | VetBioNet | 3 | APHA3 cat 2 | UK | N |
| DEFRA | VetBioNet | 4 | APHA4 viro lab | UK | N |
| DEFRA | VetBioNet | 5 | APHA5 insectary | UK | N |
| FLI | VetBioNet | 12 | In vivo | DE | N |
| FLI | VetBioNet | 13 | In vitro | DE | N |
| TPI | EVA | 1 | TPI-1 | UK | N |
| TPI | EVA | 2 | TPI-2 | UK | N |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| TPI | EVA | 1 | Vectors | UK | N |
| TPI | EVA | 2 | Infections | UK | N |
| CSIRO | EVA | 1 | CSIRO-1 | AU | N |
| CSIRO | EVA | 2 | CSIRO-2 | AU | N |
| IZSVE | EVA | 1 | IZSVE-1 | IT | N |
| IZSVE | EVA | 2 | IZSVE-2 | IT | N |
| IZSVE | EVA | 3 | IZSVE-3 | IT | N |
| IZSVE | EVA | 4 | IZSVE-4 | IT | N |
| DSMZ | EVA | 3 | DSMZ-3 | DE | N |
| JKI | EVA | 1 | JKI-1 | DE | N |
| JKI | EVA | 2 | JKI-2 | DE | N |
| ARC | EVA | 1 | ARC-1 | ZA | N |
| WR | VetBioNet | 1 | In vivo animal facility | NL | N |
| WR | VetBioNet | 2 | In vitro | NL | N |
| MRI | VetBioNet | 1 | MRI | UK | N |
| IRTA | VetBioNet | 1 | RG3 RG3 challenge | ES | N |
| IRTA | VetBioNet | 2 | Arbo | ES | N |
| IRTA | VetBioNet | 3 | SARS-CoV-2 challenge | ES | N |
| IRTA | VetBioNet | 1 | Vectors | ES | N |
| IRTA | VetBioNet | 2 | Infections | ES | N |
| IRTA | VetBioNet | 3 | Facility infections | ES | N |
| IRTA | VetBioNet | 3 | Facility | ES | N |
| EDI-IVI | VetBioNet | 2 | In vivo | CH | N |
| EDI-IVI | VetBioNet | 1 | In vitro | CH | N |
| PIWET | VetBioNet | 1 | In vivo | PL | N |
| AU | VetBioNet | 2 | In vivo | DK | N |
| AU | VetBioNet | 1 | In vitro | DK | N |
| ANSES | VetBioNet | 1 | SPPAE | FR | N |
| ANSES | VetBioNet | 2 | Seleac | FR | N |
| ANSES | VetBioNet | 3 | LRFSN | FR | N |
| UEDIN | VetBioNet | 1 | Roslin | UK | N |
| InSCREENeX | VetBioNet | 1 | ISX | DE | N |
| NOLDUS | VetBioNet | 1 | Tracking | NL | N |
| NOLDUS | VetBioNet | 2 | Observation | NL | N |
| NOLDUS | VetBioNet | 3 | Physiological monitoring | NL | N |
| BPRC | Transvac | 1 | VIE | NL | Y |
| BPRC | Transvac | 2 | VEE | NL | Y |
| BPRC | Transvac | 3 | PHI | NL | Y |
| BPRC | Transvac | 4 | VRD | NL | Y |
| HZI | Transvac | 1 | AD | DE | Y |
| HZI | Transvac | 1 | AM | DE | Y |
| HZI | Transvac | 2 | COV | DE | Y |
| HZI | Transvac | 1 | TBS | DE | Y |
| HZI | Transvac | 2 | PIM | DE | Y |
| IBET | Transvac | 1 | GMP Manuf | PT | Y |
| IBET | Transvac | 1 | PLS | PT | Y |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| IBET | Transvac | 2 | GLP | PT | Y |
| IBET | Transvac | 3 | AN | PT | Y |
| IBET | EATRIS | 1 | Service 1 | PT | Y |
| IBET | EATRIS | 1 | Service 2 | PT | Y |
| IBET | EATRIS | 1 | Service 3 | PT | Y |
| IBET | EATRIS | 1 | Service 4 | PT | Y |
| IBET | EATRIS | 1 | Service 5 | PT | Y |
| IBET | EATRIS | 1 | Service 6 | PT | Y |
| IBET | EATRIS | 1 | Service 7 | PT | Y |
| IBET | EATRIS | 1 | Service 8 | PT | Y |
| IBET | EATRIS | 1 | Service 9 | PT | Y |
| SSI | Transvac | 1 | HCM | DK | Y |
| SSI | Transvac | 2 | Im-Mice | DK | Y |
| SSI | Transvac | 3 | ADJF | DK | Y |
| UNISI | Transvac | 1 | MFC | IT | Y |
| UNISI | Transvac | 2 | AM | IT | Y |
| UNISI | Transvac | 3 | RNA.Seq | IT | Y |
| UNISI | Transvac | 4 | CFC | IT | Y |
| UNISI | Transvac | 5 | Multiplex | IT | Y |
| UNISI | Transvac | 6 | ELISA | IT | Y |
| VFI | Transvac | 1 | AFS | CH | Y |
| VFI | Transvac | 2 | IVS | CH | Y |
| VFI | Transvac | 3 | PSA | CH | Y |
| VFI | Transvac | 4 | TTA | CH | Y |
| VFI | Transvac | 5 | GMPA | CH | Y |
| CEA | Transvac | 1 | IMCH | FR | Y |
| LUMC | Transvac | 1 | Prof | NL | Y |
| AIGHD | Sonar-Global | 1 | Scale-up | NL | N |
| AIGHD | Sonar-Global | 1 | Benefit | NL | N |
| AIGHD | Sonar-Global | 1 | CS | NL | N |
| AIGHD | Sonar-Global | 1 | CS II | NL | N |
| AIGHD | Sonar-Global | 1 | Outbreak | NL | N |
| AIGHD | Sonar-Global | 1 | Outbreak II | NL | N |
| AIGHD | Sonar-Global | 1 | FA | NL | N |
| NIVEL | Sonar-Global | 1 | Clinical | NL | N |
| NIVEL | Sonar-Global | 1 | Clinical II | NL | N |
| NIVEL | Sonar-Global | 1 | Scale-up | NL | N |
| NIVEL | Sonar-Global | 1 | Po Scale-up | NL | N |
| NIVEL | Sonar-Global | 1 | Benefit | NL | N |
| NIVEL | Sonar-Global | 1 | FA | NL | N |
| MUW | Sonar-Global | 1 | Clinical | AT | N |
| MUW | Sonar-Global | 1 | Clinical II | AT | N |
| MUW | Sonar-Global | 1 | Vac | AT | N |
| MUW | Sonar-Global | 1 | Vac II | AT | N |
| MUW | Sonar-Global | 1 | Eval | AT | N |
| MUW | Sonar-Global | 1 | FA | AT | N |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| UOXF | Sonar-Global | 1 | Clinical | UK | N |
| UOXF | Sonar-Global | 1 | Clinical II | UK | N |
| UOXF | Sonar-Global | 1 | Ethics | UK | N |
| UOXF | Sonar-Global | 1 | FA | UK | N |
| UOXF | Instruct | 1 | cryo\_EM | UK | Y |
| BRAC | Sonar-Global | 1 | VA | BD | N |
| BRAC | Sonar-Global | 1 | Vac | BD | N |
| BRAC | Sonar-Global | 1 | Vac II | BD | N |
| BRAC | Sonar-Global | 1 | NonPharma | BD | N |
| BRAC | Sonar-Global | 1 | NonPharma II | BD | N |
| BRAC | Sonar-Global | 1 | FA | BD | N |
| UCL | Sonar-Global |  | VA | UK | N |
| UCL | Sonar-Global |  | NonPharma | UK | N |
| UCL | Sonar-Global |  | Eval | UK | N |
| UCL | Sonar-Global |  | Scale-up | UK | N |
| UCL | Sonar-Global |  | Po Scale-up | UK | N |
| UCL | Sonar-Global |  | FA | UK | N |
| CRCF | Sonar-Global |  | Vac | SN | N |
| CRCF | Sonar-Global |  | Vac II | SN | N |
| CRCF | Sonar-Global |  | NonPharma II | SN | N |
| CRCF | Sonar-Global |  | Ethics | SN | N |
| CRCF | Sonar-Global |  | FA | SN | N |
| VIB VZW | Instruct | 1 | Nanobdy Discovery | BE | Y |
| ULIEGE | Instruct | 1 | Plasma profiling | BE | Y |
| MU | Instruct | 1 | BIC | CZ | Y |
| MU | Instruct | 2 | cryo-EM | CZ | Y |
| MU | Instruct | 3 | NMR | CZ | Y |
| MU | Instruct | 4 | Proteomics | CZ | Y |
| MU | ECRIN | 1 | Service | CZ | N |
| IBT | Instruct | 1 | Biophysical techniques | CZ | Y |
| IBT | Instruct | 2 | Crystallisation | CZ | Y |
| IBT | Instruct | 3 | MS | CZ | Y |
| IBT | Instruct | 4 | Diffraction Techniques | CZ | Y |
| IBT | Instruct | 5 | Mol Targ | CZ | Y |
| GUF | Instruct | 1 | Ref mat | DE | Y |
| GUF | Instruct | 2 | NMR | DE | Y |
| CSIC | Instruct | 1 | EM | ES | Y |
| CSIC | EU-OPENSCREEN | 1 | MedChem (virtual screening) | ES | Y |
| CSIC | EU-OPENSCREEN | 2 | MedChem (SAR and hit optimisation) | ES | Y |
| CSIC | EU-OPENSCREEN | 3 | MedChem (synthesis scale up) | ES | Y |
| CSIC | Euro-Bioimaging | 1 | INIA CISA | ES | Y |
| UOULU | Instruct | 1 | BCO | FI | Y |
| UEF | Instruct | 1 | FT-ICR | FI | Y |
| UEF | Instruct | 2 | TIMS-QTOF | FI | Y |
| UH | Instruct | 1 | Biocomplex | FI | Y |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| UH | Instruct | 2 | EM | FI | Y |
| UH | Instruct | 3 | NMR | FI | Y |
| UH | Instruct | 4 | SCoPE-MS | FI | Y |
| UH | EU-OPENSCREEN | 1 | BSL2HTS (Bacterial based assay) | FI | Y |
| UH | EU-OPENSCREEN | 2 | HTS Target based | FI | Y |
| UH | EATRIS | 2 | TC | FI | Y |
| UH | EATRIS | 2 | TC | FI | Y |
| UH | EATRIS | 2 | Imaging | FI | Y |
| CERBM | Instruct | 1 | Crystallisation | FR | Y |
| CERBM | Instruct | 2 | TandC by RX | FR | Y |
| CERBM | Instruct | 3 | cryo-EM | FR | Y |
| CERBM | Instruct | 4 | FIB/SEM | FR | Y |
| CERBM | Instruct | 5 | Super resolution GDs | FR | Y |
| CERBM | Instruct | 6 | PP bact | FR | Y |
| CERBM | Instruct | 7 | PPmammalien cells | FR | Y |
| CERBM | Instruct | 8 | PP insect cells | FR | Y |
| CERBM | Instruct | 9 | Purification | FR | Y |
| CNRS | Instruct | 1 | cryo-EM | FR | Y |
| CNRS | Instruct | 2 | NMR | FR | Y |
| CNRS | Euro-Bioimaging | 1 | RLM | FR | Y |
| CNRS | Euro-Bioimaging | 2 | HS-RES | FR | Y |
| CNRS | Euro-Bioimaging | 3 | LI | FR | Y |
| CNRS | Euro-Bioimaging | 4 | LLS | FR | Y |
| CNRS | Euro-Bioimaging | 5 | EM/TEM | FR | Y |
| CNRS | Euro-Bioimaging | 6 | HCONF | FR | Y |
| CNRS | Euro-Bioimaging | 7 | CCFS | FR | Y |
| Weizmann | Instruct | 1 | PPmamm | IL | Y |
| Weizmann | Instruct | 2 | PP insect | IL | Y |
| Weizmann | Instruct | 3 | PP bact | IL | Y |
| Weizmann | Instruct | 4 | Mam cell expression | IL | Y |
| Weizmann | Instruct | 5 | Insect expression | IL | Y |
| Weizmann | Instruct | 6 | Bact exp | IL | Y |
| Weizmann | Instruct | 7 | Crystal. | IL | Y |
| CIRMMP | Instruct | 1 | NMR | IT | Y |
| NKI | Instruct | 1 | Biophysics | NL | Y |
| NKI | Instruct | 2 | Protein Expression | NL | Y |
| NKI | Instruct | 3 | PDB-REDO | NL | Y |
| ULEI | Instruct | 1 | NeCEN | NL | Y |
| ULEI | Euro-Bioimaging | 1 | Cell obs | NL | Y |
| UU | Instruct | 1 | Proteomics MS | NL | Y |
| UU | Instruct | 2 | Plasma proteome | NL | Y |
| UU | Instruct | 3 | NMR | NL | Y |
| UU | Instruct | 4 | NMR screening | NL | Y |
| IC SAS | Instruct | 1 | IC SAS\_Glycan analysis | SK | Y |
| UNIVLEEDS | Instruct | 1 | EM | UK | Y |
| UNIVLEEDS | Instruct | 2 | MS | UK | Y |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| UNIVLEEDS | Instruct | 3 | Solution NMR | UK | Y |
| Diamond | Instruct | 1 | EM | UK | Y |
| Diamond | Instruct | 2 | Beam&Lab time | UK | Y |
| RFI | Instruct | 1 | Nanobdys | UK | Y |
| IMB-BAS | Euro-Bioimaging | 1 | Live cell fluorescent imaging | BG | Y |
| IMG-CAS | Euro-Bioimaging | 1 | LMSR/CM | CZ | Y |
| IMG-CAS | Euro-Bioimaging | 2 | LC QPI | CZ | Y |
| IMG-CAS | Euro-Bioimaging | 3 | EM 3D methods | CZ | Y |
| IMG-CAS | Euro-Bioimaging | 4 | EM TEM | CZ | Y |
| IMG-CAS | EU-OPENSCREEN | 1 | Screen | CZ | Y |
| IMG-CAS | Infrafrontier | 1 | CE | CZ | N |
| IMG-CAS | Infrafrontier | 2 | AAV | CZ | N |
| IMG-CAS | Infrafrontier | 3 | KO Model Generation | CZ | N |
| IMG-CAS | Infrafrontier | 4 | KI | CZ | N |
| ABO | Euro-Bioimaging | 1 | MALM | FI | Y |
| ABO | Euro-Bioimaging | 2 | SRM | FI | Y |
| ABO | Euro-Bioimaging | 3 | EM | FI | Y |
| ABO | Euro-Bioimaging | 4 | CLEM | FI | Y |
| ABO | Euro-Bioimaging | 5 | MI | FI | Y |
| UD | Euro-Bioimaging | 1 | UNIDEB ALM | HU | Y |
| UD | Euro-Bioimaging | 2 | Semmelweis ALM | HU | Y |
| UD | Euro-Bioimaging | 3 | BRC ALM | HU | Y |
| UD | Euro-Bioimaging | 4 | Femtonics ALM | HU | Y |
| UD | Euro-Bioimaging | 1 | Unideb Medical | HU | Y |
| UD | Euro-Bioimaging | 2 | Scanomed | HU | Y |
| UD | Euro-Bioimaging | 3 | Semmelweis Medical | HU | Y |
| UD | Euro-Bioimaging | 4 | UP | HU | Y |
| CNR | Euro-Bioimaging | 1 | LM | IT | Y |
| CNR | Euro-Bioimaging | 2 | SR | IT | Y |
| CNR | Euro-Bioimaging | 3 | EM | IT | Y |
| CNR | Euro-Bioimaging | 4 | HTI | IT | Y |
| UNITO | Euro-Bioimaging | 1 | MRI | IT | Y |
| UNITO | Euro-Bioimaging | 2 | PET/SPECT | IT | Y |
| UNITO | Euro-Bioimaging | 3 | CT | IT | Y |
| ELETTRA | Euro-Bioimaging | 1 | PC | IT | Y |
| Radboudumc | Euro-Bioimaging | 1 | MRI | NL | Y |
| Radboudumc | Euro-Bioimaging | 2 | PET | NL | Y |
| Radboudumc | Euro-Bioimaging | 1 | Storage Framework | NL | Y |
| Radboudumc | Infravec | 1 | Infections | NL | N |
| UMCU | Euro-Bioimaging | 1 | CLEM | NL | Y |
| UiO | Euro-Bioimaging | 1 | LM | NO | Y |
| UiO | EATRIS | 1 | GG lab | NO | Y |
| UiO | EU-OPENSCREEN | 1 | Printing of assay ready plates | NO | N |
| UTU | Euro-Bioimaging | 1 | SPECT/CT and optical intravital imaging | FI | Y |
| UTU | Euro-Bioimaging | 2 | PET/CT | FI | Y |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| UTU | Euro-Bioimaging | 3 | MRI | FI | Y |
| UTU | Euro-Bioimaging | 4 | MEGMRI | FI | Y |
| VBCF | Euro-Bioimaging | 1 | HREM | AT | Y |
| VBCF | Euro-Bioimaging | 2 | 128 row CT | AT | Y |
| IBMC | Euro-Bioimaging | 1 | MBI | PT | Y |
| MEDI | EU-OPENSCREEN | 1 | BSL2AD | ES | Y |
| MEDI | EU-OPENSCREEN | 2 | BSL2HTS (Bacterial based assay) | ES | Y |
| MEDI | EU-OPENSCREEN | 3 | ADTB | ES | Y |
| MEDI | EU-OPENSCREEN | 4 | HTSTB | ES | Y |
| MEDI | EU-OPENSCREEN | 5 | ADMEtoxx | ES | Y |
| IBCH | EU-OPENSCREEN | 1 | Enzymat assay development | PL | Y |
| IBCH | EU-OPENSCREEN | 2 | Enzymatic Screen | PL | Y |
| IBCH | EU-OPENSCREEN | 3 | Cellbased assay development | PL | Y |
| IBCH | EU-OPENSCREEN | 4 | Cellbased screen | PL | Y |
| IBCH | EU-OPENSCREEN | 5 | ROS tox | PL | Y |
| IBCH | EU-OPENSCREEN | 6 | CellPainting Scree | PL | Y |
| IBCH | EU-OPENSCREEN | 7 | Comb screen | PL | Y |
| DTU | EU-OPENSCREEN | 1 | MedChem | DK | Y |
| LIOS | EU-OPENSCREEN | 1 | MedChem | LV | Y |
| FMP-FVB | EU-OPENSCREEN | 1 | MedChem | DE | Y |
| Fraunhofer | EU-OPENSCREEN | 1 | 10kBSL1 | DE | Y |
| Fraunhofer | EU-OPENSCREEN | 2 | 100kBSL1 Screen | DE | Y |
| Fraunhofer | EU-OPENSCREEN | 3 | 10kBSL2 Screen | DE | Y |
| Fraunhofer | EU-OPENSCREEN | 4 | 2k BSL3 Screen | DE | Y |
| UP | EU-OPENSCREEN | 1 | ADTB | CZ | Y |
| UP | EU-OPENSCREEN | 2 | HTS Target based assay | CZ | Y |
| UP | EU-OPENSCREEN | 3 | L3AD | CZ | Y |
| UP | EU-OPENSCREEN | 4 | L3screen | CZ | Y |
| UP | EU-OPENSCREEN | 5 | L2+AD | CZ | Y |
| UP | EU-OPENSCREEN | 6 | L2+HTS | CZ | Y |
| UiB | EU-OPENSCREEN | 1 | FragAssaDev | NO | Y |
| UiB | EU-OPENSCREEN | 2 | FragScree | NO | Y |
| UiB | EU-OPENSCREEN | 3 | HitConf | NO | Y |
| UiB | EU-OPENSCREEN | 4 | NMRHitVAl | NO | Y |
| SINTEF | EU-OPENSCREEN | 1 | Screen | NO | Y |
| IBB PAN | EU-OPENSCREEN | 1 | PanMC | PL | Y |
| IBB PAN | EU-OPENSCREEN | 1 | Target/T | PL | Y |
| IBB PAN | EU-OPENSCREEN | 2 | Target | PL | Y |
| IBB PAN | EU-OPENSCREEN | 3 | Pan+training | PL | Y |
| IBB PAN | EU-OPENSCREEN | 4 | Pan Pan | PL | Y |
| MSCNRIO | EU-OPENSCREEN | 1 | Nano1 | PL | Y |
| MSCNRIO | EU-OPENSCREEN | 2 | Nano2 | PL | Y |
| MSCNRIO | EU-OPENSCREEN | 3 | Nano2 na | PL | Y |
| MSCNRIO | EU-OPENSCREEN | 4 | Nano2 | PL | Y |
| MSCNRIO | EU-OPENSCREEN | 5 | NanoFunc | PL | Y |
| MUWa | EU-OPENSCREEN | 1 | L2+ nano | PL | Y |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| IRB | EU-OPENSCREEN | 1 | Ab-Ag Characterization | CH | Y |
| IRB | EU-OPENSCREEN | 2 | Binding to SARS2 variants | CH | Y |
| IRB | EU-OPENSCREEN | 3 | Ab-Ag Characterization | CH | Y |
| IRB | EU-OPENSCREEN | 4 | PvSARS2 neutralization assay | CH | Y |
| IRB | EU-OPENSCREEN | 5 | Xcomp | CH | Y |
| IRB | EU-OPENSCREEN | 6 | 3Dmod | CH | Y |
| IRB | EU-OPENSCREEN | 7 | AbAgDes | CH | Y |
| IRB | EU-OPENSCREEN | 8 | AbAgPP | CH | Y |
| IRB | EU-OPENSCREEN | 9 | Ab disco | CH | Y |
| JR | EU-OPENSCREEN | 1 | Ab tests Diagnostics | AT | Y |
| BRFAA | EU-OPENSCREEN | 1 | Diag | GR | Y |
| SCTO | ECRIN | 1 | SCTO | CH | N |
| UPJS | ECRIN | 1 | UPJS | SK | N |
| UNL | ECRIN | 1 | UNL | PT | N |
| STOH | ECRIN | 1 | STOH | NO | N |
| ISS | ECRIN | 1 | ISS | IT | N |
| ISS | EATRIS | 1 | Department of Oncology and Molecular Medicine | IT | Y |
| ISS | EATRIS | 1 | Department of Oncology and Molecular Medicine | IT | Y |
| ISS | EATRIS | 1 | Cytometry Area-FAST Core Facilities | IT | Y |
| UCC | ECRIN | 1 | UCC | IE | N |
| KKSN | ECRIN | 1 | KKSN | DE | N |
| UPecs | ECRIN | 1 | UPecs | HU | N |
| NIKARD | ECRIN | 1 | NIKARD | PL | N |
| AIBILI | EATRIS | 1 | AIBILI | PT | Y |
| FIBHULP | EATRIS | 1 | IDIPAZ | ES | Y |
| FIBHULP | EATRIS | 2 | IDIPAZ | ES | Y |
| FIBHULP | EATRIS | 3 | IDIPAZ | ES | Y |
| IGTP | EATRIS | 1 | HCGB1 | ES | Y |
| IGTP | EATRIS | 1 | HCGB2 | ES | Y |
| IGTP | EATRIS | 1 | HCGB3 (High Content Genomics and Bioinformatics Unit | ES | Y |
| IGTP | EATRIS | 1 | PGE (Translational Genomics Facility) | ES | Y |
| iMM | EATRIS | 1 | LGraca Lab / Flow Cytometry | PT | Y |
| iMM | EATRIS | 1 | LGraca Lab / Flow Cytometry | PT | Y |
| iMM | EATRIS | 1 | LGraca Lab / Flow Cytometry | PT | Y |
| iMM | EATRIS | 1 | LGraca Lab / Flow Cytometry | PT | Y |
| iMM | EATRIS | 1 | LGraca Lab / Flow Cytometry | PT | Y |
| iMM | EATRIS | 1 | LGraca Lab / Flow Cytometry | PT | Y |
| OUH | EATRIS | 1 | Flow Cytometry Core Facility | NO | Y |
| OUH | EATRIS | 1 | Flow Cytometry Core Facility | NO | Y |
| OUH | EATRIS | 1 | Cell Th | NO | Y |
| OUH | EATRIS | 1 | Cell Th | NO | Y |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab002 | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| VHIR | EATRIS | 1 | Lab 002 (113 Tissue Culture Room P2+) | ES | Y |
| EATRIS | EATRIS | 1 | Ab char. | IT | Y |
| EATRIS | EATRIS | 1 | Device | IT | Y |
| EATRIS | EATRIS | 1 | Abdjuv | IT | Y |
| EATRIS | EATRIS | 1 | Regul | IT | Y |
| CCMAR | EMBRC | 1 | CCMARSZN | PT | N |
| SZN | EMBRC | 1 | SZN | IT | N |
| APHP | EMERGEN | 1 | HMNseq | FR | N |
| APHP | EMERGEN | 1 | HMNmet | FR | N |
| HCL | EMERGEN | 1 | HCLseq | FR | N |
| IHU | EMERGEN | 1 | IHUseq | FR | N |
| UG | INFRAVEC | 1 | siRNA2 | UK | N |
| UG | INFRAVEC | 2 | siRNA3 | UK | N |
| IRD | INFRAVEC | 1 | BSL1 | FR | N |
| IRD | INFRAVEC | 2 | BSL3 | FR | N |
| IRD | INFRAVEC | 3 | Vectors | FR | N |
| IRD | INFRAVEC | 4 | Infected | FR | N |
| IPNC | INFRAVEC | 1 | Vectors | FR | N |
| IPNC | INFRAVEC | 2 | Facility | FR | N |
| CUNI | INFRAVEC | 1 | Vectors | CZ | N |
| CUNI | INFRAVEC | 2 | Infections | CZ | N |
| CUNI | INFRAVEC | 3 | Facility | CZ | N |
| CIRAD | INFRAVEC | 1 | Ticks HardTicks -Tse-tse | FR | N |
| CIRAD | INFRAVEC | 2 | Facility | FR | N |
| Imperial | INFRAVEC | 1 | VGE | UK | N |
| MPG | INFRAVEC | 1 | Infections-dsRNA | DE | N |
| MPG | INFRAVEC | 2 | Facility | DE | N |
| FORTH | INFRAVEC | 1 | Bioinfo-RNAseq | GR | N |
| FORTH | INFRAVEC | 1 | Genotyping | GR | N |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| FORTH | INFRAVEC | 2 | Resistance | GR | N |
| FORTH | INFRAVEC | 3 | Cuticle | GR | N |
| FANS | INFRAVEC | 1 | FANS | RS | N |
| SUPSI | INFRAVEC | 1 | SUPSI | CH | N |
| IP Dakar | INFRAVEC | 1 | IPD | SN | N |
| USTTB | INFRAVEC | 1 | USTTB | ML | N |
| WU | INFRAVEC | 1 | Behaviour | NL | N |
| WU | INFRAVEC | 2 | Infections | NL | N |
| CNRFP | INFRAVEC | 1 | CNRFP | BF | N |
| PoloGGB | INFRAVEC | 1 | RNAseq | IT | N |
| PoloGGB | INFRAVEC | 2 | DNAseq | IT | N |
| PoloGGB | INFRAVEC | 3 | Metagen | IT | N |
| PoloGGB | INFRAVEC | 4 | smRNAseq | IT | N |
| PoloGGB | INFRAVEC | 5 | LgDNAseq | IT | N |
| PoloGGB | INFRAVEC | 6 | Bioinfo-DNAseq | IT | N |
| PoloGGB | INFRAVEC | 7 | Bioinfo-Metagen | IT | N |
| PoloGGB | INFRAVEC | 8 | Bioinfo-smRNAseq | IT | N |
| PoloGGB | INFRAVEC | 9 | Bioinfo-LgDNAseq | IT | N |
| PoloGGB | INFRAVEC | 10 | LargeCages | IT | N |
| CAA | INFRAVEC | 3 | 100000 | IT | N |
| TropIQ | INFRAVEC | 1 | Vect1 | NL | N |
| TropIQ | INFRAVEC | 2 | Vect2 | NL | N |
| AVIA-GIS | INFRAVEC | 1 | Spatial epidemiology | BE | N |
| AVIA-GIS | INFRAVEC | 2 | Risk assessments and mapping | BE | N |